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Thesis overview 
This thesis is composed of three distinct chapters, all of which aim to improve our 
understanding of the relationship between physical activity and oesophageal 
adenocarcinoma.  
In the first two chapters, two specific aspects of physical activity are explored:  
 Physical activity in the aetiology of oesophageal adenocarcinoma; through its role 
in the development of pre-malignant Barrett’s oesophagus. 
 A preoperative physical activity programme (prehabilitation) prior to oesophageal 
cancer surgery to improve fitness and reduce the incidence of postoperative 
complications.  
 
In the third chapter, the association between preoperative physical fitness and 
postoperative outcome after oesophageal cancer surgery is investigated. 
 
The main aims of this thesis are to: 
1) Consider whether physical activity should be added to the aetiological model of 
Barrett’s oesophagus and oesophageal adenocarcinoma.  
2) Inform and justify a future randomised controlled trial of prehabilitation prior to 
oesophagectomy. 
3) To stratify a patient’s risk of post-oesophagectomy complications according to 
their preoperative physical fitness. 
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Abstract  
 
Oesophageal adenocarcinoma has the fastest growing incidence of any solid tumour in 
the western world. Physical activity affects gastric emptying, intra-gastric pressure, 
systemic inflammation, and the regulation of body weight and may play an important role 
in the aetiology of the metaplasia-dysplasia-carcinoma sequence of oesophageal 
adenocarcinoma. Furthermore, exercise causes physiological adaptations resulting in 
improved cardiac output and lung ventilation volumes, as well as increased capillary and 
mitochondrial density in skeletal muscle, all of which improves efficiency in cellular 
aerobic respiration. As major surgery places large physiological stresses on the human 
body through; blood loss, catabolic muscle breakdown, systemic inflammatory 
vasodilation, and disruption of normal lung mechanics, the adaptive changes, achieved 
through preoperative exercise, may maximise cardiopulmonary and skeletal muscle 
reserves and reduce the risk of postoperative complications after cancer resection surgery 
(oesophagectomy).  
 
This research aimed to investigate: 1) associations between both occupational and 
recreational levels of physical activity and the development of Barrett’s oesophagus, the 
precursor lesion of oesophageal adenocarcinoma; 2) the feasibility of delivering a short-
term preoperative exercise programme (prehabilitation) in a feasibility randomised 
controlled trial; and (3) associations between preoperative aerobic fitness, as measured 
objectively by cardiopulmonary exercise testing, and postoperative outcomes after 
oesophagectomy.   
 
Results from a population-based prospective cohort study of 30 445 participants 
suggested a U-shaped association between occupational levels of physical activity and the 
risk of Barrett’s oesophagus, where moderate levels of activity in standing occupations 
had an inverse association with disease risk (when compared to sedentary occupations), 
HR=0.50, 95% CI 0.31-0.82, p=0.006, but heavy manual occupations were associated with 
an increased risk, HR=1.66, 95% CI 0.91-3.00, p=0.09. No associations were found 
between recreational activity and the risk of Barrett’s oesophagus (HR 1.34, 95% CI 0.72-
2.50, p=0.35, highest vs. lowest levels of activity).   
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A single blinded, parallel group, randomised controlled feasibility trial of prehabilitation 
in 11 patients with oesophageal adenocarcinoma showed that a hospital -based exercise 
programme in the time period between completion of neoadjuvant chemotherapy and 
surgery was safe and acceptable to patients awaiting curative surgery. 
 
A hospital-based cohort study of 254 patients found that there was no association 
between aerobic fitness (VO2peak) and postoperative complications after oesophagectomy 
(OR 1.00, 95% CI 0.94-1.07, p=0.86). This suggests that the impact of fitness on 
postoperative outcome, in the context of oesophagectomy, is likely to be insubstantial. 
 
Overall, this thesis suggests that occupational levels of physical activity may play a role in 
the aetiology of oesophageal adenocarcinoma, but preoperative fitness, even if feasibly 
modifiable with prehabilitation, may not significantly affect the risk of short-term 
postoperative morbidity after oesophagectomy.  
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Chapter 1: Physical activity in the aetiology of oesophageal 
adenocarcinoma 
An overview 
In this chapter, the associations between both occupational and recreational levels of 
physical activity and the risk of developing oesophageal adenocarcinoma, as well as its 
precursor diseases, gastroesophageal reflux disease (GORD) and Barrett’s oesophagus, 
are examined.  
 
Firstly, overviews of the definitions, descriptive epidemiology and aetiology, as well as the 
management of oesophageal adenocarcinoma, are presented.  
 
Secondly, the literature investigating associations between physical activity and the risk 
of developing GORD, Barrett’s oesophagus oesophageal adenocarcinoma is reviewed.  
 
Thirdly, the results of an original prospective cohort study of 30 445 people resident in 
Norfolk in the United Kingdom (UK) enrolled in The European Prospective Investigation of 
Cancer (EPIC-Norfolk) examining the associations between both recreational and 
occupational levels of physical activity and the development of Barrett’s oesophagus (the 
precursor lesion of oesophageal adenocarcinoma) are presented, the first such 
epidemiological study in this field.  
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1.1 Introduction  
 
 
1.1.1 Definition of oesophageal adenocarcinoma 
 
Histological subtypes 
The two main histological types of oesophageal cancer are adenocarcinoma and 
squamous cell carcinoma. These two cancers are very different in their; pathogenesis, 
epidemiology, clinical management and prognosis. Squamous cell cancer progresses from 
epithelial dysplasia to carcinoma in situ and then invasive oesophageal carcinoma, with 
tobacco and alcohol use identified as major positive risk factors. 1 Oesophageal 
adenocarcinoma occurs due to dysplastic change in the mucosa, where chronic reflux of 
gastric and duodenal contents into the lower oesophagus results in reactive metaplasia 
of the normal squamous epithelium into a glandular mucosa (Barrett’s oesophagus).2 
Proliferation of this altered mucosa generates biologically unstable cells, with damaged 
DNA, that are prone to subsequent malignant degeneration.3 Oesophageal 
adenocarcinoma is the histological subtype which is investigated in this thesis as there is 
epidemiological evidence that sedentary behaviours4 and obesity5 are associated with its 
aetiology. Furthermore, the incidence of oesophageal adenocarcinoma is rapidly rising in  
the Western world,  and now represents the commonest histological subtype of 
oesophageal cancer in the UK.6  Understanding the aetiology of this cancer is therefore 
important to develop and institute preventative measures.  
 
Oesophageal junctional tumours 
Cancer of the oesophagus describes tumours which may involve either the oesophagus in 
isolation, or the junction between the oesophagus and stomach - so called junctional or 
oesophagogastric junction (OGJ) tumours. Historically, there has been confusion about 
the distinction between oesophageal and gastric cancers when they occur at the 
junction.7 Defining which group a cancer belongs to has importance because, as with the 
differences between the histological subtypes of oesophageal cancers, gastric cancers are 
also distinct from oesophageal cancer in both their aetiology and clinical management.8  
The Siewert classification system, proposed in the 1980’s, defined junctional tumours as 
three distinct types based on their anatomic positions relative to the OGJ.9  Type I are 
distal oesophageal tumours which infiltrate the OGJ from above. Type II are those arising 
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at the OGJ. Type III, are subcardial gastric tumours which invade the OGJ and distal 
oesophagus from below (figure 1.1). The most recent definition of oesophageal junctional 
cancers, in the eighth addition of the American Joint Committee on Cancer (AJCC) and the 
Union for International Cancer Control (UICC) staging manual, defines junctional tumours 
to be oesophageal cancer if the tumour epicentre is located no more than 2cm into the 
proximal stomach (Siewert types I/II).10 Tumours with the epicentre located more than 
2cm into the proximal stomach are gastric cancers (Siewert type III). Therefore, according 
to these recent staging definitions, Siewert type I and II tumours are oesophageal cancers, 
while type III (where the tumour centre is located >2cm in the stomach) are defined as 
gastric cancers.  
 
Figure 1.1 Schematic of Siewert type I, II and III oesophagogastric cancers showing a dashed 2cm 
boundary l ine, which differentiates oesophageal from gastric cancers. 
 
Image from Siewert J, Stein H, Carcinoma of the cardia: Carcinoma of the gastroesophageal 
junction—classification, pathology and extent of resection. Dis Esophagus. 9:173–182.11 
 
1.1.2 Incidence of oesophageal adenocarcinoma  
 
Approximately 52 000 cases of oesophageal adenocarcinoma occurred worldwide in 
2012, with an age standardised incidence rate (ASR) of 0.7/100 000 (1.1 in men and 0.3 in 
women). 12 Of these, 46% occurred in Northern and Western Europe, North America and 
Oceania (figures 1.2 and 1.3). The regions with the lowest incidences were East/South 
East Asia and Sub-Saharan Africa (0.3/100 000), although this figure may represent less 
comprehensive data collected from these regions. 12 The highest ASR for oesophageal 
adenocarcinoma in the world was in the UK (7.2/100 000 in men and 1.4/100 000 in 
women).12 An analysis of population-based cancer registry data in England between 1971 
and 2009, estimated a continued increase in incidence of approximately 2-3 cases/ 100 
000 person years per decade.13  
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The highest reported incidence of oesophageal adenocacrinoma in the world was in the UK 
(7.2/100 000 in men and 1.4/100 000 in women). Images from Arnold M, Soerjomataram I, Ferlay 
J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 
2015;64(3):381-7.12 
Figure 1.2 A world map showing the distribution of age-standardised incidence rates for oesophageal 
adenocarcinoma in men. 
Figure 1.3 A world map showing the distribution of age-standardised incidence rates for oesophageal 
adenocarcinoma in women. 
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1.1.3 Aetiology of oesophageal adenocarcinoma 
 
Histological surveillance studies have demonstrated that oesophageal adenocarcinoma 
develops through a morphological sequence of inflammation, metaplasia, dysplasia and 
eventual cancer.14 Two early distinct diseases mark this progression to cancer: 
gastroesophageal reflux disease (GORD) and Barrett’s oesophagus.  
 
Gastro-oesophageal reflux disease 
Whilst occasional reflux of gastric contents into the lower oesophagus is a normal 
physiological occurrence, prolonged reflux, which causes troublesome symptoms  is 
described as gastro-oesophageal reflux disease (GORD).15 GORD is the single most 
important risk factor for oesophageal adenocarcinoma.16 A systematic review estimated 
the prevalence of GORD to be 10-20% in the Western world, with a lower prevalence in 
Asia.17 The main causative mechanism underlying reflux is thought to be failure of the 
lower oesophageal sphincter (LOS),18 either through anatomical disruption of the LOS and 
diaphragm, or through its inappropriate relaxation. 19 20    
 
Anatomical disruption of the LOS occurs in hiatal hernia disease, a condition in which the 
gastroesophageal junction and stomach are displaced superiorly above the diaphragm 
and through the oesophageal hiatus into the mediastinum. Hiatus hernias are thought to 
occur through damage to the phrenoesophageal ligament (responsible for maintaining 
the normal position of the gastroesophageal junction). Excessive stresses from increased 
intra-abdominal pressures as in pregnancy, central adiposity and strenuous vigorous 
exercise are thought to play important roles.21  If anatomical displacement of the 
gastroesophageal junction occurs, then contractions of the crural diaphragm are no 
longer over and around the LOS, compromising the anti-reflux barrier. Hiatus hernia 
disease is present in up to 72- 96% of patients with Barrett’s oesophagus.22   
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Figure 1.4 Schematic of the lower oesophageal sphincter showing the related adjacent structures. 
 
Image taken from Ganong’s Review of Medical Physiology.23 
 
 
Inappropriate relaxation of the LOS is described as transient lower oesophageal sphincter 
relaxations (TLOSRs). These are pathological prolonged relaxations of the LOS and crural 
diaphragm in the absence of swallowing. 18 Distension of the stomach by air or food is 
thought to activate gastric vagal afferents and/or stretch receptors in the subcardiac 
region, triggering a TLOSR. 18 Prolonged GORD as a result of hiatus hernia and TLOSRs lead 
to endoscopic histological inflammation of the oesophagus (oesophagitis). The clinical 
symptoms of GORD and oesophagitis typically include dyspepsia and regurgitation.24 
Other less common symptoms are epigastric discomfort, nausea, bloating, belching and 
fullness.24 Rare symptoms are dysphagia, cough, wheeze and laryngitis.24  
 
The constituents of reflux most likely to cause oesophagitis are both gastric (hydrochloric 
acid and pepsin) and duodenal (bile acids and trypsin). Animal models have demonstrated 
the injurious effect of various gut secretions on oesophageal mucosa including: high 
concentrations of acid, lower concentrations of acid  in the presence of the enzyme 
pepsin, and bile acids and the pancreatic proteolytic enzyme trypsin. 25 Hydrochloric acid 
is thought to damage cellular pump mechanisms, notably Na+/K+ ATP and amiloride 
sensitive Na+ pumps, causing a raised intracellular Na+ concentration with resultant cell 
swelling and death. 25 Both pepsin and trypsin are proteolytic and cause shedding of the 
epithelial cell surface, probably by digestion of intercellular structures.26 The pathogenic 
mechanism of bile acids is less clear, but may be via its detergent properties causing break 
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down of lipid membranes.27 Alternatively, because of the lipophilic nature of bile, it may 
cross cell membranes and interfere with cellular functions.28  
 
Barrett’s Oesophagus 
The injurious effects of acid, bile and enzymes in GORD results in the release  of 
inflammatory cytokines, with an increase in IL-1β, IL-8 (pro-inflammatory neutrophil 
chemo attractants) and IFN- γ (Th-1 cytokine).29 30 This local inflammatory environment is 
highly mutagenic,31  resulting in the intracellular accumulation of genetic defects. This 
promotes mutagenesis in columnar cells with a selective proliferative advantage over 
genetically normal squamous cells, resulting in metaplasia.32 Barrett’s oesophagus is 
defined as an oesophagus in which any portion of the normal distal squamous epithelial 
lining has been replaced by such metaplastic columnar epithelium.33  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Barrett’s oesophagus can be appreciated macroscopically at endoscopy, where the normal pale-
pink squamous mucosa is contrasted with the deep salmon-pink metaplastic mucosa of Barrett’s 
oesophagus. A prominent tongue of Barrett’s mucosa can be seen in the 4 o’clock position, with a 
smaller projection at 8 o’clock. 
 
 
 
 
Figure 1.5 Macroscopic view of Barrett's oesophagus obtained at endoscopy. 
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Three subtypes of metaplastic columnar epithelium have been identified and classified in 
Barrett’s oesophagus: junctional-type (containing cardiac mucous glands),  atrophic 
gastric fundic or oxyntocardiac (containing mucous, chief and parietal cells), and 
specialised/intestinal (with mucous glands, a villiform surface and goblet cells like those 
in the intestines). Intestinal epithelium is thought to be the most biologically unstable and 
most prone to malignant degeneration, which occurs in a sequence from metaplasia to 
dysplasia to malignant infiltration.  
 
Approximately 3-5% of patients with GORD will progress to Barrett’s oesophagus.34 
However, the precise prevalence of Barrett’s oesophagus is unknown as approximately 
45% of affected people are asymptomatic and therefore go undiagnosed by endoscopy.14 
Evidence from population based studies, where asymptomatic people had an upper 
gastrointestinal endoscopy, estimated the prevalence to be 0.5-1.5% in Western 
populations.14  The public health importance of Barrett’s oesophagus lies in its association 
with the development of oesophageal adenocarcinoma16 with an absolute risk of 
progression of 0.2 to 0.7%, per patient, per year.35 
 
Dysplasia 
Histologically, progression from Barrett’s mucosa  to invasive cancer occurs through a 
sequence of increasing grades of dysplasia.36 Dysplasia is defined as a morphologically 
changed (neoplastic) epithelium confined within the basement membrane of the gland 
from which it arises.37 The level of dysplasia can be determined by microscopy of 
oesophageal tissue biopsies obtained at upper gastrointestinal endoscopy, and described 
in terms of both the architectural and cytological abnormalities (figures 1.6-1.8). 
Architectural changes include glandular distortion and crowding, while cytological 
abnormalities include enlargement of the nucleus and nucleolus, and hyperchomatism.37 
Based on the number and degree of abnormalities present, dysplasia is graded from low-
grade dysplasia (LGD) to high-grade dysplasia (HGD). Surveillance cohort studies of 
patients with Barrett’s oesophagus have established that those with dysplasia are at an 
increased risk of oesophageal adenocarcinoma, 38 with HGD representing the highest risk 
of invasive progression. 
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The epithelium is composed of goblet cells interspersed between intermediate mucous cells, both in the 
surface and glandular epithelium. The nuclei are basally located, small and ovoid. All images on this page are 
from Flejou, J-F, Barrett’s oesophagus: from metaplasia to dysplasia and cancer, Gut 2005;54(Suppl I):i6–i12.36 
 
 
 
 
 
 
 
 
 
Low grade architectural and cytological abnormalities are present including some patchy loses of basal 
orientation of surface nuclei  with an increase in nuclear s ize. 
 
 
 
 
 
 
 
 
 
 
High grade architectural and cytological abnormalities are present including scant cytoplasm, and enlarged 
and hyperchromatic nuclei .  
  
Figure 1.6 Histology slide of Barrett's oesophagus (haematoxylin–eosin, original magnification x400) 
Figure 1.7 Histology slide of low grade dysplasia (haematoxylin–eosin, original magnification x400) 
Figure 1.8 Histology slide of high-grade dysplasia (haematoxylin–eosin, original magnification x400) 
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As the level of dysplasia is based on the interpretation of morphology, assessment of 
dysplasia is highly subjective resulting in substantial variations in diagnoses between 
pathologists.16 Therefore, the precise conversion rates from LGD to HGD and/or 
adenocarcinoma are uncertain as there is great variability in estimates between studies.  
A recent review of 12 studies with 971 patients estimated an annual incidence of 
progression from LGD to HGD and/or oesophageal adenocarcinoma of between 0.5% and 
4% per year.39 However, the difficulties in accurately diagnosing LGD were noted. For LGD, 
only 37.5% of samples had a consensus on diagnosis after review by two or more expert 
pathologists. Furthermore, LGD was frequently not detected on follow-up biopsies, 
suggesting either regression may occur or an incorrect initial diagnosis was made.16 The 
above pooled estimate is therefore likely to be affected by misclassification bias. 
Estimates from different studies for the progression from HGD to adenocarcinoma are 
also variable, with 5-year cumulative incidences of between 10% and 59%.16 
 
Other risk factors for oesophageal adenocarcinoma 
Why some patients with GORD progress to Barrett’s oesophagus and then to 
adenocarcinoma is poorly understood. The rapidly rising incidence of oesophageal 
adenocarcinoma in the UK is thought to be related to environmental exposures, including 
obesity, which, due to changes in diet and decreased levels of physical activity is rapidly 
increasing.40 Body fat, in particular visceral fat, is metabolically active, releasing 
adipocytokines, resulting in low-grade inflammation, chronic hyperinsulinemia and an 
increased risk of insulin-like growth factor-mediated carcinogenesis.41 However, obesity 
may also increase disease risk through a mass effect, where central adiposity raises intra-
gastric pressures, which in turn compromises the LOS, resulting in reflux disease.42  Meta-
analyses of epidemiological studies have estimated that obesity (BMI>30kg/m2), 
compared to a normal weight (18.5-24.9 kg/m2), is a positive risk factor for GORD (OR= 
1.94, 95% CI 1.47-2.57)43, Barrett’s oesophagus (OR= 1.70, 95% CI 1.36-2.12)44 and 
oesophageal adenocarcinoma (OR =2.78, 95% CI 1.85-4.16).43 Currently, it is unclear if 
fatty foods are an independent risk factor for oesophageal adenocarcinoma, but data 
from case-control studies suggests that an increased intake of fruit, 45 plant-based fibre 46 
47 and vegetables 48 is inversely associated with disease; although spurious over-
estimations of the effect sizes due to recall  bias, which are inherent in case-control 
studies, may explain these findings. Based on a review of population-based case-control 
studies it is likely that  alcohol consumption is not associated with oesophageal 
27 
 
adenocarcinoma risk, although the methodological weaknesses of case-control studies in 
terms of selection and information biases were noted.49 Smoking does appear to be 
associated with disease risk, with summarised case-control data suggesting it 
approximately doubles the risk of disease.16 
 
Unmodifiable risk factors include age, with 56% of cases diagnosed in people aged 70 
years and over50, and gender,40 with a striking disparity between incidence in both sexes; 
which is as high as 5:1 (men: women) in the UK. 12 The reasons for this higher incidence in 
men are unknown, but a possible explanation is the difference in distribution of excess 
adiposity, where men are prone to centripetal storage, while premenopausal women tend 
to store fat in the buttocks, thighs and hips, but not around the waist. 51 Adiposity in men 
may therefore predispose to raised intra-gastric pressures and reflux. Premenopausal 
oestrogens may also be influential, both in terms of determining fat distribution in 
premenopausal women and via their anti-inflammatory properties, which may also be 
protective.14 The role of physical activity in the aetiologies of both Barrett’s oesophagus 
and oesophageal adenocarcinoma is discussed in detail later in this chapter.  
 
1.1.4 Management of oesophageal adenocarcinoma 
 
Screening for oesophageal adenocarcinoma 
The British Society of Gastroenterology has published guidelines relating to the use of 
screening for Barrett’s oesophagus by endoscopy.33 It is recommended that patients with 
chronic GORD symptoms are not screened unless multiple risk factors are present (>50 
years, white, male, obesity, family history). It is further recommended that patients with 
Barrett’s oesophagus (shorter than 3cm with intestinal metaplasia) should receive 
endoscopic surveillance every 3-5 years, or 2-3 years if ≥3cm, while those with low-grade 
dysplasia should receive an endoscopy every 6 months.33 However, a recent review found 
that up to 90% of patients with Barrett’s oesophagus die from causes unrelated to their 
Barrett’s disease and that up 93% of oesophageal adenocarcinomas are not detected by 
endoscopic screening programmes, but rather present as symptomatic cancers.52 This 
represents both significant over-diagnosis of Barrett’s oesophagus and under-diagnosis of 
oesophageal adenocarcinoma through endoscopic screening.  
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Future advances in genome technology may present a more accurate screening method 
to stratify patients with Barrett’s oesophagus with the highest risk of cancer progression. 
Genetic studies have attempted to identify the molecular events which can be used to 
predict the risk of progression. In a multivariable analysis from a genetic study examining 
both tumour suppressor genes (including TP53 and CDKN2A) and DNA abnormalities in 
Barrett’s oesophagus: chromosome instability markers, loss of heterozygosity (LOH) and 
DNA content abnormalities (tetraploidy and aneuploidy) were all independent risk factors 
for cancer progression.31 Future research in this area is required to help make surveillance 
programmes more effective, both clinically and financially.  
 
Presentation and prognosis of patients with oesophageal adenocarcinoma 
Most patients with oesophageal adenocarcinoma tend to present with late symptoms of 
tumour invasion of the oesophagus (difficulty and pain with swallowing resulting in 
associated weight loss). The commonest route of diagnosis is via a ‘two week wait’ referral 
from a General Practitioner, where subsequent hospital endoscopy obtains tissue 
diagnosis.53 The chance of survival from oesophageal cancer is bleak, with only 15% of 
patients alive at 5 years and 12% at 10 years.53 This poor survival is related to both the 
aggressive nature of the cancer and its late clinical presentation.   
 
Staging and treatment of oesophageal adenocarcinoma 
The clinical staging of oesophageal adenocarcinoma is crucial in determining the 
appropriate treatment. Staging usually always includes endoscopy and computed 
tomography (CT) of the chest, abdomen and pelvis. If at this stage there is clear evidence 
of metastatic disease, no further investigations are usually indicated. However, if a patient 
is being considered for potentially curative treatment, further staging modalities, such as 
positron-emission (PET) CT (to determine T and M staging), endoscopic ultrasound (EUS) 
(to determine precise T staging), or laparoscopy (to determine N and M staging) may be 
used. Management is informed by the depth of tumour invasion (T), lymph node 
involvement (N) and the presence or absence of distant metastasis (M). A cancer staging 
system maintained by the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC) developed the TNM classification based on these 
three variables. The latest TNM staging system in current clinical use (7th Edition) is based 
on data from 4 627 patients from three different continents who underwent 
oesophagectomy without adjuvant therapy.54 Generally, superficial tumours (T1a) 
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without nodal or metastatic spread may be treated by endoscopic mucosal resection, 
although surgery may also be indicated. T1b tumours may be managed surgically without 
the need for adjuvant chemotherapy or radiotherapy. For tumours with nodal 
involvement and up to T4a, oesophagectomy with adjuvant chemotherapy and or 
radiotherapy is indicated.55 Metastatic tumours or those with invasion of structures 
unamendable to surgery are usually treated palliatively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image from Rice TW, Ishwaran H, Ferguson MK, et al. Cancer of the 
Esophagus and Esophagogastric Junction: An Eighth Edition Staging 
Primer. J Thorac Oncol 2017;12(1):36-42. 10 
 
 
The roles of surgery, chemotherapy and radiotherapy in the management of 
oesophageal adenocarcinoma 
Surgery is the only treatment modality to date, which consistently offers a potential cure 
for oesophageal adenocarcinoma.34 However, surgery as monotherapy, particularly when 
there is node positive disease, has a poorer survival compared to surgery combined with 
other therapies such as chemotherapy or radiotherapy.55 Whether combination therapy 
should be bimodal (surgery and chemotherapy) or trimodal (inclusion of radiotherapy) 
remains unclear. The MAGIC trial reported that induction chemotherapy without 
radiotherapy provided a survival benefit at 5 years over surgery alone (HR 0.75, 95% CI 
0.60-0.93), p=0.009 and is the treatment adopted in the United Kingdom for oesophageal 
Figure 1.9 Schematic of the TNM staging system for oesophageal 
adenocarcinoma 
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adenocarcinoma. This chemotherapy regimen consists of three preoperative and three 
postoperative cycles of epirubicin, cisplatin and fluorouracil. The exception to this regime 
is in patients with T1N0 disease who may undergo surgery alone. 34 
 
 
1.1.5 Plausible biological mechanisms for the effects of physical activity on the 
development of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma 
 
As the incidence of oesophageal adenocarcinoma is rapidly rising and the prognosis is 
poor, understanding the aetiology of this cancer, including its pre-malignant stages (GORD 
and Barrett’s oesophagus) is important to aid prevention. Physical activity may influence 
the risk of GORD in opposing ways depending on both its type and intensity. Therefore, 
consideration of physical activity related to both occupation and recreation may have 
relevance to its aetiology. There are several plausible mechanisms through which exercise 
could induce reflux, although the precise details are not fully understood. Intra-abdominal 
pressure is increased by recreational activities which involve abdominal straining such as 
weightlifting or cycling (with a bent over posture), which may force gastric contents 
retrograde, beyond the lower oesophageal sphincter into the oesophagus. 56 Also, 
vigorous exercise, that is above 75% of VO2max,  has been shown to delay gastric 
emptying,57 likely by decreasing splanchnic blood flow.58 These mechanisms may account 
for the documented positive relationship between reflux episodes and high intensity 
exercise,59 with a high prevalence of GORD in elite athletes (estimated at 60%). 56 
Occupational activity may also increase the risk of GORD, particularly in heavy manual 
jobs, which involve bending and heavy lifting. Occupational activities are also more likely 
to occur post-prandially when reflux episodes are common.60 Associations between heavy 
manual occupations and reflux have not been previously studied in the literature, but an 
increased risk of reflux in occupations which involve intra-abdominal straining, such as in 
wind instrument players61 62 and choir or opera singers62 63 are documented. 
 
Alternatively, moderate levels of recreational physical activity may protect against GORD. 
Engagement in regular exercise helps maintain a normal body weight,64 preventing 
obesity induced reflux disease.65-68 It has also been postulated that regular exercise 
strengthens the crural diaphragm,69 which is an important component of the anti-reflux 
barrier of the LOS. Finally, low or moderate intensity (30-60% of VO2max) running or walking 
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increases, rather than delays, gastric emptying and may therefore decrease reflux 
episodes.57 As the type, duration  and intensity of physical activity at both work and leisure 
may influence reflux in opposing ways, measuring the precise characteristics of 
recreational and occupational activities is likely to be important in aetiological 
epidemiological investigations, although to the best of our knowledge this has not been 
studied previously.  
 
Physical activity may also influence the development of Barrett’s oesophagus. As 
discussed previously, the metaplastic transition from a squamous to columnar 
oesophageal epithelium is thought to be driven by inflammation, 29 30 where chronic 
exposure of oesophageal mucosa to reflux results in the release of pro-inflammatory 
cytokines and a subsequent reactive metaplastic change.29 30 Regular physical activity 
reduces inflammatory biomarker expression, and may prevent this inflammation-driven 
process.70-73 However, further work is required to elucidate the relative importance of the 
potential anti-inflammatory mediated effect of physical activity.  
 
Finally, physical activity may have direct anticancer effects. Regular physical activity may 
not only regulate body fat levels, but also lower plasma insulin and insulin resistance over 
and above the effect of weight loss alone.74 Hyperinsulinemia and insulin resistance are 
both associated with increased cancer risk.75 Furthermore, aerobic exercise is thought to 
reduce oxidative stress and improve DNA repair, which may inhibit carcinogensis.76  
Therefore, increased levels of physical activity could have protective pathways which may 
or may not rely on modification of BMI, although more work is needed to determine the 
relevance and importance of these mechanisms.  
 
To support the biological mechanisms for how physical activity may influence the risk of 
oesophageal adenocarcinoma and its precursor diseases (GORD, and Barrett’s 
oesophagus) evidence from epidemiological studies is needed. The next section of this 
chapter reviews the published epidemiological evidence for associations between 
physical activity and the risk of all three disease states, which together constitute a 
metaplasia-dysplasia-carcinoma sequence. The methodological strengths and 
weaknesses of such work are also discussed.  
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1.2 Does physical activity influence the development of 
gastroesophageal reflux disease, Barrett’s oesophagus and 
oesophageal adenocarcinoma? A review of the literature with a 
meta-analysis 
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1.2.1 Abstract 
 
Background: Physical activity affects the functioning of the gastrointestinal system 
through both local and systemic effects and may play an important role in reducing the 
risk of oesophageal adenocarcinoma. This review assesses the published epidemiological 
literature for associations between physical activity and the development of oesophageal 
adenocarcinoma and its precursor diseases; gastroesophageal reflux disease (GORD) and 
Barrett’s oesophagus.  
 
Methods: A search of PubMed, Medline, Embase and CINAHL was conducted from their 
inceptions to 25th March 2017 for analytical studies that examined associations between 
recreational and/or occupational levels of physical activity and the risk of GORD, Barrett’s 
oesophagus and oesophageal adenocarcinoma. Where appropriate , a meta-analysis of 
effects was undertaken.  
 
Results: Seven studies were included (2 cohort, 5 case-control). For GORD, there were 3 
case-control studies with 10 200 cases among 78 034 participants, with a pooled 
estimated OR of 0.67 (95% CI 0.57-0.78) for high vs. low levels of recreational physical 
activity. In Barrett’s oesophagus, there was a single case-control study, which reported no 
association between recreational activity and disease risk, OR 1.19 (95% CI 0.81-1.73). 
Occupational activity was not investigated. For oesophageal adenocarcinoma there were 
3 studies (2 prospective cohort, 1 case control) with 666 cases in 910 376 participants. 
The largest cohort study reported an inverse association for high vs. low levels of 
recreational physical activity (RR 0.68, 95% CI 0.48-0.96). The remaining 2 studies 
reported no associations with either occupational or combined recreational and 
occupational activities.  Heterogeneity in the measurement of exposure (recreational, 
occupational and both) made a pooled estimate for oesophageal adenocarcinoma 
inappropriate. 
 
Conclusion: Although limited, there is some evidence that higher levels of recreational 
physical activity may reduce the risk of both GORD and oesophageal adenocarcinoma, but 
further large cohort studies examining the type, intensity and duration of activities that 
may be beneficial are needed. 
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1.2.2 Introduction 
 
As discussed in the previous section there is an ongoing rise in the incidence of 
oesophageal adenocarcinoma, which is reaching epidemic proportions.12 13 77 78  
Geographical variations, with higher incidences in more affluent countries, suggests that 
aspects of lifestyle may be involved in its aetiology.12 Increasingly sedentary behaviours 
with reduced levels of both occupational and recreational physical activity may be an 
important contributing factor.79 Histological surveillance studies have demonstrated that 
oesophageal adenocarcinoma develops through a morphological sequence of 
inflammation, metaplasia, dysplasia and eventual cancer, with gastroesophageal reflux 
disease (GORD), Barrett’s oesophagus, and oesophageal adenocarcinoma clinically 
marking the progression. If moderate levels of physical activity have a protective effect, 
inverse associations in published studies between regular engagement and the 
development of all three diseases would be anticipated. Similarly, if vigorous exercise, 
particularly though occupation, is hazardous; then consistent positive associations would 
be found. Therefore, the aim was to review the reported associations between physical 
activity and GORD, Barrett’s oesophagus and oesophageal adenocarcinoma in the 
published literature. 
 
1.2.3 Methods 
 
Eligibility criteria 
Original investigations with an analytical design and control group (i.e. randomised 
controlled trials (RCTs), cohort and case-control studies) that examined levels of physical 
activity (occupational and/or recreational) and the incidence of GORD, Barrett’s 
oesophagus and oesophageal adenocarcinoma were selected. Only studies which 
described both the method of measuring physical activity (e.g. questionnaire) and its 
quantification (e.g. ≥30mins of recreational exercise/day) were included. The 
measurement of the disease outcome needed to be clearly stated (e.g. endoscopic and 
histological confirmation). Furthermore, only studies which specifically investigated 
oesophageal adenocarcinoma as a distinct histological subtype were included.  
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Search strategy 
A literature search of PUBMED, EMBASE, MEDLINE and CINAHL (from commencement to 
25th March 2017) was conducted using the terms: “exercise”,  “activity”,  “physical”, 
“occupational”, “recreational”, “Barrett's”, “oesophagus”, “oesophageal”, 
“adenocarcinoma”, “cancer”, “carcinoma”, “GORD”, “heartburn”, “reflux”, “acid”, “bile”, 
“gastro-oesophageal”, “oesophagitis”, “oesophageal inflammation”.  An independent 
search of each disease was undertaken using both English and American (e.g. GERD, 
esophagus) spellings. The reference lists of all selected articles, as well as reviews, were 
also searched to identify other relevant papers.  
 
Data synthesis and statistical analysis 
A total of 7 studies were included in this review (2 cohort, 5 case-control). No RCTs were 
identified. Data was extracted from each study (table 1.1). For a meta-analysis of GORD, 
Review Manager (RevMan) Version 5.3 (The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014) was used to calculate a summary effect using the inverse variance 
method, based on the odds ratios (ORs) and upper and lower boundaries of the 
confidence intervals (CIs) in the included studies. Due to variations in the type, duration 
and intensity of recreational physical activity between studies, a random effects model 
was applied to estimate the mean of a distribution of effects.  Only a single study in 
Barrett’s oesophagus was identified. For oesophageal adenocarcinoma, there was 
significant heterogeneity in the measurement of exposures (either recreational 4 or 
occupational activity80 or a combination of both).81 Therefore, meta-analyses were not 
appropriate for these two diseases. 
 
1.2.4 Results  
 
Physical activity and the development of GORD 
The search terms identified 1 426 potentially relevant articles, which were screened by 
title; with inclusion of 66. After removal of duplicates, 6 were included by abstract. Of 
these, 3 were excluded by full paper review according to the inclusion criteri a. One paper 
was identified from the reference lists, but later excluded after full review. In total, 3 
papers were included and the characteristics are shown in table 1.1. All 3 were case-
control studies with a total of 10 200 symptomatic cases of GORD identified among            
78 034 participants. The largest case-control study was of 43 363 men and women aged 
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≥20 years from a single county in Norway. In this study, physical activity levels were 
measured with a questionnaire and divided into 4 categories according to the number of  
30 min recreational exercise sessions engaged in per week (none, <1/week, 1-3/week and 
>3/week). GORD was defined as self-reported ‘severe and recurrent heartburn or 
regurgitation during the previous 12 months’. The authors reported an OR of 0.50 (95% 
CI 0.40-0.70) for 30mins/week vs none and development of GORD,69 but a lesser 
association with exercise levels above this, OR 0.70 (95% CI 0.60-0.90) for >90mins vs. 
none. The second largest study was of 27 717 monozygotic twins aged 42-104 years 
recruited from the Swedish Twin Registry. Both recreational and occupational activities 
were measured by questionnaire and divided into 4 categories. The highest recreational 
physical activity category was defined as ‘much’, the lowest as ‘almost no’. GORD 
symptoms were assessed by questionnaire. The authors reported an OR of 0.60 (95% CI 
0.47-0.77) for men (highest vs. lowest levels of recreational physical activity and GORD 
symptoms) and 0.56 (95% CI 0.41-0.75) for women, with a dose-dependent trend, 
p=0.002 and p=0.001, respectively.82 No associations were found for high vs. low levels of 
occupational activity for either men, OR 1.23 (95% CI 0.99-1.53), or women, OR 1.16 (95% 
CI 0.78-1.72). The smallest study was of 6 954 German men and women aged 18-79 years 
recruited by national survey. Only sports activities were measured and categorised as: 
none, ≤2hrs/week and >2hrs/week. GORD was established by self-reported questionnaire 
on symptoms of heartburn or regurgitation. The authors reported an OR of 0.75 (95% CI 
0.60-0.93) for sports activity of >2hrs/week vs. no sports.83 All studies adjusted for known 
covariates (age, gender), but also for unestablished risk factors (e.g. education, coffee 
consumption and intake of salt, dietary fibre and bread). All adjusted for BMI, and by 
doing so they assumed that physical activity has an independent effect that does not rely 
on a reciprocal change in BMI. None conducted an unadjusted BMI analysis to assess the 
effect of physical activity via the regulation or reduction of BMI (the BMI mediated e ffect). 
In a meta-analysis, the estimated mean effects of the 3 studies produced an OR of 0.67 
(95% CI 0.57-0.78) for the highest vs lowest levels of physical activity and the risk of GORD 
(figure 1.9). Statistical heterogeneity was low (I2 = 39%).  
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Figure 1.10 Forest plot of the association between high vs. low levels of recreational physical activity (PA) and the risk of GORD 
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The findings from this meta-analysis suggests that higher levels of physical activity may 
reduce the risk of GORD by a third. However, there are several potential sources of bias 
which should be considered when interpreting the result. None of the three studies used 
a validated questionnaire to measure physical activity, which may represent a source of 
measurement error, reducing any associations towards the null. Furthermore, the specific 
types of physical activities (e.g. cycling, swimming, running) were not analysed in any of 
the studies. Instead, all were grouped together and categorised according to duration 
(e.g. ‘physical activity of at least 30mins’ or ‘sports ≤2hrs/week’). This may suffice to 
explore the cardiometabolic benefits of physical activity, but in the context of reflux 
disease; where specific activities or intensities might increase risk, such categorisation 
may confound associations. Not accounting for occupational activity is a further potential 
source of error as it is likely to be an important confounder, particularly in the case of 
heavy manual work, which may involve intra-abdominal straining. However, only one of 
the studies undertook a separate analysis of both occupational and recreational 
activities,82 where the risk of GORD did appear to be increased in strenuous occupations, 
OR 1.23 (95% CI 0.99-1.53 - most physically strenuous vs. sedentary), although 
conventional statistical significance was not demonstrated, ptrend = 0.055. Use of a 
validated questionnaire to measure GORD was used in two studies,69 82 but none, by the 
nature of their retrospective designs, measured exposure prior to disease onset. This may 
be a significant source of measurement bias (if cases reduced their exercise levels due to 
reflux symptoms and exercise was measured during their symptomatic period). Finally, 
the study of monozygotic same sex twins represents a select population, and although 
participants were specifically chosen to examine the genetic influences of GORD, the 
generalisability of these findings is limited. 
 
Summary of findings: There is limited observational evidence that engaging in any 
recreational physical activity may reduce the risk of GORD by up to a third. However, to 
clarify such associations, a large and well-designed prospective cohort study, where 
exposure is accurately measured prior to disease onset, is required. The specific effect of 
occupational physical activities is uncertain as there is only one study, highlighting the 
need for further investigations. 
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Physical activity and the development of Barrett’s oesophagus 
Sixty seven potentially relevant articles were screened by title and 10 were suitable for 
abstract review. After removal of duplicates and screening by abstract, only 1 remained, 
which was included by full paper review. This was a case-control investigation of 307 cases 
of Barrett’s oesophagus and 1724 controls. The participants were US war veterans (men 
and women) aged 40-80 years recruited by a screening and surveillance endoscopy 
programme in Texas, USA. One hundred and six (35%) of the cases were known to have 
Barrett’s oesophagus prior to recruitment. The exposure was measured using the 
International Physical Activity Questionnaire (IPAQ), which asks about the previous 7 days 
recreational exercise (occupational exercise was not measured). Cases were confirmed 
both endoscopically and histologically. The authors reported no association between the 
highest vs. lowest levels of physical activity and odds of Barrett’s oesophagus (OR = 1.19, 
95% CI 0.82-1.73).84 The statistical model used in the study adjusted for age, sex, race, 
GORD symptoms, Helicobacter pylori infection status (which may reduce risk if positive), 
BMI and high waist to hip ratio (WHR).  
 
Although IPAQ is a validated physical activity questionnaire, its use in this study 
population (to measure lifelong physical activity exposure) may introduce significant 
measurement error. This is because war veterans are likely to have engaged in high levels 
of physical activity during their military service, which would not be reflected in their 
previous 7 days post-retirement activities as measured by IPAQ.  Measurement bias is also 
likely to occur in the 106 surveillance cases of Barrett’s disease who may have changed 
their physical activity levels due to symptoms. Therefore, physical activity would have 
been inappropriately measured during the symptomatic period, or after disease onset. 
The authors also adjusted for GORD and BMI/WHR which lie along the presumed causal 
pathway (figure 1.10). If we assume that the protective effect of exercise is largely by 
regulation of weight and reduction of reflux risk (a reasonable assumption) then 
controlling on these variables is likely to reduce any association between physical activity 
and Barrett’s oesophagus towards the null. Collinearity between BMI and WHR is also 
likely to be high, yet the authors adjusted for both in the same model. Finally, the study 
sample (US war veterans) is unlikely to be representative of the general population. 
Overall, the findings of this study are difficult to interpret and definitive conclusions about 
physical activity and Barrett’s oesophagus risk are unable to be made based on its results.  
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Summary of findings: There is insufficient evidence to define the association between 
physical activity and Barrett’s oesophagus. Evidence from large and well -designed 
prospective cohort studies are needed, which use an accurate and validated measure of 
both recreational and occupational physical activity prior to disease onset.     
 
 
The blackline represents a potential independent pathway which does not rely on modification of 
BMI (e.g. by decreasing inflammation or improving insulin sensitivity). 
 
 
Physical activity and the development of oesophageal adenocarcinoma 
Five hundred and seventy three potentially relevant articles were screened by title with 
inclusion of 49. After removal of duplicates, 17 were included by abstract. Of these, 14 
were excluded by full paper review according to the inclusion criteria. Two papers were 
included by reference lists but later excluded after full review. In total, 3 papers were 
included in this review (2 large prospective cohort studies4 81 and one case-control study)80 
and the characteristics are shown in table 1.1. A total of 666 cases of oesophageal 
adenocarcinoma were identified among 989 046 participants. The largest prospective 
cohort study investigated men and women aged 50-71 years recruited from the general 
population by postal questionnaire in the US.31  Only recreational physical activity was 
measured (by questionnaire) and categorised into 5 levels based on the number of 
sessions lasting ≥20mins/week (0, <1, 1-2, 3-4, ≥5). Disease outcome was confirmed using 
cancer registry data. The authors reported a RR of 0.68 (95% CI 0.48-0.96) for recreational 
physical activity of ≥5 sessions/week vs. none, with a dose-dependent trend (p=0.007). 
There was some attenuation of the effect size when BMI was added to the model; 
OR=0.75 (95% CI 0.53-1.06).  The second largest cohort study identified men and women 
aged 25-70 years from 9 European countries recruited by postal questionnaire.33 Exposure 
Figure 1.11 A simplified diagram of the proposed causal  pathway for physical activity in the aetiology 
of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma.  
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was measured using a questionnaire for both recreational and occupational physical 
activities, which was combined into a 4-level physical activity index: inactive, moderately 
inactive, moderately active and active. Confirmation of cases was largely confirmed by a 
panel of pathologists, but also from cancer registry data. This study reported a HR of 0.98 
(95% CI 0.48-2.01) for the highest levels of occupational and recreational physical activity 
vs the lowest. Finally, the case-control study was of US men and women aged between 
30-74 years identified from a cancer surveillance programme. 80 Only occupational 
physical activity was measured and based on job title. Case confirmation was by using 
cancer surveillance data. The authors reported an OR of 0.67 (95% CI 0.38-1.19, p trend 
=0.07), for the highest vs lowest physically active occupations. All 3 studies adjusted for 
known confounders (age, gender, smoking status), but also for unconfirmed potential risk 
factors (e.g. education, fruit and vegetable intake). All 3 adjusted for BMI, but only one 
included results of a multivariable model excluding BMI. 31 
 
Whilst the largest prospective study31 (374 cases) measured leisure time activity, the 
specific types of exercise were not defined. Furthermore, occupational activity was not 
measured or adjusted for as a potential confounder. Nonetheless, the estimated RR of 
0.68 (95% CI 0.48-0.96) (unadjusted for BMI) likely represents the least biased estimate 
of effect size currently in the literature for recreational physical activity and the risk of 
oesophageal adenocarcinoma. The second largest study33 used a validated questionnaire 
to measure physical activity, but both recreational and occupational activities were 
combined to produce a physical activity index (ranging from inactive to active) and were 
not reported separately. Therefore, all groups contained a heterogeneous population in 
terms of the types of physical activity they engaged in. The reported HR for the active vs. 
inactive category of 0.98 (95% CI 0.48-2.01) may represent the dilution of any potential 
protective effect of recreational exercise by the hazardous effect of heavy manual work. 
The number of cases (n=80) was also relatively small resulting in statistical imprecision of 
the effect size. The case-control study80 measured physical activity identified by job title 
from which an index was created based on the levels of activity associated with each job 
(from sedentary to highly active). Jobs with high levels of exertion may involve bending 
and lifting which could increase the risk of reflux disease, particularly if done post-
prandially. This was not accounted for in the study, but rather all high energy expenditure 
jobs were categorised together without any distinction. Furthermore, recreational 
exercise was not measured and therefore could not be included in the statistical model.   
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Summary of findings: There is a limited evidence from a large prospective cohort study 
that recreational physical activity of at least 100mins every week vs. no activity may 
reduce the risk of oesophageal adenocarcinoma by up to 32%.  
 
1.2.5 Discussion 
 
This review shows there is some evidence, although limited, that increasing levels of 
recreational physical activity may be associated with a reduced risk of GORD and 
oesophageal cancer.  However, the type, duration and intensity of recreational exercise 
that may be protective is poorly defined. Whilst there are no other reviews on physical 
activity and risk of GORD and Barrett’s oesophagus, there have been several for 
oesophageal adenocacinoma.85-88 All estimated a pooled risk reduction for the highest vs. 
lowest levels of physical activity of between 21-52%.85-88 However, pooling of 
observational data from different study designs is methodologically questionable,89 
particularly when some examined different exposures (occupational or recreational 
activity). Case-control studies, by virtue of their design, also have inherent selection and 
recall biases which may give erroneous findings. The only review to investigate one type 
of activity (recreational) and pool data only from prospective cohorts studies reported a 
HR of 0.58 (95% CI 0.37-0.89) for high vs. low levels of physical activity and the risk of 
oesophageal adenocarcinoma.85 The authors also included a BMI adjusted HR estimate of 
0.62 (95% CI 0.40-0.97), suggesting that physical activity has a mostly non-BMI mediated 
effect as the magnitude of the effect size was not markedly affected. However, pooling of 
data from different cohort studies, particularly where the measurements of physical 
activity differ introduces potential error. 
 
An important point to consider when investigating associations between physical activity 
and the risk of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma is the 
complex interplay which likely occurs between levels of physical activity, diet and BMI. 
People who engage in higher levels of recreational physical activity would be expected to 
eat a healthier diet and avoid high levels of alcohol consumption. These factors may 
therefore confound any associations with physical activity and disease risk. However, 
although dietary modification is often recommended to control symptoms of GORD,90 it 
is currently unknown from the literature whether specific dietary components are 
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involved in the aetiology.91 A comprehensive review of published epidemiological studies 
(case-series, cross-sectional and case-control studies) did not support a role for diet 
(including fatty foods, chocolate, fruit and vegetables) in the development of symptoms 
of GORD.91 However, in the absence of prospective cohort data, where diet is measured 
prior to disease onset, results could be subject to recall bias.  For Barrett’s oesophagus 
and oesophageal adenocarcinoma, a review has suggested that a diet low in fruit and 
vegetable intake may represent a modest risk factor for both diseases.16 This is based on 
evidence from case-control studies that an increased intake of fruit, 45 plant-based fibre 
46 47 and vegetables 48 was inversely associated with disease risk. However, spurious over-
estimation of the effect sizes due to recall bias in those with disease may explain these 
findings, which are derived from retrospective investigations. Alcohol does not seem to 
have an important role in the aetiology of all three disease states. Large case -control 
studies found no associations between alcohol intake and the risk of GORD. 69 82 Consistent 
with these findings, a review of population-based case-control studies reported no overall 
effect of alcohol consumption on the development of Barrett’s oesophagus or 
oesophageal adenocarcinoma, although the methodological weaknesses of case-control 
studies in terms of selection and information biases were noted.49 Large prospective 
cohort studies are now required to examine dietary intake prior to disease onset, which 
would reduce the effects of reverse causation bias (i.e., patients are more likely to avoid 
foods which they feel exacerbate their symptoms or eat foods which alleviate them). As 
there are no consistent associations documented between any specific dietary factors and 
the risk of GORD, Barrett’s oesophagus or oesophageal adenocarcinoma, it is reasonable 
not to currently include dietary intake in statistical modelling. However, emerging data in 
the future from prospective studies may show this is required. For BMI, the 
epidemiological evidence does support a positive correlation between being overweight 
and disease risk, which was discussed in the previous section (1.1.3). BMI is therefore an 
established risk factor, which should be measured and analysed when considering 
physical activity and the risk of all three disease states. An approach to this would be to 
provide both BMI adjusted and unadjusted values when estimating the effect size of 
physical activity on disease risk, as this would clarify whether the effect of physical activity 
is mediated through BMI.  
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In conclusion, this review is the first to examine the associations between physical activity 
and the risk of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma. All three 
disease states were included in this review as consistent associations (in a disease which  
occurs in sequence) would provide supportive evidence for causality. The evidence from 
biological and epidemiological studies does suggest a potential protective eff ect of 
moderate levels of recreational physical activity on the risk of GORD and oesophageal 
adenocarcinoma, but there is insufficient data for an assessment for Barrett’s 
oesophagus, highlighting an absence in the literature. An inverse association between 
increased recreational activity with both GORD and oesophageal adenocarcinoma does 
provide some credibility to a causal association, but the evidence should be interpreted 
with caution as it is mainly derived from case-control investigations. As discussed in the 
previous section (1.1.5), the association between physical activity and risk of oesophageal 
adenocarcinoma is likely to be non-linear, where both low and very high levels of 
recreational activity may increase risk, but moderate levels decrease risk (figure 1.11).  
 
 
 
 
 
 
 
 
Figure 1.12  A graph of the proposed U-shaped association between levels of physical activity and the 
risk of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma. 
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However, the potentially hazardous effect of high intensity recreational exercise, or heavy 
manual occupations; particularly those that raise intra-gastric pressure, has not been fully 
investigated in epidemiological studies. In fact, only one of the studies in this review 
considered a possible differential effect of occupational and recreational activities, which 
suggested that vigorous work may indeed increase GORD risk.82 However, further large 
prospective studies are required investigating the type, duration and intensity of 
recreational and occupational physical activity that may be protective or hazardous. If 
these find consistent inverse associations with the development of GORD, Barrett’s 
oesophagus and oesophageal adenocarcinoma, physical activity could be included in the 
aetiological model and may offer a public health intervention to reduce the rising 
epidemic of oesophageal adenocarcinoma. 
 
The absence of prospective data investigating the associations between recreational and 
occupational physical activity and the risk of Barrett’s oesophagus, the precursor lesion of 
oesophageal adenocarcinoma, is addressed in the next section in a large prospective 
cohort study (EPIC-Norfolk). 
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     Table 1.1 Characteristics of the included studies (Does physical activity influence the development of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma? A review of the literature) 
 
 
First author and 
year of 
publication  
Study 
design 
Study sample Validated 
exposure 
measure? 
Quantification of 
physical activity 
Outcome measure Validated 
outcome 
measure? 
Cases 
(n) 
Adjusted 
variables in 
statistical model 
Effect size (95% CIs) 
GORD 
Ni lsson, 2004 20 Case-
control   
Men and women aged ≥20 
years  from a single county in 
Norway recruited by postal 
questionnaire (n=43 363) 
No Recreational physical 
activi ty of at least 
30mins  duration. 
Categorised as: never, 
<1/week, 1-3/week and 
>3/week 
Sel f-reported 
questionnaire of 
severe and recurrent 
heartburn or 
regurgi tation during 
the past 12 months 
Yes  3 153 Age, gender, BMI, 
smoking and 
intake of coffee, 
sa lt, dietary fibre 
and bread  
OR for highest vs  lowest 
level of  physical activi ty  
=0.70 (0.60-0.90) 
Zheng,  
2007 37 
Case-
control   
Monozygotic same sex twins 
aged between 42-104 years 
recrui ted from the Swedish 
Twin Registry by postal 
questionnaire (n=27 717) 
No Ordinal scale from 1-4 
for both occupational 
and recreational 
phys ical activi ty 
separately.  
Occupational = 
sedentary, walking, 
l i fting, strenuous.  
Recreational = a lmost 
no, l i ttle, medium and 
much 
Questionnaire 
del ivered by 
telephone interview  
Yes  4 083 Age, BMI, 
smoking, coffee 
intake and  
education  
OR for highest vs . lowest 
recreational physical 
activi ty in men = 0.60 
(0.47-0.77). In women = 
0.56 (0.41-0.75).  OR for 
highest vs . lowest 
occupational physical 
activi ty in men= 1.23 
(0.99-1.53). In women= 
1.16 (0.78-1.72) 
Nocon,  
2006 38 
Case-
control  
Men and women aged 18-79 
years  in Germany recruited 
by national survey (n=6 954) 
No Recreational sports 
only. Categorised as 
none, ≤2hrs/week or >2 
hrs/week 
Sel f-reported 
heartburn or acid 
regurgi tation. 
Categorised as no, 
mi ld, moderate and 
severe  
No 2 964 Age, gender, BMI, 
smoking, alcohol 
and 12 nutri tional 
factors  
OR for highest vs  lowest 
level of sport =0.75 
(0..60-0.93) 
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First author 
and year of 
publication  
Study design Study sample 
Validated 
exposure 
measure 
Quantification of physical 
activity 
Outcome 
measure 
Validated 
outcome 
measure? 
Cases (n) 
Adjusted variables 
in statistical model 
Effect size (95% 
CIs) 
Barrett’s oesophagus 
Hi lal,  
2015 39 
Case-control  Men and women 
aged 40-80 years in 
Texas USA 
attending a  Veteran 
Affa i rs Medical 
Centre for an 
elective endoscopy  
(n=2 172) 
Yes  Recreational levels of physical 
activi ty categorised as low, 
moderate or high. Moderate is 
defined as 150mins moderate or 
<75 mins vigorous 
exercise/week. Low =<moderate. 
High=>moderate 
Endoscopic 
and 
his tological 
appearance 
cons istent 
with Barrett’s 
oesophagus 
Yes  323 Age, gender, race, 
GORD symptoms, 
H.pylori infection 
s tatus, BMI and 
high WHR  
OR for highest vs  
lowest level of  
phys ical activi ty  
=1.19 (0.82-1.73) 
Table 1.1 continued 
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First author 
and year of 
publication  
Study design Study sample 
Validated 
exposure 
measure 
Quantification of physical 
activity 
Outcome 
measure 
Validated 
outcome 
measure? 
Cases (n) 
Adjusted variables 
in statistical model 
Effect size (95% 
CIs) 
Oesophageal adenocarcinoma 
Lei tzmann, 
2009 34 
Prospective 
cohort 
US men and women 
aged between 50-
71 years . Recruited 
from the general 
population by a  
postal 
questionnaire 
(n=487 732) 
No 5 categories according to the  
number of moderate 
recreational physical activity 
sessions lasting ≥20 minutes 
(0,<1,1-2,3-4,≥5 
Cancer registry  n/a  374 Age, gender, race, 
smoking, alcohol,  
education, marital 
s tatus, family 
his tory of cancer, 
intake of fruit, 
vegetables and red 
meat (+/- BMI) 
RR for highest vs . 
lowest  physical 
activi ty  
category=0.68 
(0.48-0.96) 
(unadjusted for 
BMI) 
Huerta ,  
2010 36 
Prospective 
cohort 
Men and women 
from 9 European 
countries aged 25-
70 years . Recruited 
from general 
population by 
postal 
questionnaire 
(n=420 449) 
Yes  A va l idated physical activity 
index of four ordinal categories 
combining both occupational 
and recreational levels of  
phys ical activi ty  (inactive, mod 
inactive, mod active, active) 
Confi rmed by 
a  panel of 
pathologists 
(69%), 
pathology 
reports  (15%) 
and cancer 
registry (16%) 
n/a  80 Age, gender, height, 
weight, education, 
smoking, alcohol, 
energy intake, fruit, 
red meat and 
processed meat 
intake 
HR for highest vs . 
lowest category = 
0.98 (0.48-2.01) 
Vigen,  
2005 35 
Case-control US men and women 
aged 30-74 years 
identified by a  
cancer surveillance 
programme. 
Controls were 
matched based on 
gender, race, date 
of bi rth and 
res idence 
(n=2 195) 
No A Tota l Activity Index calculated 
by multiplying the number of 
years  worked in a  sedentary (0), 
moderate (1) or highly active (2) 
job over a  l ifetime 
Cancer 
surveillance 
programme 
data  
n/a  212 Age, gender, race, 
smoking status,  
education, 
bi rthplace and BMI 
OR for highest vs  
lowest category = 
0.67 (0.38-1.19) 
Table 1.1 continued 
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1.3 The association between physical activity and the risk of  
symptomatic Barrett’s oesophagus - a UK prospective cohort study 
(EPIC-Norfolk) 
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1.3.1 Abstract 
 
Background: Physical activity affects the functioning of the gastrointestinal system 
through both local and systemic effects and may play an important role in the aetiology 
of GORD, Barrett’s oesophagus and oesophageal adenocarcinoma; the so called 
metaplasia-dysplasia-carcinoma sequence. For the first time, in a large prospective cohort 
study, this study examined associations between recreational and occupational levels of 
physical activity and the incidence of Barrett’s oesophagus, the precursor lesion of 
oesophageal adenocarcinoma.   
 
Methods: EPIC–Norfolk recruited 30 445 men and women between 1993 and 1997. 
Occupational and recreational levels of physical activity were measured using a baseline 
questionnaire. The cohort was followed up until 2015 to identify symptomatic cases of 
Barrett’s oesophagus. Cox proportional hazard regression estimated hazard ratios (HR) 
for physical activity (occupational and recreational separately) and the risk of developing 
disease.  
 
Results: Two hundred and three participants developed Barrett’s oesophagus (mean age 
70.6 years) the majority of whom were male (70.9%).  There was an inverse association 
between standing occupations and disease risk when compared to sedentary jobs (HR 
0.50, 95% CI 0.31-0.82, p=0.006).  Heavy manual occupations were positively associated 
with disease risk (HR 1.66, 95% CI 0.91-3.00), but conventional statistical significance was 
not reached (p=0.09). No associations were found between recreational activity and the 
risk of Barrett’s oesophagus (HR 1.34, 95% CI 0.72-2.50, p=0.35, highest vs. lowest levels 
of activity).   
 
Conclusion: This study suggests that occupational levels of physical activity may be 
associated with the risk of Barrett’s oesophagus. However, further aetiological work in 
other populations is required to confirm and describe specific occupations which may be 
protective or indeed hazardous.  
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1.3.2 Introduction 
 
Physical activity affects gastric emptying,57 intra-gastric pressure,56 systemic 
inflammation,70 and the regulation of body weight64 and may play an important role in the 
metaplasia-dysplasia-carcinoma sequence. As described in the previous section of this 
thesis (1.2), several epidemiological studies have examined associations between physical 
activity and the risk of both GORD69 82 83 and oesophageal adenocarcinoma,4 80 81 and 
reported a potential protective role for recreational physical activity in the risk of both 
diseases. The evidence for occupational activity from these studies was inconsistent. 80 82 
To date, only one study (case-control) has investigated Barrett’s oesophagus and reported 
no association between recreational exercise and disease risk (occupational activity was 
not measured). 84  The aim of this study was to investigate, for the first time in a 
prospective cohort study, the relationship between both occupational and recreational 
levels of physical activity and the incidence of Barrett’s oesophagus.  
 
1.3.3 Methods 
 
Recruitment and measurement of exposure 
The European Prospective Investigation of Cancer (EPIC-Norfolk) study92 recruited 30 445 
men and women, aged 39 to 79 years, between the years 1993 and 1997, who were 
identified from 35 general practices across the county of Norfolk in the United Kingdom 
(EPIC-Norfolk is part of the wider EPIC study, one of the largest cohort studies in the world, 
with more than half a million (521 000) participants recruited across 10 European 
countries). At baseline, participants completed a questionnaire documenting their health 
and lifestyle including both occupational and recreational levels of physical activity. The 
physical activity component contained questions relating to participants’ physical 
activities over the previous 12 months both at work and at home (appendix 1). For 
occupational activity, participants were asked to choose one of four categories which best 
described the physical demands of their job (sedentary, standing occupation, manual 
work or heavy manual work). In a validation study; this simple four-level occupational 
classification was strongly associated with objective measures of daytime energy 
expenditure (Ptrend <0.001).93 Recreational activity was measured during both winter and 
summer months by asking how many hours participants typically spent per week during 
the last year participating in: walking, cycling, gardening, housework, do-it-yourself (DIY) 
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and other forms of physical exercise (e.g. aerobics, swimming, jogging). A four category 
recreational index was derived based on the average number of hours per week that 
participants engaged in cycling or other recreational physical activity (0, <3.5, <7 and >7 
hrs/week). Anthropometric measurements including height and weight were recorded at 
baseline health-check visits, conducted between 1993 and 1998. The EPIC-Norfolk study 
was approved by the Norwich District Health Authority Ethics Committee and all 
participants provided their written consent for involvement. 
 
 
 
Figure 1.13 A map showing the boundary l i ne for the county of Norfolk in East Anglia.  
 
Image from www.maps-of-britain.co.uk/map-of-norfolk.html [accessed on 24/10/2017]. 
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Figure 1.14 Photograph of London Street, Norwich in Norfolk. The spire of Norwich Cathedral can 
be seen in the distance.  
 
Image from http://www.tournorfolk.co.uk/shopsnorwich.html  [accessed on 24/10/2017]. 
 
Follow-up and identification of cases 
After recruitment, the cohort was followed up to June 2015 to identify participants 
subsequently diagnosed with Barrett’s oesophagus detected due to reflux symptoms. 
Cases were identified by linking the EPIC-Norfolk database with the Norfolk and Norwich 
Hospital histology database, with all potential cases verified by review of the ir medical 
notes. To be included, cases had to meet the diagnostic criteria as defined by the British 
Society of Gastroenterology,33 i.e., required both endoscopic characteristics of Barrett’s 
oesophagus of ≥1cm and histological confirmation of metaplasia.  The medical notes of 
all potential cases were reviewed to exclude participants with prevalent Barrett’s 
oesophagus at recruitment. To ensure the physical activity levels were more likely to  
represent pre-symptomatic levels, symptomatic Barrett’s oesophagus cases were 
excluded if diagnosed within 1 year of recruitment into EPIC-Norfolk. 
 
Statistical analysis 
Participants were followed up from study entry until the earliest date of: first diagnosis, 
death, or last data collection date (June 2015). Comparative analyses between cases and 
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controls were undertaken using Student t-tests for continuous, and X2 tests for categorical 
variables. In multivariable analyses, Cox proportional hazard regression models estimated 
hazards ratios (HRs), with 95% confidence intervals (CI), for associations between both 
recreational and occupational physical activity. The fully adjusted model contained the 
covariates: age, gender, smoking category (never, ex-smoker, current smoker) and alcohol 
intake (units/week). As it is unclear whether body mass index (BMI) lies along the causal 
pathway between physical activity and Barrett’s oesophagus (whether or not the effect 
of physical activity is by regulation of BMI) both BMI unadjusted and adjusted analyses 
were presented.   
 
1.3.4 Results 
 
Of 30 445 individuals aged between 39 and 79 years in EPIC-Norfolk, 24 110 (79.2%) had 
a record of physical activity, attended a base-line health check, had no previous cancer 
diagnosis, subsequent diagnosis of oesophageal adenocarcinoma or diagnosis of Barrett’s 
oesophagus within the first year of recruitment (figure 1.15). Follow-up ended a mean of 
17.6 years (SD 4.5) after cohort entry, totalling 424 336 person years. During the 
maximum follow-up of 22 years, 203 of 24 110 individuals (0.84%) developed reflux 
symptoms which led to referral for gastroscopy and diagnosis of Barrett’s oesophagus. 
The mean age at diagnosis was 70.6 years (± SD 9.3), and 70.9% were male. The median 
time of diagnosis after study enrolment was 12 years (interquartile range (IQR), 8 to 17 
years). The subtypes of metaplasia were documented as: intestinal (69.5%, n=141), gastric 
(9.9%, n=20), mosaic (9.9%, n=20), and non-specified in 10.8% (n=22). Dysplasia was 
present in 5% of cases. A hiatal hernia was present in 72% of participants. In the 
descriptive analyses, cases of Barrett’s oesophagus, compared to controls, were more 
likely to be male and older at the time of recruitment (table 1.2). They were also more 
likely to have formerly smoked and be overweight, with higher levels of alcohol 
consumption. Finally, a greater percentage of cases had either sedentary or heavy manual 
occupations.    
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Figure 1.15 Study flow chart (The association between physical activity and the risk of symptomatic 
Barrett’s oesophagus - a UK prospective cohort study). 
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Table 1.2 Comparative characteristics of cases and controls (The association 
between physical activity and the risk of symptomatic Barrett’s oesophagus - a UK 
prospective cohort study). 
 
Data shown are the number of patients and percentage unless otherwise stated. 
 
 
 
 
Variable Barrett’s 
oesophagus 
(n=203) 
Controls  
(n=23 907) 
P-value 
Age at recruitment 
(mean, years & SD) 
 
60.3 (±8.6) 
 
59.0 (±9.3) 
 
0.05 
 
Gender (male) 
 
144 (70.9) 
 
10 978 (45.9) 
 
<0.001 
 
Cigarette smoking 
Never 
Former 
Current 
Missing data 
 
 
66 (32.5) 
109 (53.7) 
26 (12.8) 
2 (1.0) 
 
 
10 938 (45.8) 
9 985 (41.8) 
2 781 (11.6) 
203 (0.8) 
 
 
<0.001 
0.001 
0.60 
0.83 
 
WHO BMI category (kg/m2) 
Underweight (<18.5) 
Normal weight (18.5 to <25) 
Overweight (25 to <30) 
Class I obesity (30 to <35) 
Class II obesity (35 to <40) 
Class III obesity (≥40) 
 
 
0 
65 (32.3) 
107 (52.7) 
25 (12.3) 
4 (2.0) 
2 (1.0) 
 
 
115 (0.5) 
9 293 (38.9) 
10 826 (45.3) 
2 935 (12.3) 
532 (2.2) 
206 (0.9) 
 
 
0.32 
0.05 
0.03 
0.98 
0.81 
0.85 
 
Alcohol 
(mean units/week & SD) 
Missing data  
 
 
9.8 (11.4) 
n=2 (1.0) 
 
 
7.2 (9.5) 
n=244 (1.0) 
 
 
0.001 
 
Occupational  activity 
Sedentary 
Standing 
Manual 
Heavy manual  
Unemployed 
 
Recreational activity 
None 
<3.5 hours 
3.5 to <7 hours 
>7 hours 
 
 
57 (28.1) 
24 (11.8) 
39 (19.2) 
14 (6.9) 
69 (34.0) 
 
 
116 (57.1) 
49 (24.1) 
22 (10.8) 
16 (7.9) 
 
 
6 362 (26.6) 
6 002 (25.1) 
4 161 (17.4) 
575 (2.4) 
6 807 (28.5) 
 
 
12 651(52.9) 
7 201 (30.1) 
2 591 (10.8) 
1 464 (6.1) 
 
 
0.64 
<0.001 
0.50 
<0.001 
0.08 
 
 
0.23 
0.06 
1.00 
0.30 
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In the adjusted Cox model for physical activity and the risk of Barrett’s oesophagus, there 
was a suggestion of a U-shaped association between levels of occupational activity and 
disease risk (table 1.3); with a decreased risk in participants with a standing vs sedentary 
occupation (HR 0.50, 95% CI 0.31-0.82, p=0.006) and an increased risk with heavy manual 
jobs, although conventional statistical significant was not reached (HR 1.66, 95% CI 0.91-
3.00, p=0.09). The effect sizes were not attenuated by adjustment for BMI. No 
associations were found for levels of recreational activity in either models; adjusted, or 
unadjusted, for BMI. In a sub-analysis of only the cases with intestinal metaplasia (n=141) 
the results remained similar to the findings for all types of metaplasia. In a model adjusted 
for: age, sex, smoking and levels of recreational activity the results for standing vs. 
sedentary occupations estimated a HR of 0.55, 95% CI 0.31-0.99, p=0.046. For heavy 
manual vs. sedentary occupations the HR was 1.78, 95% CI 0.87-3.61, p=0.11. 
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Table 1.3 Multivariable Hazard Ratios (HRs) for physical activity and the risk of 
symptomatic Barrett’s oesophagus. 
 HR (95% CI), P-value  
Type of physical activity Not BMI adjusted BMI adjusted 
Occupationala   
Sedentary Reference (1.00) Reference (1.00) 
Standing 0.50 (0.31-0.82), p=0.006 0.51 (0.31-0.83). p=0.006 
Manual 
Heavy manual  
0.91 (0.61-1.34), p=0.67 0.93 (0.61-1.40), p=0.71 
Heavy manual  1.66 (0.91-3.00), p=0.09 1.66 (0.92-3.02), p=0.09 
Recreationalb   
None/week Reference (1.00) Reference (1.00) 
<3.5 hours/week 0.84 (0.56-1.30), p=0.43 0.85 (0.56-1.30), p=0.46 
3.5 to <7 hours/week 0.98 (0.56-1.72), p=0.94 0.99 (0.57-1.75), p=0.98 
>7 hours/week 1.34 (0.72-2.50), p=0.35 1.36 (0.73-2.51), p=0.33 
Multivariable models were adjusted for age, gender, smoking status and alcohol 
consumption +/- BMI. aAdditional adjustment for recreational activity. bAdditional 
adjustment for occupational activity.  
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1.3.5 Discussion 
 
This is the first prospective cohort study to investigate associations between levels of 
physical activity and the development of Barrett’s oesophagus. Although there were no 
associations with recreational activity, a possible U-shaped association between levels of 
occupational activity and disease risk was found. There are biologically plausible 
mechanisms how such an association could exist which were discussed in detail in the 
previous section of this thesis (1.1.4). In brief, low to moderate levels of physical activity 
in standing occupations, which involve frequent walking, may protect against GORD by 
helping to maintain a normal body weight,64 thus preventing obesity induced reflux 
disease 65 (central adiposity increasing intra-gastric pressure, creating a gastro-
oesophageal reflux gradient and hiatus hernia formation). 66-68 Low intensity exercise such 
as walking also increases gastric emptying and may therefore decrease reflux episodes.57 
Finally, regular physical activity reduces inflammatory biomarker expression, and thus 
may prevent the inflammation-driven metaplastic process involved in the aetiology of 
Barrett’s oesophagus. 70-73 Alternatively, heavy manual occupations may involve both 
bending and heavy lifting, increasing intra-abdominal pressure and forcing gastric 
contents retrograde, beyond the lower oesophageal sphincter into the oesophagus. 56 
Activity at work is also likely to occur post-prandially, when reflux episodes are most 
likely.60  
 
The finding of no association between recreational physical activity and the risk of 
Barrett’s oesophagus is consistent with the only other epidemiological study (a case-
control investigation of 307 cases of Barrett’s oesophagus and 1724 controls), where the 
authors reported no association between the highest vs. lowest levels of physical activity 
and odds of Barrett’s oesophagus (OR = 1.19, 95% CI 0.82-1.73).84 Limitations of that study 
included the potential for both measurement error and bias in their assessment of 
exposure through the use of a 7-day exercise questionnaire in patients who had already 
developed the disease of interest. A further potential limitation was adjustment for 
GORD, BMI and WHR, which lie along the presumed causal pathway and would therefore 
be likely to reduce any association between physical activity and Barrett’s oesophagus 
towards the null. The findings of their study are difficult to interpret and definitive 
conclusions about physical activity and Barrett’s oesophagus risk are unable to be made 
based on its evidence.  
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The strengths of this study include; its prospective design, which minimised both selection 
and recall biases; adjustment in the analyses for potential confounders; confirmation of 
all incident cases of Barrett’s oesophagus by medical note review; and a long follow-up 
period of up to 22 years. Follow-up bias was minimised by studying a cohort that was 
geographically stable, with 94.6% of participants still living in the county of Norfolk 20 
years after recruitment.  As this is a large population based-study, the findings are also 
generalisable, with inclusion of both men and women from: rural, suburban and inner city 
areas. However, exclusion of participants from larger UK urban areas such as London and 
Manchester may limit the UK-wide generalisability of the findings. Nonetheless, the case 
numbers are similar to larger UK cohorts. Cohort data derived from primary care 
databases in the UK reported 12 312 Barrett’s oesophagus cases among 6 885 420 people 
(0.18%) aged ≥18 years 94, compared to the 0.84% found in this study. The higher figure 
in this study likely reflects an older population (aged 39-79 years). Finally, by measuring 
both occupational and recreational activity, an estimate of the differential effects of both 
could be undertaken. A study limitation was the inability to identify participants with 
asymptomatic Barrett’s oesophagus in the cohort. Including only symptomatic disease, 
diagnosed by oesophagogastroduodenoscopy (OGD), may identify as little as 55% of all 
cases within a population. 40 Nevertheless, it would be expected that misclassification of 
asymptomatic Barrett’s oesophagus cases (as non-cases) would be non-differentially 
distributed between physical activity categories and therefore draw associations to the 
null. The only way to identify all cases of Barrett’s oesophagus within a population would 
be by screening with gastroscopy, which is unfeasible in large studies.  A further potential 
limitation was the use of a questionnaire measure of physical activity, rather than an 
objective physiological variable. Questionnaires are a pragmatic necessity of measuring 
physical activity in large population studies and although measurement error could arise 
it would again reduce the magnitude of the effect size of any association, rather than 
inflate it.  
 
In summary, this study was the first to examine the associations between both 
occupational and recreational levels of physical activity and the risk of Barrett’s 
oesophagus.  The findings suggest that whilst differing levels of recreational exercise may 
not be associated with disease risk, occupational physical activity may be either protective 
(as in standing occupations), or possibly hazardous (as in heavy manual occupations). The 
public health importance of Barrett’s oesophagus lies in its association with oesophageal 
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adenocarcinoma.16 If further work is able to confirm specific occupations which may be 
hazardous then occupational physical activity would form an important component of the 
aetiological model for Barrett’s oesophagus and oesophageal cancer.  
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Chapter Two: Prehabilitation to reduce the risk of short-term 
complications after oesophagectomy 
Overview 
This thesis will now progress from investigating physical activity in the aetiology of 
oesophageal adenocarcinoma and explore whether short-term physical activity 
programmes could be used as a preoperative intervention to reduce the risk of 
complications after oesophageal adenocarcinoma resection surgery (oesophagectomy).  
 
Firstly, the adaptations of the human body to exercise training are discussed. 
 
Secondly, the pathophysiology of both the intraoperative and early postoperative periods 
are reviewed.  
 
Thirdly, the protective role of physical fitness in reducing post-oesophagectomy 
complications are discussed.  
 
Finally, the methodology and results of a feasibility single-blinded randomised control trial 
of prehabilitation prior to oesophagectomy for oesophageal adenocarcinoma are 
presented. Such a feasibility trial is required to both justify and inform a future multi-
centre randomised controlled trial of preoperative supervised hospital exercise to reduce 
postoperative complications. 
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2.1 A review of adaptations to physical activity training 
 
Physical activity is defined as “bodily movement produced by skeletal muscles that 
requires energy expenditure”.95 The ability to engage in prolonged physical activity is 
dependent on a series of integrated physiological events involving the heart, lungs and 
skeletal muscles, where the predominant goal is to transport oxygen from the 
environment to working muscle (figure 2.1). Regular physical activity training produces 
adaptations to both the musculoskeletal and cardiopulmonary systems to improve the 
body’s efficiency and capacity to utilise oxygen for exercise. For clarity, training is defined 
as regular physical activity which “exceeds the capacity for endurance in the untrained 
state, and therefore acts as a stimulus for change in an organism”.96  
 
Figure 2.1 Schematic showing the independent organ systems that contribute to the movement of 
gases to and from the environment to mitochondria.  
 
 
 
Adapted from Wasserman, et al. Principles of Exercise Testing and Interpretation.97 
 
 
 
 
 
 
 
 
Environment Muscle 
64 
 
2.1.1 Cardiovascular adaptations to training 
 
During exercise one of the primary functions of the cardiovascular system (the heart, 
blood vessels and blood) is to provide working muscle with oxygen. As work rate 
increases, oxygen uptake (VO2) increases linearly.98  Increasing oxygen demand is met by 
an increased cardiac output (Q), defined as the volume of blood in mls/min pumped from 
the left ventricle of the heart. Q is the product of (SV) stroke volume (volume of blood 
pumped per beat) x (HR) heart rate (number of heart beats/min). There is an almost linear 
response of Q to an increase in oxygen demand, with increasing work rate (figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Image from Physical Activity and Health: A Report of the Surgeon General, Centers for Disease 
Control and Prevention.98 
 
 
 
 
 
 
 
 
 
Figure 2.2 Graph showing the changes in cardiac output with increasing rates of work on a cycle 
ergometer.  
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In a study of college students, before and after bed rest, followed by a two-month training 
programme, 99 there was almost no change in the mean maximal heart rate after training, 
but an increase in SV and Q (figure 2.3).  
 
 
College students (n=5), Olympic athletes (n=6). Mean values are shown. bSignificantly different 
from the college students after training, p<0.05. Adapted from: Blomqvist et al. Cardiovascular 
adaptations to physical training. 99 
 
 
 
The comparatively lower maximal HR in Olympic athletes (who had significantly higher SV 
and Q), demonstrates adaptations to intense and longer-term training, where the heart is 
able to supply the body with much higher volumes of blood at a lower heart rate, which 
demonstrates greater cardiac efficiency. Laboratory work by Levine, et al, using direct 
invasive techniques, explored how higher SVs are achieved in elite athletes. They 
demonstrated that myocardial contractility was not markedly different between athletes 
and non-athletes. 98 However, the difference in SV between the groups was due to a larger 
end-diastolic volume in the athlete’s hearts: attributed to enhanced cardiac chamber 
compliance. The Starling mechanism predicts that an increased left ventricle filling 
pressure (end-diastolic pressure) increases SV.100 Training appears to result in a more 
compliant myocardium, capable of generating a greater Q through increased SV, rather 
than improved cardiac contractility, which is minimally affected by training. 101 Other 
changes due to training include an increase in capillary density of the ventricular 
myocardium, providing greater blood flood to the heart to support cardiac work and an 
increase in left ventricle cavity size and wall thickness. 98   
 
Figure 2.3 Cardiovascular and pulmonary functional capacities determined during maximal 
exercise in college students and Olympic athletes.  
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2.1.2 Respiratory adaptations to training 
 
The respiratory system also has the capacity to adapt to increased tissue oxygen demands 
through training, although in a less dramatic fashion than the heart. There is no marked 
lung parenchyma or airway differences between athletes and non-trained controls.102 
Rather, respiratory muscles improve in strength and endurance with training, just as other 
skeletal muscles do, allowing an increased ventilatory effort. 98 
 
2.1.3 Musculoskeletal adaptations to training 
 
Skeletal muscle mass increases with most types of physical activity, as does capillary 
density; which increases oxygen flow to working muscle.98 Training also produces large 
increases in both the volumes of mitochondria96 and oxidative enzymes in skeletal muscle 
tissue103, which improves adenosine triphosphate (ATP) availability (the energy source 
required for all muscle action).104 ATP is produced either in the presence of oxygen via the 
oxidative pathway or, in its absence, via the glycolytic pathway. Training has little or no 
effect on enzymes of the glycolytic pathway, but large and rapid effects on oxidative 
enzymes.103 The net result of these changes due to exercise is muscle which is larger in 
size with a greater blood flow and an increased capacity to produce ATP from oxygen.  
 
2.1.4 Adaptations summary 
 
Exercise training may improve the efficiency of oxygen delivery to active muscle tissue. 
This is mostly achieved through changes in the cardiovascular, respiratory and 
musculoskeletal systems. Improvements in cardiac output are achieved through an 
increase in myocardial compliance, while ventilatory effort is increased through greater 
respiratory muscle strength. Finally, muscle tissue develops a greater capacity to produce 
ATP, via an increase in capillary and mitochondrial densities.  
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2.2 A review of the pathophysiology of the postoperative period 
 
Surgery can be considered as controlled tissue trauma. As with any traumatic injury, of 
whatever size, a series of processes occur within the body that are evolved to evoke 
healing and ensure survival.105  In severe trauma, such as that induced by major surgery, 
a complex hyper-metabolic and hyper-inflammatory state is initiated, involving the 
secretion of catabolic hormones, inhibition of anabolic hormone effects and systemic 
inflammation.106  These processes are termed the ‘surgical stress response’, where the 
net effect is catabolism of stored body fuels including muscle protein; with an associated 
increase in oxygen consumption to meet metabolic needs - a state which persists for 
several days after an operation. 107 In the context of modern surgery this ‘stress response’ 
may be detrimental to the patient and be an underlying cause of postoperative 
complications. Anaesthesia and bedrest are also important factors which challenge 
normal body functions, particularly lung mechanics. The next section will discuss the 
effect of surgery and the perioperative period on the cardi ovascular, respiratory and 
musculoskeletal systems.  
 
2.2.1 Intraoperative and postoperative changes to the cardiovascular system 
 
Early observations in the 1950’s demonstrated that Q increases after surgery dependent 
on the severity of the operation, which is maximal at day one and returns to baseline 
levels by days 4-7 (in patients undergoing surgery without complications).108 The increases 
in Q reflects higher tissue oxygen demands. Oxygen consumption increases significantly 
up to 8 hours after surgery and may reach levels 1.5 times above a normal resting state 
(5ml/kg/min vs. 3ml/kg/min).109 Postoperative blood loss and systemic inflammatory 
vasodilation may threaten the ability of the cardiovascular system to maintain adequate 
pressure to meet this increased oxygen demand. In a volume depleted or hypotensive 
patient, splanchnic vasoconstriction maintains an adequate circulating volume, but 
increases the risk of gut ischaemia. As the myocardium has an almost complete 
dependence on aerobic metabolism it is vulnerable to damage if oxygen supply is not 
constant.98 A decreased end-diastolic volume through systemic inflammatory vasodilation 
requires an increased HR to maintain Q. This greater myocardial work increases the risk 
of myocardial ischaemia and infarction, particularly in patients with underlying coronary 
artery disease.  
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2.2.2 Intraoperative and postoperative changes to the respiratory system  
 
Functional Residual Capacity (FRC) is the volume of gas that remains in the lungs at the 
end of expiration, also known as the End Expiratory Lung Volume (EELV). FRC is important 
in lung mechanics because it prevents collapse of the small airways at the end of 
expiration, preventing atelectasis (collapse or closure of the lung parenchyma). 110 During 
general anaesthesia, functional residual capacity (FRC) is decreased by approximately 
20%.111  The factors which contribute to this are firstly; loss of respiratory muscle tone, 
resulting in chest wall recoil and increased lung recoil, and secondly; increased intra-
abdominal pressure, displacing the diaphragm superiorly.111 An investigation of 
perioperative patients by serial CT scans demonstrated lower lobe bilateral compressive 
atelectasis within 5 mins of induction of anaesthesia, which persisted in 5 out of 10 
patients after 24 hours.112 Even more dramatic effects on lung mechanics occur 
postoperatively, due to incisional pain and reflex diaphragmatic dysfunction, which may 
result in a reduction of FRC by up to 80%.111 Loss of the diaphragmatic contribution to 
tidal volume (TV, the volume of air moved during normal breathing) results in shallow 
rapid breathing, propagating compressive atelectasis; causing perfusion ventilation 
mismatching and inefficient gas exchange. Vital capacity (VC) is the volume of air that can 
be forced from the lungs after maximal forced inspiration. VC is important in producing a 
sufficient voluntary cough flow to clear airway secretions. VC is reduced by up to 50% 
post-surgery, thus reducing a patient’s ability to cough effectively. 111  This is compounded 
by decreased mucociliary clearance, 111  promoting the onset of pulmonary infections. On 
assuming a standing position from supine; FRC is increased by up to 25%; lung compliance 
by 25%; and airways resistance decreases by 40%.111 These collective improvements are 
thought to occur mostly due to descent of the diaphragm and expansion of alveoli (due 
to gravity acting on lung parenchyma), reflecting the importance of posture on normal 
lung mechanics.  
 
2.2.3 Postoperative changes to the musculoskeletal system 
 
After any surgical incision, afferent neural stimuli acting on the hypothalamus cause the 
release of stress hormones.106 Cortisol, secreted from the adrenal cortex after trauma is 
an important catabolic hormone, which promotes gluconeogenesis, with resultant 
hyperglycaemia providing a rapid fuel source to muscle for “fight or flight”. Substrates for 
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gluconeogenesis are provided by breakdown of skeletal muscle as a source of protein. 
This muscle loss after major surgery is compounded by further muscle wasting through 
both bedrest and anorexia. The overall result for the patient is muscle weakness, delaying 
both early mobilisation and the restoration of normal lung mechanics. Hyperglycaemia 
also increases the risk of infection and delays wound healing.  
 
2.2.4 Postoperative inflammation 
 
Tissue damage, due to surgical incisions and resections, results in inflammation; with the 
release of several pro-inflammatory cytokines, leukocytes and acute phase reactants.113 
Whilst this response initiates the healing and repair of damaged tissue; high levels of 
inflammatory markers leads to capillary leakage. 106  This results in  oedema  and potential 
hypotension mediated through a systemic inflammatory response syndrome (SIRS), which 
in turn may lead to organ hypo-perfusion and failure.114 Furthermore, both local and 
systemic postoperative inflammation is thought to be a cause of postoperative atrial 
fibrillation (AF), particularly when there is surgical dissection of or around the 
pericardium. 115 116 
 
2.2.5 Intraoperative and postoperative changes summary 
 
Both the intraoperative and early postoperative periods after major surgery are 
physiologically demanding on the human body. There is an increase in oxygen demand at 
a time when the cardiopulmonary system is challenged by: blood loss, systemic 
inflammatory vasodilation, and disruption of normal lung mechanics. Catabolic muscle 
losses further delay patient mobilisation, thus prolonging recovery of normal function. 
Whilst this section of the thesis has examined the physiological changes common to all 
major surgeries, the next focuses specifically on the unique physiological challenges 
related to oesophageal cancer resection surgery (oesophagectomy) and how 
improvements due to fitness training may attenuate the risk of complications unique to 
this operation.  
 
 
70 
 
2.3 A review of how an increase in physiological fitness 
hypothetically decreases the risk of postoperative complications 
after oesophagectomy 
 
The risk of a complication after an oesophagectomy is multifactorial and includes both 
patient factors and those associated with aspects of clinical care (figure 2.4).  
 
 
 
Adapted from Minto, et al, Assessment of the High-Risk Perioperative Patient.117 
 
2.3.1 Patient factors 
 
Ageing is associated with a decline in cardiopulmonary fitness, muscle mass, organ 
function and wound healing,118 as well as an increasing burden of co-morbidities. The 
Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality 
and morbidity (P-POSSUM) is one of the most accurate risk stratification tools to predict 
complications after oesophagectomy. 119 It is a multivariable model which includes age, 
cardiac and respiratory disease, preoperative physiological parameters, Glasgow Coma 
Scale (GCS) score and operative parameters to calculate a risk of morbidity and mortality. 
The numerous variables included in this scoring system demonstrates the complex 
interplay between patient factors and clinical care, which may determine postoperative 
outcome. Patient factors are a part of a casual pathway to an outcome, which may 
influence but do not necessarily decide it; particularly in surgeries of such great magnitude 
of physiological insult as an oesophagectomy. Physical fitness needs to be considered in 
the context of this complex model.  The next section describes the operative steps of an 
oesophagectomy and its anaesthesia. 
 
 
Figure 2.4 Schematic of the factors involved in determining postoperative outcomes.  
71 
 
2.3.2 Clinical care 
 
Surgery for cancer of the oesophagus (oesophagectomy) 
To appreciate the potential complications after oesophagectomy, and the possible 
influence on these of physical activity, the anatomy of the oesophagus and adjacent 
structures, as well as operative details of an oesophagectomy, including anaesthesia, are 
described. 
 
 
 
 
UES= upper oesophageal sphincter, EGJ= oesophagogastric junction. Image from Hong SJ, Kim TJ, 
Nam KB, et al. New TNM staging system for esophageal cancer: what chest radiologists need to 
know. Radiographics 2014;34(6):1722-40.120 
 
 
 
Figure 2.5 Schematic of the anatomy of the oesophagus and its related structures.  
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Surgical anatomy 
The oesophagus is a muscular tube connecting the pharynx to the proximal stomach,  
measuring approximately 25cm in length in most adults. It starts at the cricopharyngeal 
sphincter, transverses the posterior mediastinum, passes from the chest into the 
abdomen via the oesophageal hiatus within the diaphragm and connects to the cardia of 
the stomach (figure 2.5).  Anatomically, it lies posterior to the pericardium and trachea 
but anterior to the spine. The left atrium and inferior pulmonary veins lie in contact with 
the anterior and left wall of the lower third of the oesophagus, while more proximally the 
arch of the azygous vein lies on the right lateral side, with the aortic arch on the left lateral 
side. The cervical oesophagus is defined superiorly by the upper oesophageal sphincter 
and inferiorly by the sternal notch. The upper oesophagus runs from the sternal notch to 
the level of the bifurcation of the trachea. The middle oesophagus is defined superiorly 
by the bifurcation of the trachea to the midpoint between this and the oesophagogastric 
junction. The lower oesophagus is from the lower margin of the middle oesophagus to 
the oesophagogastric junction.  
 
Operative details of oesophagectomy  
Whilst the surgical approach to an oesophagectomy differs depending on both the 
individual patient and the training and preference of the surgeon, the operative steps are 
similar.34 The operation begins with abdominal exploration via laparotomy or laparoscopy 
for evidence of metastatic disease and resectability of the tumour. This is followed by 
gastric mobilisation from the hiatus and fashioning of the stomach into a conduit (figure 
2.6). The oesophagus is then transected and the specimen delivered. An oesophagogastric 
anastomosis is then formed between the gastric conduit and the remaining oesophagus 
(figure 2.7) 
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Figure 2.6 Schematic showing formation of a gastric conduit from the stomach  
 
 
 
 
 
 
 
 
 
 
Image from www.ctsnet.org/article/transhiatal -esophagectomy  [accessed on 24/10/2017]. 
 
 
 
 
Figure 2.7 Schematic showing the anatomical phases of an oesophagectomy 
 
Image from http://www.mayoclinic.org/diseases-conditions/esophageal-cancer/multimedia/esophageal -
cancer-surgery/img-20006034 [accessed on 24/10/2017]. 
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The commonest operative approach at the Norfolk and Norwich Hospital is a two stage 
oesophagectomy via a right thoracotomy, originally described by Lewis121 and Tanner122 
(Ivor Lewis oesophagectomy).  A laparotomy or laparoscopic approach is used for the first 
abdominal phase (figure 2.8), during which the stomach is mobilised and fashioned into a 
conduit.  
 
 
Figure 2.8 Port placement for the laparoscopic abdominal phase of Ivor Lewis minimally invasive 
oesophagectomy.  
 
 
Image from Wizorek JJ, Awais O, Luketich JD: Minimally invasive esophagectomy. In 
Zwischenberger JB, editor: Atlas of Thoracic Surgical Techniques, 1st edition. Philadelphia, 2010, 
Saunders, pp 305–319.). 
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The second thoracic phase involves a thoracotomy usually at the 5th intercostal space or 
a VATS mini-thoracotomy (figure 2.9) where the stomach is delivered into the chest and 
the anastomosis formed. 
 
 
Figure 2.9 Port placement and a low mini -VATS thoracotomy incision for the thoracic stage of a 
minimally invasive oesophagectomy 
 
Image from Robotic-assisted Ivor Lewis esophagectomy: technique and early outcomes. Nora  I, 
Shridhar R, Meredith K. Robotic Surgery: Research and Reviews. 27 September 2017. Volume 
2017:4 Pages 93—100. 
 
 
This operation can be performed with a laparotomy and thoracotomy (open Ivor Lewis), 
a laparoscopic abdominal stage and thoracotomy (partially minimally invasive Ivor Lewis) 
or a laparoscopic abdomen and VATS thoracotomy (minimally invasive Ivor Lewis). Some 
surgeons prefer to divide the oesophagus in the neck, which allows better access for 
anastomosis. This requires an additional neck incision phase, or three phase 
oesophagectomy. The approach was recommended by McKeown on the basis that 
anastomotic leak at the neck has a lower risk of mortality compared to a thoracic leak.34 
Finally a transhiatal oesophagectomy can also be performed without a thoracotomy, with 
abdominal and cervical stages, similar to a McKeown oesophagectomy. These operations 
describe the approach for any lesion, which may or may not be a cancer, located in the 
upper, mid and lower portions of the oesophagus. Lesions located in the hypopharynx and 
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cervical oesophagus, require a pharyngolaryngo-oesophgaecomy, which is beyond the 
scope of this thesis. 
 
The challenges of anaesthesia for oesophagectomy 
The anaesthetic challenges of an oesophagectomy are related to: prolonged operating 
times, one lung ventilation, and providing effective postoperative analgesia.123 Prolonged 
surgery increases the risk of hypothermia, which; reduces oxygen delivery,  increases 
myocardial work, and propagates the surgical stress response.123 Collapse and re‐
expansion of the lung on the thoracotomy side (to permit surgical access) may cause acute 
lung injury via an ischaemic reperfusion mechanism, with resultant increased vascular 
permeability and oedema.124 Furthermore, over-ventilation of the dependent lung can 
induce acute lung injury through barotrauma.124 Both these factors, accompanied by 
widespread systemic inflammation due to the surgical  stress response, may propagate an 
acute respiratory distress syndrome (ARDS) with impaired pulmonary gas exchange from 
alveolar inflammation (loss of endothelial integrity with extravasation of fluid, protein and 
inflammatory cells). 123 124 Postoperative reductions in FRC and VC are largely attributed 
to incisional pain and reflex diaphragmatic dysfunction as described previously. 111  
 
2.3.3 Short-term postoperative complications after oesophagectomy 
 
Oesophagectomy is a high-risk and complex surgical procedure associated with significant 
postoperative morbidity and mortality. This is related to both the long duration of surgery 
and the magnitude of surgical resection and reconstruction.  UK national audit figures 
reported 33% of patients suffered a complication after oesophagectomy, most of which 
(74%) were cardiopulmonary (52% respiratory and 22% cardiac).125 Other common non-
cardiopulmonary complications included anastomotic leak and chyle leak (due to intra-
operative thoracic duct damage).  
 
Pneumonia 
During surgery, both lungs are subjected to compressive forces. One lung is collapsed to 
allow surgical access, while the other dependent lung is compressed due to patient 
positioning (the weight of the mediastinum and abdominal contents, compounded by 
diaphragm paralysis) 34 Furthermore, postoperative pain inhibits both deep breathing to 
fully expand the lungs and an effective cough to clear secretions. Both mechanisms are 
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important in reducing the risk of atelectasis and pneumonia. Clinical measures to reduce 
such risks include adequate postoperative pain control. Epidural analgesia with opiates 
and or local anaesthetic agents provide optimal postoperative pain management. This is 
reflected in a reduction of respiratory complications when used in patients undergoing 
oesophagectomy.126  
 
Atrial Fibrillation 
The precise cause of postoperative atrial fibrillation (AF) after oesophagectomy is 
unknown, but this dysrhythmia constitutes a common complication after thoracic 
surgery; reflecting the pro-arrhythmogenic impact of surgical resection close to the 
heart.127 During an oesophagectomy, the lower oesophagus is dissected from the 
pericardium which is likely to induce local pericardial inflammation resulting in 
dysrhythmias. 128 Other potential causes include: an altered sympathovagal balance, 
systemic inflammation and premature atrial complexes associated with sympathetic 
stimulation due to pain.127 Furthermore, AF can be a heralding event of an anastomotic 
leak, likely due to the local inflammatory effects on the pericardium of extravasated 
gastric contents. Indeed, the experience from the upper gastrointestinal surgery 
department at the NNUH in patients with early post-oesophagectomy AF, is that 30% will 
have subsequent evidence of an anastomotic leak.  
 
Anastomotic leak 
Early anastomotic leak (within 72 hours) is thought to be a result of technical error. 34 Such 
technical factors may include 1) tension on the anastomosis, 2) poor approximation or 
suturing inadequacy and 3) lack of adequate blood supply.34 Other, non-technical aspects 
may include hypoperfusion of the anastomosis due to hypotension and splanchnic 
vasoconstriction.  
 
Other complications 
Other complications such as chylothorax, recurrent laryngeal  nerve damage, and 
anastomotic stricture may also be attributed to intra-operative technique.34  
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Mortality 
National UK postoperative mortality rates reported between 2012 and 2015, at 
postoperative days 30 and 90 were, 2.2% (95% CI 1.7.-2.8) and 4.3% (95% CI 3.6-5.1), 
respectively.129 These figures demonstrate a slight decrease in mortality since a 2010 
report, where 30 and 90 day mortalities were 3.8 and 5.7%, respectively.129 
 
How improved aerobic fitness may attenuate early postoperative complications 
following oesophagectomy 
There are several plausible mechanisms for how an increased aerobic fitness may reduce 
the number of complications after oesophagectomy. Physical activity training results in 
improved oxygen delivery to metabolising tissue by: increasing cardiac output (Q), lung 
ventilation, and the mitochondrial and capillary densities of skeletal muscle. Such gains 
are likely to attenuate the surgical consequences of anaesthesia, tissue trauma, and bed-
rest. A more efficient Q is likely to reduce the risk of myocardial and gut hypo-perfusion 
reducing the incidence of myocardial and anastomosis ischaemia. Improved respiratory 
muscle strength may attenuate losses in FRC and VC, reducing the risk of atelectatic 
infection.  Greater skeletal muscle bulk, particularly of the major legs muscles, will allow 
increased reserves for catabolic losses - retaining strength for early mobilisation to 
enhance lung mechanics. How physical activity training may reduce the incidence of atrial 
fibrillation is unclear, as its occurrence is likely to be related to postoperative 
inflammatory changes, either local or systemic. 116 However, tachycardia on the first day 
postoperatively has been shown to be a risk factor for AF post-oesophagectomy, 130 and 
exercise training results in a lower resting HR. Furthermore, distention of atrial muscle 
fibres is associated with an increased risk of AF, while a more compliant myocardium 
(through exercise training) may also better tolerate acute atrial stretch due to over-
administration of perioperative intravenous fluids.  
 
Randomised controlled trials are required to investigate whether improved physical 
fitness, through a preoperative exercise intervention, results in a reduced risk of 
complications after oesophagectomy. The next section of this thesis presents the 
methodology and results of a feasibility randomised controlled trial of short-term exercise 
therapy versus standard care prior to surgery to reduce the risk of postoperative 
cardiopulmonary complications. Such feasibility trials are important before a full RCT to 
both justify and inform its conduct.  Important questions to answer are 1) whether 
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patients are willing to be recruited into such trials, and 2) if the exercise programme 
offered is safe and adhered to. This feasibility trial was designed and commenced at the 
beginning of my research time and was based on my interpretation of the available 
published observational studies showing that fitness, as measured objectively by 
cardiopulmonary exercise testing, was associated with a decreased risk of 
cardiopulmonary complications after oesophagectomy. Later during my research training, 
with a deeper understanding of study methodology and medical statistics, I subsequently 
re-analysed in more detail and breadth the existing evidence for the association between 
preoperative fitness and postoperative complications before major cancer resection and 
found the limitations in such work, including in oesophagectomy, which are detailed and 
addressed in chapter 3.  
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2.4 Prehabilitation to improve physical fitness and reduce 
postoperative cardiopulmonary complications after 
oesophagectomy in patients with oesophageal adenocarcinoma – a 
feasibility randomised controlled trial. The ExPO Trial (Exercise Prior 
to Oesophagectomy)  
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2.4.1 Abstract  
Background: Increasing physical fitness prior to oesophagectomy has the potential to 
decrease postoperative complication risk, but to date, no trials have investigated this 
hypothesis. The aim of the EXPO feasibility trial was to use the preoperative period (during 
and after neoadjuvant chemotherapy, but before to surgery) to improve a patient’s 
physical fitness through exercise. Such data are required to justify and inform a future 
randomised controlled trial (RCT), which would investigate if exercise before surgery 
(prehabilitation) can reduce the incidence of postoperative cardiopulmonary 
complications.  
Methods: ExPO was a single centre, parallel group, single-blinded, RCT investigating a 
specifically designed multi-modal personalised exercise programme (prehabilitation) 
versus standard care in adults with oesophageal adenocarcinoma due to undergo 
neoadjuvant chemotherapy and oesophagectomy. The prehabilitation intervention 
consisted of: i) home inspiratory muscle training (IMT), ii) standard care home exercise 
advice, and iii) a 4 week hospital-supervised aerobic and muscle strengthening exercise 
programme. Standard care was home exercise advice only. Cardiopulmonary exercise 
testing (CPEX) before and after the interventions documented any objective changes in 
physiological fitness. Quality of life (QOL) as well as baseline levels of physical activity and 
reasons for non-participation were also measured. Cardiopulmonary complications were 
measured at post-operative day 30 by blinded assessors.  
Results: Between October 2016 and June 2017 (9 months), a total of 20 patients were 
screened, 11 (55%) provided consent for participation and were randomised (5 to the 
prehabilitation group and 6 to the control group). Of the 11 recruited participants there 
was 100% retention in the trial. In the prehabilitation arm there was full attendance to all 
of the sessions offered (median of 5 sessions per participant). There were no adverse 
reactions reported in either arm to exercise. Overall, adherence to home exercise sessions 
was low (25% to 49%) mostly due to side effects of chemotherapy. The mean change in 
VO2peak was +2.0ml/kg/min in the intervention group and +0.3ml/kg/min in the control 
group (p=0.61). AT increased by +1.5ml/kg/min in the prehabilitation group but decreased 
by -1.2ml/kg/ml in the control group (p=0.26).  Quality of life did not differ significantly 
between groups. The 30-day postoperative cardiopulmonary complication rates were also 
similar in both arms. 
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Discussion: The ExPO trial provides ‘proof of concept’ for prehabilitation prior to 
oesophagectomy in patients with oesophageal adenocarcinoma undergoing 
chemotherapy. That is, there was a reasonable recruitment rate and the exercise regime 
was safe, acceptable and well adhered to. The study lacked statistical power to detect 
whether the improvement in fitness over standard care was statistically significant. This 
work informs the design of a larger feasibility study in this patient population to 
investigate whether the fitness of oesophagectomy patients can be improved in the short 
time between neoadjuvant chemotherapy and surgery.  
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2.4.2 Introduction 
 
Background 
Increasing physical fitness prior to oesophagectomy has the potential to decrease 
postoperative complications. Such reductions may also have an impact on other 
important outcomes including: mortality, chronic morbidity, length of hospital stay (LOS), 
hospital readmission and financial costs, whilst increasing quality of life (QOL). 9 The 
current accepted clinical standard in the UK is to allow 5-6 weeks after completion of 
neoadjuvant chemotherapy before oesophagectomy in patients with operable 
oesophageal adenocarcinoma.10 This recovery period may be used to improve patient 
postoperative outcomes with a preoperative exercise programme (prehabilitation).  
 
The association between aerobic fitness and postoperative outcome 
Cardiopulmonary exercise (CPEX) testing is the current gold standard test to measure 
aerobic fitness, offering an objective, quantitative and composite measure of a person’s 
ability to deliver oxygen to tissues during exercise. Two specific CPEX variables; VO 2peak 
(the maximal oxygen consumed at peak exercise) and VO2 at estimated anaerobic 
threshold (AT) have shown promise in observational studies for predicting both morbidity 
and mortality.131-139 In an observational study of 187 elderly patients undergoing major 
abdominal surgery, a preoperative AT cut-off of <11ml/kg/min had a sensitivity of 91% 
and specificity of 74% for predicting short-term mortality.131 In two large multi-centre 
studies in lung cancer patients undergoing resection via thoracotomy, with a combined 
sample size of 2 030 patients, a VO2peak of <15ml/kg/min was associated with a 2-fold 
increased risk of early major respiratory complications138 and death.138 139  There are 3 
relatively small observational studies of CPEX testing prior to oesophagectomy (n=78,136 
n=91,134 n=103 patients135), two of which reported an inverse association between VO2peak 
and cardiopulmonary complications (p=0.0014 and p=0.04136).  The remaining study 
reported no association for VO2peak (p=0.07), but a significant inverse association between 
AT and cardiopulmonary complications (p=0.05).135 Whilst this observational work 
suggests that increased fitness may be beneficial, the findings are likely subject to biases 
associated with observational work, such as detection and selective reporting bias, which 
can be addressed in RCTs. To date, no RCT has demonstrated that increased physical 
fitness improves clinical outcomes after oesophagectomy.   
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The safety and fitness improvements of prehabilitation 
Both the safety of prehabilitation and its improvements in fitness have been investigated 
in several RCTs140-142 (although not in oesophageal cancer surgery) and observational 
studies.143 144 In these investigations, exercise sessions were delivered as 4 to 8 week 
programmes, usually consisting of an aerobic component (either walking or cycling) and 
muscle strengthening. A systematic review133 of 4 randomised trials and 6 observational 
studies, totalling 524 patients, reported that exercise training prior to cardiac, lung and 
colorectal surgeries was: safe, feasible and well tolerated, with only 2 exercise-related 
adverse events (transient hypotension) reported. Such exercise therapy was also found 
to be effective in improving objective measures of physical fitness, including VO 2peak, 
which was increased by to 2.4 to 2.8ml/kg/min.145 146 To the best of my knowledge, no 
interventional studies of aerobic exercise prior to oesophagectomy have been published.  
 
Reduction in postoperative complications due to prehabilitation 
Although there is trial evidence reporting that physical fitness can be improved in the 
limited time between diagnosis and surgery, at the time of writing,  there have been only 
two adequately powered randomised controlled trials reporting on prehabilitation to 
reduce postoperative complications (neither of which were in oesophageal cancer 
surgery).147,148 The first was a recently published RCT of a preoperative exercise 
intervention in lung cancer patients.148  This Swiss trial of 151 patients, compared a high 
intensity aerobic exercise programme (20 min sprint interval training on a static exercise 
bike and muscle strengthening) with standard care and found that whilst VO 2peak was 
significantly increased in the intervention group, this did not translate into a significant 
reduction in postoperative complications (35% of prehabilitation patients suffered a 
complication vs. 50.6% in the usual care group, p=0.08).148 However, the authors 
commented that a larger sample size may have detected a smaller effect. A second UK 
trial in 124 participants investigated a 6-week supervised exercise programme prior to 
open or endovascular aortic aneurysm repair.147  The exercise sessions consisted 
predominantly of muscle strengthening with minimal aerobic exercise (2 mins of cycling 
on an exercise bike). The authors documented a reduction in the number of both cardiac 
(8.1% vs. 22.6%, p=0.025) and pulmonary (11.3% vs. 21.0%, p=0.143) complications in the 
exercise group compared to the non-exercise group. Unfortunately, a standardised 
primary outcome measure was not used to report complications, which may have 
resulted in selective reporting bias and an over estimation of the effect size.  The  findings 
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from both of these trials are unlikely to be comparable to oesophageal surgery due to 
differences in both the preoperative management and the nature of the surgeries. Unlike 
lung and vascular surgery, most oesophagectomy patients are exposed to 3 cycles of 
preoperative neoadjuvant chemotherapy lasting approximately 9-10 weeks, which in 
itself decreases aerobic fitness.149 Oesophagectomy is also unique in that there is breach 
of two anatomical cavities, namely the thorax and abdomen. Therefore, the postoperative 
complication profile consists of both cardiopulmonary and abdominal complications. As 
such, inferences from trials in lung or vascular surgery applied to oesophagectomy, or 
indeed any other surgical specialties, cannot be reliably made, highlighting the need for 
exercise trials in oesophageal cancer patients.  
 
The role of both endurance and high intensity inspiratory muscle training (IMT) in 
prehabilitation 
A further component of prehabilitation to increase physical fitness is inspiratory muscle 
training (IMT). This consists of a course of breathing exercises using a hand-held resistance 
device to increase the strength of respiratory muscles. Whilst IMT is normally used by 
athletes or patients with asthma and COPD, it has been investigated prior to cardiac and 
abdominal surgeries to reduce pulmonary complications. It is proposed that 
strengthening of respiratory muscles may attenuate their decline and dysfunction 
following major surgery. To support this hypothesis, there is evidence from systematic 
reviews that a 2-4 week programme of preoperative IMT is safe and effective at reducing 
pulmonary complications after major elective cardiac42,43 and abdominal surgeries43 
(oesophageal surgery was not included). A 2012 Cochrane Review of 8 RCTs in 856 
participants42 reported that IMT in patients undergoing cardiac surgery was safe and 
reduced the risk of atelectasis (RR=0.52, 95% CI=0.32-0.87) and pneumonia (RR=0.45, 95% 
CI=0.24-0.83) compared to no IMT. However, some trials were small (4 had less than 50 
patients) and there were differences in the interventions (2 trials incorporated aerobic 
exercise as well as IMT). In a later 2015 Cochrane Review43 of 12 trials with 695 
participants awaiting cardiac (5 trials) and major abdominal (7 trials) surgery (oesophageal 
surgery was not included), IMT was without adverse events and also reduced atelectasis 
(RR=0.53, 95% CI=0.34-0.82) and pneumonia (RR=0.45, 95% CI=0.26-0.77) compared to 
no IMT. However, the review commented on possible over-estimation of treatment 
effects due to inadequate blinding and publication bias. These trials investigated 
endurance IMT (IMT-E) which starts at 15-40% of a patient’s maximal inspiratory pressure 
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(Pi-max) and increases progressively up to 60%. IMT that starts at 60-80% of Pi-max, and 
increases progressively upwards (from this higher starting point) is called high intensity 
IMT (IMT-HI). This type of IMT has been investigated in patients with COPD150 and heart 
failure151 and may be superior to IMT-E at increasing a patient’s Pi-max. There is only a single 
published investigation of perioperative IMT in oesophagectomy patients.152  This Dutch 
randomised pilot study of 39 participants, planned for neoadjuvant chemo-radiotherapy 
and oesophagectomy for oesophageal cancer, assigned participants to a 3 week 
preoperative programme of either IMT-HI or IMT-E (with no control group). Intervention 
adherence was high in both groups (98% and 99%, respectively) with only one adverse 
event (tension headache). The authors reported no significant difference in the mean 
increase in Pi-max between groups (35% in the IMT-E group vs. 12% in the IMT-HI group, 
p=0.316). Nonetheless, they stated that the frequency of higher grade postoperative 
pulmonary complications (e.g. pleural effusion, pneumonia, ventilator assistance)  was 
almost three times lower in the IMT-HI group (20% vs. 58%; p=0.015).  Although, as a 
seemingly contradictory finding, the IMT-HI group had almost double the number of lower 
severity pulmonary complications (e.g. atelectasis, hypoxaemia, hypercarbia) compared 
to the IMT-E group (80% vs. 42%; p=0.015). The authors also reported suboptimal IMT 
training in 6 of the 19 participants assigned to IMT-E (due to equipment issues). In 
summary, the small sample size, lack of significant difference in P i-max between groups, 
conflicting findings and equipment issues raises concerns over both the validity and 
reliability of their findings. As such, it is unclear whether IMT-HI has any benefit over other 
forms of IMT in oesophagectomy patients.  
 
The optimal components of a prehabilitation intervention 
There is no current and accepted prehabilitation programme routinely offered to patients 
prior to oesophagectomy. Indeed, there is no consensus on the most effective 
prehabilitation programme prior to any type of surgery to reduce complications. It is 
unknown whether an exercise programme should consist exclusively of aerobic exercise, 
muscle strengthening or IMT (either endurance or high intensity) or a combination of 
some or all. Only IMT, but no other components of prehabilitation have been assessed in 
any RCT in patients awaiting oesophagectomy, with unclear benefit. 152 However, all 
components have some trial evidence of efficacy in other surgery types. 147 153 Perhaps 
most importantly, the content of an exercise programme should be determined by the 
specific complication profile of the surgery with a plausible biological reason why the 
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exercise programme could prevent such complications. In oesophagectomy patients, 
where the complications are mostly cardiopulmonary, there are physiological reasons 
why all exercise modalities (aerobic exercise, IMT and muscle strengthening) are likely to 
be beneficial (as explained in the previous section). As such, all may reduce the risk of 
complications after surgery, and warrant investigation in clinical trials.  
 
The need for a feasibility trial of prehabilitation prior to oesophagectomy 
To date, no trial has reported on preoperative exercise in patients undergoing 
oesophagectomy. However, before a full RCT to assess the potential efficacy of 
prehabilitation prior to oesophagectomy to reduce complications can be conducted, 
important feasibility criteria need to be fulfilled to both justify and inform its conduct. 
These include demonstrating that a short period of exercise prior to oesophagectomy is 
safe and that sufficient participants are suitable, can be recruited and retained in such a 
programme. If a future RCT could demonstrate benefits to patients this would support 
the use of exercise prior to oesophagectomy as standard care across the NHS to reduce 
the current high number of postoperative cardiopulmonary complications. The purpose 
of the ExPO feasibility trial was therefore to provide evidence to guide both the design 
and conduct of a future definitive trial.  
 
2.4.3 Methods 
 
Study design 
The ExPO study was a prospective, parallel group, feasibility randomised controlled trial 
with a recruitment target of 32 participants (16 per arm) The work was registered at the 
National Institutes of Health ClinicalTrials.Gov (NCT02962219) and conducted in the 
department of Upper Gastrointestinal (UGI) Surgery at the Norfolk and Norwich 
University Hospitals (NNUH) Foundation Trust, Norwich, United Kingdom. The NNUH is a 
1,000 bed teaching hospital, which provides care to a population of approximately 
825,000 residents in Norfolk and its adjacent counties. Approximately 45 
oesophagectomies are performed at this unit each year.  The NNUH takes referrals from 
its neighbouring hospitals: the James Paget University Hospital (JPUH) in Great Yarmouth 
and the Queen Elizabeth Hospital (QEH) in King’s Lynn. Both these neighbouring hospitals 
acted as patient identification centres (PICs) for the ExPO trial. The full detailed trial 
protocol is shown in appendix 3. 
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Figure 2.10 The ExPO trial CONSORT flow diagram 
 
OAC = oesophageal adenocarcinoma, NAC = neoadjuvant chemotherapy, CPEX = cardiopulmonary 
exercise testing,  
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Figure 2.11 Arial photo of The Norfolk and Norwich University Hospital  
 
Image taken from http://www.panoramio.com/photo/82330913 [accessed 24/10/2017]. 
 
Patients 
After written approval from the Leicester-South research ethics committee (ref: 
16/EM/0317) on behalf of the Health Research Authority (IRAS ID: 206608) patients were 
identified at weekly NNUH oesophagogastric cancer specialist multidisciplinary team 
meetings between October 2016 to June 2017. Written informed consent was obtained 
from all eligible adult patients with histology proven oesophageal adenocarcinoma 
planned for both neoadjuvant chemotherapy and oesophagectomy. Patients were 
excluded if there were contraindications to performing exercise training (e.g. severe 
musculoskeletal disease or uncontrolled cardiac disease). Patients with other histological 
types of oesophageal cancer (e.g. squamous cell carcinoma) or those proceeding to 
surgery without chemotherapy were also excluded, as their clinical timelines differed, 
often with insufficient time for an exercise programme.  
 
Randomisation 
Using a CPEX VO2peak cut-off of 15ml/kg/min derived from observational work in thoracic 
surgery patients138 139, consenting participants were stratified into ‘high’ and ‘low’ fitness 
score groups. This stratification was to help equally distribute those with a ‘low’ level of  
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fitness between trial arms, reducing the risk of selection bias, which can occur with 
relatively small numbers of patients. Randomisation was done by a statistician on a 1:1 
basis into prehabilitation and usual care arms using random block sizes (known only to 
the statistician) generated by computerised randomisation (www.randomzation.com). 
Allocations were placed in opaque envelops by a secretary independent of the ExPO trial.  
 
Interventions 
Both the prehabilitation arm and the usual care arm received usual standard care advice 
(in written form) to exercise at home both during and after neoadjuvant chemotherapy 
and up to the time of surgery (a period of approximately 14-16 weeks). The recommended 
activities were 30 mins of moderate intensity aerobic exercise (e.g. fast walking,  cycling) 
on at least 5 days of the week, or 20 mins of vigorous activity (e.g. jogging) on 3 days of 
the week in line with general recommendations by the UK Department of Health (DH) 154 
and the American College of Sports Medicine (ACSM). 155 In addition to this, those in the 
prehabilitation arm were asked to complete home exercise diaries and were offered two 
further exercise interventions:  
 
1) Prehabilitation arm participants were asked to engage in home inspiratory muscle 
training (IMT) for 20 mins every day both during and after neoadjuvant chemotherapy. 
The IMT programme was as per Hulzebos, et al153 where maximal inspiratory pressure (Pi-
max) was measured at baseline, after which participants were given an inspiratory 
threshold loading device (POWERBreathe Medic). Resistance was set on their device at 
30% of their Pi-max and participants were instructed to perform IMT for 20 mins 7 days a 
week and to incrementally increase the resistance on the device by 5% if their rate of 
perceived exertion was less than 5 as scored on the New Category (0-10) Borg RPE Scale156 
(figure 2.13) Participants were also given an exercise diary to record their use and any 
adverse events.  
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Figure 2.12 An inspiratory muscle trainer (IMT) device (The POWEBREATHE Medic) 
 
Image from www.powerbreathe.com/powerbreathe-medic [accessed on 24/10/2017]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Borg, G. Psychophysical bases of perceived exertion, Med Sci 
Sports Exerc 1982;14 (5):377-81.156 
RPE 
(UNIT) 
Patients Perceived Exertion Alternative perceived exertion 
0 Nothing at all  
0.5 Very, very weak Just noticeable 
1 Very weak  
2 Weak l ight 
3 Moderate  
4 Somewhat strong  
5 Strong heavy 
6   
7 Very strong  
8   
9   
10 Very, very strong Almost max 
Figure 2.13 The new category Borg rating of perceived exertion (RPE) scale. 
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2) Prehabilitation arm participants were also offered an inpatient Hospital exercise 
programme in the clinical trials unit at the NNUH consisting of both aerobic exercise on a 
static exercise bike (Monarch Energy 915) and muscle strengthening. This programme was 
designed in co-operation with experienced physical therapists specialised in rehabilitation 
and utilised the standard care period between the end of neoadjuvant chemotherapy and 
surgery, which is approximately 6 weeks. The aim was to achieve a maximum of 8 
sessions, with 2 sessions per week for 4 weeks, each lasting 60 mins. For the aerobic 
component, participants were invited to begin with 4 mins of warm up by cycling to a 
perceived exercise intensity of ‘light’ on the Borg scale (score 9-11) (Figure 2.14).156 After 
warm up, remaining on the bike, the participants were invited to engage in aerobic 
interval training aiming to achieve up to 30 mins of moderate intensity (Borg scale rate of 
perceived exertion (RPE) of 12-13) aerobic exercise. The pedal resistance of the static bike 
was adjusted to achieve this. Progression was achieved at the discretion of the doctor 
supervising the programme by increasing exercise intensity on the BORG scale and 
decreasing the duration and rest periods. After the aerobic component, participants 
attempted the following sets of muscle strengthening exercises, each for 2 minutes (as 
per the programme of Barakat, et al 147): heel-raises, knee extensions, knee bends, step-
up lunges and biceps curls. This was followed by warm-down stretching.  
 
Figure 2.14 The 15-grade scale for rating of perceived exertion, the Borg’s 6-20 
RPE scale 
RPE 
(UNIT) 
Patients Perceived Exertion Alternative perceived exertion 
6     
7 Very, very light   
8     
9 Very light   
10     
11 Fairly light   
12   Moderate 
13 Somewhat hard Moderate 
14   Vigorous 
15 Hard Vigorous 
16   Vigorous 
17 Very hard Vigorous 
18     
19 Very very hard   
20     
Adapted from Borg, G. Psychophysical bases of perceived exertion, Med Sci 
Sports Exerc 1982;14 (5):377-81.156 
 
93 
 
Figure 2.15 The Monarch 915E static exercise bike, which was used in the ExPO trial.  
 
Image from www.monarkexercise.se [accessed 24/10/2017]. 
 
 
Safety measures 
Many measures were incorporated into the programme to ensure its safety. The home 
and hospital aerobic and muscle strengthening programmes closely followed guidance 
from the UK DH and ACSM for exercise in older adults. The supervised in-hospital exercise 
programme in the ExPO trial was also developed in collaboration with a senior clinical 
physiotherapist experienced in the rehabilitation of patients following oesophagectomy 
to ensure it was both safe and realistic for this patient group. Additionally, the exercise 
regime was discussed with two patient groups, the Oesophageal Patients’ Association 
(OPA) and Norfolk Together Against Cancer (TAC), who agreed that the regime would 
likely be acceptable to participants.  The exercise programme was also similar to exercise 
regimes used in RCTs of different surgical patient populations, which were shown to be  
safe and achievable.8 The following trial procedures were also followed to ensure safety 
in the ExPO trial.  
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i. only recruiting patients who were deemed fit for both neoadjuvant 
chemotherapy and surgery by consultant clinicians.  
ii. including a baseline health screening assessment (to ensure there were no co-
existing diseases which would be exacerbated by exercise). 
iii. use of a baseline CPEX test, to measure fitness and allow personalisation of the 
hospital exercise programme.   
iv. tailoring exercise to each participants perceived exertion level (through the use 
of the Borg scale), which was frequently re-assessed so that the participant could 
rest or stop exercise if they felt that they were over-exerting themselves.  
v. oral consent to exercise was obtained prior to each exercise session to ensure 
ongoing approval for continuation in the programme.  
vi. a short medical history was re-taken at each exercise visit, to ensure the patient 
was suitable for exercise at each session.  
vii. a medically qualified doctor was present during all hospital exercise sessions 
trained in life support with resuscitation equipment available.  
viii. the participant’s underwent baseline observations (HR, BP, RR, temperature and 
oxygen saturations) before each exercise session to ensure they were within 
acceptable limits.  
ix. the participants were informed that they may cease any or all components of 
exercise at any stage at their choice without prejudicing future clinical care.  
 
It was anticipated that any adverse reactions to exercise would be both transient and mild 
including: an exacerbation of existing medical conditions (e.g. angina), delayed onset 
muscle soreness, soft tissue strains, nausea and transient hypotension. Nonetheless, an 
ExPO safety management plan was developed prior to patient recruitment and a trial 
safety committee (TSC) assembled to regularly review any adverse events which occurred 
during the trial. Full details of the definitions of adverse events, adverse reactions and 
causality of these events are detailed in the ExPO Safety Management Plan (appendix 4). 
As an additional measure to ensure the safety of trial participants, an ExPO trial 
management group (TMG) and an independent trial steering committee (TSC) were 
assembled. These groups reviewed the progress of the trial and reported to the TSC 
regarding adverse events.   
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Surgery 
Surgery occurred approximately 6 weeks after completion of chemotherapy and 1 week 
after completion of the hospital exercise programme. At surgery, patients underwent 
either: a partially laparoscopic assisted (hybrid), or a fully laparoscopic (minimally 
invasive) Ivor Lewis oesophagectomy. All patients were admitted to a high dependency 
unit (HDU) for the first night following surgery. Step down to ward care was decided by 
the HDU consultant. All patients were managed as per the local enhanced recovery after 
surgery programme (ERAS).  
 
Measurements and outcomes 
In order to determine any changes in levels of physical activity, quality of life and fitness 
before and after the interventions, measurements were taken both prior to 
commencement of neoadjuvant chemotherapy and one week prior to surgery. At these 
times, all participants were asked to complete; the International Physical Activity 
Questionnaire (IPAQ) which consists of 4 questions,  each relating to physical activity 
performed in the last 7 days; and two quality of life (QOL) questionnaires (EORTC QLQ-
C30 and disease specific Oesophago-Gastric QLQ-OGC25). Participants were additionally 
asked to undergo both a cardiopulmonary exercise test and inspiratory pressure test.  
Both of these tests were undertaken in a respiratory laboratory at the NNUH by blinded 
laboratory staff not involved in any other aspect of the trial.   CPEX testing was done on an 
electromagnetically braked cycle ergometer (Ergoselect 200, Ergoline GmbH, 
Lindenstrasse 5, D-72475, Bitz, Germany). Testing consisted of a 3 minute rest period, 3 
minutes of free pedalling and an incremental ramped phase, usually lasting 8-12 minutes, 
until volitional termination. Gas exchange was measured using a metabolic cart (Jaeger 
Oxycon Pro, CareFusion, Germany 234 GmbH, Leibnizstrasse 7, 97204, Hoechberg). AT 
was estimated using the V-slope method (change in the linear relationships between VCO2 
and VO2) and VO2peak was averaged over 30 seconds during peak exercise. Pi-max was 
measured using a respiratory pressure meter (MicroMedical MicroRPM 01), where the 
average of 3 tests, each within 5cmH2O of each other were used.  
 
At recruitment, patients in the intervention arm were additionally asked to complete a 
Determinants of Physical Activity Questionnaire (DPAQ), which contained 34 questions 
relating participants’ knowledge about exercise, social influences, levels of motivation and 
emotional responses to physical activity. These measures provided information about 
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factors that may have represented personal barriers or facilitators to participating in an 
exercise programme. These could then be addressed or encouraged during hospital 
exercise sessions. 
 
In order to allow comparison of clinical and demographic data between patients both 
willing and not willing to join the trial, the following variables were obtained for all eligible 
patients: age, gender, smoking status (never, former, current), comorbidities and TNM 
staging. After oesophagectomy 30-day postoperative morbidity was measured for all 
randomised patients by hand review of the medical notes. This outcome assessment was 
by two blinded consultant anaesthetists not involved in the patients’ care, in strict 
accordance with Esophageal Complications Consensus Group (ECCG) definitions.157 Each 
complication was then graded by the assessors in accordance with the Clavien-Dindo 
classification.158 In brief; grade 1 complications do not require pharmacological 
intervention above usual postoperative care, while grade 2 complications do. Grade 3a 
complications require a surgical intervention without general anaesthesia; grade 3b 
require a return to theatre; and grade 4 require organ support on ITU.  
 
The primary outcome was to assess the feasibility of prehabilitation in this patient 
population. Therefore, the primary measures were the number of eligible patients that 
could be recruited and retained in the trial and both the adherence to and the safety of 
prehabilitation. Secondary measures to inform future work were: reasons for non-
participation in the study and baseline levels of physical activity as well as differences in; 
quality of life; fitness (VO2peak and Pi-max); 30-day postoperative complications; and 30-day 
mortality between arms before and after the interventions.  
 
Sample size 
As this was a feasibility trial, a formal sample size calculation was not required to 
determine the statistical significance of the effect size of the intervention on the number 
of cardiopulmonary complications between groups. However, this trial was powered to 
detect a statistically significant change in VOpeak of 3.6ml/kg/min between the two groups 
after the intervention. The sample size calculation was based on data from previous 
observational studies145 146 and a randomised controlled trial142 investigating preoperative 
exercise therapy of similar durations to the ExPO trial. These studies suggested that an in-
hospital exercise regime may increase baseline VO2max by 2.6ml/kg/min. This was 
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calculated from two observational studies, where VO2max was increased by 2.8 and 
2.4ml/kg/min after 4-6 week out-patient exercise programmes.145 146 To estimate the 
effect size in the baseline standard care arm, information was taken from a randomised 
controlled trial of 35 subjects, demonstrating that standard advice to exercise at home 
may cause a worsening of VO2max of at least -1ml/kg/min.142 Therefore, assuming a mean 
difference of VO2max of 3.6ml/kg/min and a standard deviation of 3.0,142 145 146 then using 
a two sample t-test the trial would require 11 individuals per group for the trial to have 
80% power at the 5% level of significance to detect a statistically significant difference in 
VO2peak between treatment arms. Accounting for a participant drop-out rate of 27%,142 146 
at least 30 subjects were needed to be recruited to achieve 11 individuals per group for a 
per-protocol analysis.  Based on the above information the aim was to recruit 32 patients 
in total. 
 
Statistical analysis 
The baseline participant demographic and clinical characteristics and trial outcomes for 
participants in each of the 2 arms were reported. For categorical variables, the numbers 
and percentages were presented and for continuous variables the means (and standard 
deviations) or medians (and interquartile ranges) depending on their distributions. Mean 
differences between groups were compared using Student-t tests. 
 
 
2.4.4 Results 
 
Between October 2016 and June 2017, a total of 20 patients were screened, 11 (55%) 
provided consent for participation and were randomised. Of these, 5 were randomised to 
the prehabilitation group and 6 to the control group (table 2.1). There was a smaller than 
anticipated number of eligible patients over the 9 month recruitment period (at least 35 
patients were expected in line with figures from the previous 6 years at the NNUH). 
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Table 2.1 Baseline characteristics of the two allocation arms in the ExPO trial  
Data shown are the number of patients and percentage unless otherwise stated. 
 
 
 
 
Variable Control (n=6) Intervention (n=5) 
Male gender 6 (100) 4 (80) 
Mean age at operation (years + SD) 65.4 (9.1) 66.3 (9.4) 
Hypertension  1 (17) 1 (20) 
Coronary artery disease  0  1 (20) 
Diabetes 1 (17) 2 (40) 
T staging 
T3 
T4 
 
5 (83) 
1 (17) 
 
5 (100) 
0 
N staging  
N0 
N1 
N2 
 
1 (17) 
2 (33) 
3 (50) 
 
3 (60) 
1 (20) 
1 (20) 
Smoking status  
Never 
Former 
Current 
 
1 (17) 
3 (50) 
2 (33) 
 
3 (60) 
1 (20) 
1 (20) 
BMI (mean in kg/m2 + SD) 27.0 (4.4) 27.1 (4.4) 
IPAQ category of recreational physical activity 
Low 
Moderate 
High 
 
2 (33) 
1 (17) 
3 (50) 
 
4 (80) 
0 
1 (20) 
Quality of life summary scores (mean +SD) 
C30 
OG25 
 
75 (13.0) 
34.9 (13.8) 
 
78.2 (14.0) 
34.4 (14.9) 
CPEX variables (mean in ml/kg/min + SD) 
VO2peak 
AT 
 
22.6 (6.4) 
13.3 (1.6) 
 
21.4 (6.4) 
12.8 (1.7) 
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Primary outcomes  
Of the 20 patients approached all were deemed eligible to participate in the ExPO trial. 
The recruitment rate was 55%, with 9 patients not recruited: 7 did not want to participate 
(3 were unwilling to travel, 2 felt that they did not require any additional  support to 
engage in exercise, 1 felt that exercise was too much work, and 1 expressed a dislike for 
exercise) and 2 patients who were willing to participate were excluded as CPEX testing 
was unable to be arranged due to no availability at the laboratory. The demographics and 
clinical characteristic of both willing and non-willing patients were similar (table 2.2).  
 
 
Table 2.2 Comparison of the demographic and clinical characteristics of patients that were 
will ing (n=13) and not will ing (n=7) to join the ExPO trial. 
Variable Willing  to join (n=13) Not willing to join (n=7) 
Male gender 12 (92) 7 (100) 
Mean age at operation (years + SD) 66.9 (9.7) 67.0 (6.8) 
Hypertension  3 (23) 4 (57) 
Coronary artery disease  1 (8) 2 (29) 
Diabetes 3 (23) 1 (14) 
Smoking status  
Never 
Former 
Current 
 
5 (39) 
5 (39) 
3 (23) 
 
3 (43) 
3 (43) 
1 (14) 
T staging 
T3 
T4 
 
12 (92) 
1 (8) 
 
7 (100) 
0 
N staging  
N0 
N1 
N2 
 
6 (46) 
3 (23) 
4 (31) 
 
5 (71) 
0 
2 (29) 
Data shown are the number of patients and percentage unless otherwise stated. 
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Of the 11 recruited patients none dropped-out during the trial period, representing 100% 
retention. The median number of in-hospital exercise sessions attended was 5 
(interquartile range of 4-5 sessions). There was 100% attendance of all of the sessions 
offered with complete adherence to the aerobic and muscle strengthening exercises. It 
was not feasible to offer the maximum 8 sessions to any of the patients, due to the earlier 
than anticipated scheduling of either surgery or second CPEX test. There were no adverse 
reactions to any of the in hospital exercise sessions. Adherence to home exercise sessions 
was variable in the intervention arm ranging from low to good (table 2.3). Reasons for low 
adherence included side effects of chemotherapy, during which time the patients felt 
unable to engage in exercise. No adverse reactions to exercise were documented in the 
exercise diaries. Similarly, adherence to IMT was variable. Diaries showed gaps in IMT use 
due to side-effects of chemotherapy such as “dry mouth”, “mouth ulcers” and “cold 
sores”, which made using the device uncomfortable.  
 
Table 2.3 Adherence to prehabilitation in the ExPO trial  
Categories of adherence are based on the percentage of suggested exercises that the patients 
documented as completed in their exercise diaries, where non-adherence=0%, very low=1-24%, 
low=25-49%, moderate=50-74%, good=75-99%, and complete adherence=100%.  
 
 
 
 
 
 
 
 
 
Patient number No. of hospital 
exercise sessions 
attended 
Adherence to home 
exercise 
Adherence to IMT 
1 5 Low Low 
2 7 Good Good 
3 5 Moderate Low 
4 3 Moderate Good 
5 2 Very low Very low 
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Secondary outcome results 
Of the 5 patients that completed the exercise sessions, all of whom had comparative CPEX 
data, the differences in mean VO2peak and AT before and after the intervention were 
+2.0ml/kg/ml and +1.5ml/kg/min, respectively (Table 2.4). Of the 6 patients in the control 
group, only 4 had comparative CPEX test data (2 standard care CPEX tests were not 
arranged), which showed a small mean change in VO2peak (+0.3ml/kg/min) and a decrease 
in mean AT of -1.2ml/kg/min. The mean differences between arms were not statistically 
significant. Due to equipment issues, comparative P i-max testing of inspiratory mouth 
pressure could not be done. Because 2 patients in the control arm did not attend a second 
CPEX test, physical activity and QOL data were also missing for these participants, which 
would have been measured, per protocol, at this time. Physical activity levels as measured 
by IPAQ increased in the prehabilitation arm, but remained the same in the control arm. 
Quality of life did not differ significantly between groups. The 30-day postoperative 
cardiopulmonary complication rates were also similar between arms (table 2.5). No 
deaths occurred at 30 days.  
 
 
Table 2.4 Changes in mean variables before and after standard care or prehabilitation in the ExPO 
trial  
 
 
 
 
 
 
 
ΔVariable mean Standard care (n=4) Prehabilitation (n=5) p-value 
VO2peak ml/kg/min +0.3 (SD 3.2) +2.0 (SD 1.4) 0.61 
AT ml/kg/min -1.2 (SD 2.3) +1.5 (SD 1.1) 0.26 
MET-mins/week -432 (SD 315) +883 (SD 1893) 0.12 
QOL (C30 summary score, 
max score = 100) 
-3 (SD 2.9) + 2 (SD 1.5) 0.18 
QOL (OG25 summary score, 
max score = 100) 
13 (SD 7.4) 5 (SD 15.0) 0.46 
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Table 2.5 Complications after oesophagectomy in the ExPO trial  
Data shown are the number of patients and percentage. 
 
 
2.4.5 Discussion 
 
This work represents the first feasibility trial of prehabilitation prior to oesophagectomy. 
The findings demonstrate proof of concept for a future trial in that: all patients referred 
for neoadjuvant chemotherapy and oesophagectomy were eligible for exercise, could be 
recruited in reasonable numbers and engaged in the aerobic and muscle strengthening 
exercises offered; which were safe and well tolerated, with no significant adverse effects 
or decrease in their quality of life. However, whilst there was an improvement in fitness 
in the intervention arm, this study was unable to demonstrate a statistical difference, as 
measured objectively by CPEX testing, over standard care. More participants would be 
needed to see if there was a difference. This study measured complication data to assess 
the safety of prehabilitation rather than its efficacy and no serious adverse reactions were 
reported. Much larger patient numbers would be required in a definitive RCT to 
investigate the effect of prehabilitation on postoperative complications.  
 
Strengths of this study included the design of a unique personalised exercise regime with 
input from physiotherapists, clinicians, patients and patient groups, which was well 
tolerated by patients. A weakness of the study was the small sample size, which was due 
to both a much lower than anticipated number of oesophagectomies at the NNUH over 
the recruitment period and logistical problems with arranging baseline CPEX testing for 
potential participants who wanted to join the trial. As such, I demonstrated proof of 
concept for a future trial with this feasibility information. This was also a single-centre 
study, and patients from Norwich may not be representative of those in other areas of 
the UK, including those from more urban areas, limiting the generalisability. However, I 
was able to demonstrate that patients that declined to participate were similar in 
demographics to recruited patients.  
Outcomes Standard care (n=6) Prehabilitation (n=5) 
30-day morbidity 
Cardiopulmonary complications 
Non-cardiopulmonary complications  
 
4 (67) 
4 (67) 
 
3 (60) 
3 (60) 
30-day mortality 0 0 
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Additional measures to improve recruitment in future work could include the capacity to 
offer supervised exercise sessions closer to patient’s homes as a long travel distance was 
the commonest reason for non-participation. As 18% of participants in this study did not 
receive a second comparative CPEX test (as part of their usual clinical care) and I was 
unable to arrange a baseline CPEX for two potential participants (due to unavailability of 
the CPEX laboratory), it is questionable whether CPEX testing would be feasible in a larger 
future trial to demonstrate the efficacy of an exercise programme. Other tests of fitness 
such as a 6-minute walk test, which does not require any specialist equipment, may be 
more a more feasible measure of fitness improvement in future work.   
 
In summary, the ExPO trial demonstrates that prehabilitation prior to oesophagectomy in 
patients with oesophageal adenocarcinoma undergoing chemotherapy is safe, acceptable 
and well adhered to, but was not able to demonstrate a statistically signi ficant 
improvement in fitness due to small patient numbers (the referral rate for 
oesophagectomy was less than expected). Therefore, this work informs the design and 
planning of a larger feasibility study in this patient population to investigate whether the 
fitness of oesophagectomy patients can be improved in the short time between 
neoadjuvant chemotherapy and surgery by an intervention. Such feasibility data is 
required prior to a full RCT investigating whether prehabilitation can reduce the incidence 
of postoperative complications.  
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2.4.6 An introduction to the next chapter 
 
During the ExPO trial it became clear to me that not all patients would require a 
supervised exercise intervention as some were already engaging in very high levels of 
physical activity (above that offered by the ExPO trial). One of the patients who declined 
to join the study was a keen amateur triathlon competitor, another participant in the 
control arm had a VO2peak of 35.4ml/kg/min - the highest CPEX value recorded for any 
oesophagectomy patient at the NNUH since CPEX testing was introduced 6 years 
previously. Due to this observation, I commenced an observational study while recruiting 
into the ExPO trial, which analysed all oesophagectomy postoperative outcomes at the  
NNUH where preoperative CPEX testing was used. The aim was to determine a threshold 
value for either VO2peak or AT at which patients were at an increased risk of postoperative 
complications. Such a cut-off could then be used to identify a sub-population of relatively 
‘unfit’ oesophagectomy patients that may benefit from exercise prehabilitation. These 
‘unfit’ patients could then be randomised in a future trial, whereas those that were 
objectively deemed ‘fit’ would not be offered prehabilitation as they would be unlikely to 
benefit. The results of this observational work, which was the largest of its kind, were 
surprising in that they were contrary to previously published studies in oesophagectomy 
patients134-136. All studies reported that a lower fitness predicted poor outcomes, and thus 
justified the conduct of the ExPO trial. This new observational work reported that, in this 
specific patient population, there was no association between preoperative fitness, as 
measured by CPEX testing, and postoperative complications of any type or severity. 
Therefore, the evidence base for fitness as an interventional target to reduce 
complications was now inconsistent. As such, after discussion with the chief investigator, 
recruitment into the ExPO trial was paused. This decision was then reviewed by the trial 
management group and trial steering committee. The final decision was to end 
recruitment 6 weeks earlier than originally intended. The basis of this decision was that 
previous retrospective work had methodological flaws, which were addressed in this new 
work. Therefore, further well conducted observational studies were now needed to justify 
a future interventional trial. A review of the available observational evidence and the new 
observational study is presented in the next chapter.  
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Chapter Three: Preoperative aerobic fitness and short-term 
complications after oesophagectomy – a review of the literature 
and an observational study.   
 
Overview 
In this chapter, the association between cardiopulmonary fitness, as measured objectively 
using cardiopulmonary exercise (CPEX) testing, and short term morbidity after 
oesophagectomy are examined in an observational study. A purpose of this work was to 
help stratify patients who may benefit from a future preoperative exercise programme.  
 
Firstly, the laboratory method of CPEX testing and details about its derived variables is 
described. 
 
Secondly, the current literature is reviewed to examine whether there is an association 
between fitness, as measured using CPEX, and short term outcomes after major cancer 
resection surgery, including oesophagectomy.  
 
Thirdly, the results of an original retrospective observational study examining the 
associations between CPEX variables and postoperative outcome in patients who 
underwent an oesophagectomy at the Norfolk and Norwich University Hospital between 
September 2011 and February 2017 is presented. In the discussion, the impact of this 
research and whether future trials in exercise interventions should be progressed is 
considered.   
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3.1 Cardiopulmonary exercise testing (CPEX) an objective measure 
of fitness 
 
 
 
3.1.1 CPEX overview 
 
Cardiopulmonary exercise testing is a clinical exercise “stress test”, which assesses 
exercise limitation. CPEX provides an objective and quantitative assessment of the 
integrated responses of the cardiopulmonary and skeletal muscle systems to increasing 
exercise intensities159, and is considered the gold standard measurement of aerobic 
fitness.160  As a reasonably inexpensive and non-invasive investigation, it is increasingly 
being used for a wide range of clinical applications including: to investigate 
breathlessness, to detect cardiac ischaemia, to monitor patients with cardiac disease 
including heart failure, and provide an assessment of functional cardiopulmonary reserve 
in patients prior to  undergoing major surgery.161  
 
3.1.2 CPEX exercise protocol 
 
There are many different protocols used for exercise testing, but most are similar. The 
test protocol used at the Norfolk and Norwich Hospital is described here. Prior to the test, 
the patient is connected to an electrocardiogram (ECG) monitor as well as a pulse 
oximeter and sphygmomanometer (figure 3.1). A facemask is then fitted tightly to ensure 
there is no air leak and the patient is seated on a static exercise bike with the seat and 
handlebar height adjusted for both comfort and optimal cycling performance (a treadmill 
can be used, but an exercise bike has the advantages of allowing accurate quantification 
of work rate and is more inclusive of patients with limited mobility). A predicted number 
of watts of power that the patient should be able to achieve is calculated by the CPEX 
testing software using the patient variables: age, height and weight. A 10 minute exercise 
protocol is then selected, which incrementally increases pedal resistance over 10 mins to 
achieve their predicted watts. The patient is instructed to pedal at 60 revolutions per 
minute and to exercise to their limit.  The test contains 4 different phases. The first is a 
Rest Phase, typically lasting 3 mins, where the patient sits still on the bike. This allows the 
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patient’s heart rate and respiratory rate to ‘settle’, particularly if they are feeling anxious 
by their surroundings and equipment.  The second phase is Unloaded Cycling lasting 3 
mins, which allows assessment of oxygen consumption without a load applied to the 
pedals, and the effect of hyperventilation usually resolves during this phase. The Ramp 
Phase, describes the incremental loading or breaking of the bike as though the patient 
were cycling up a hill, which is gaining in steepness. The test is stopped by the clinician if 
the patient develops ischaemic ST segment changes on the ECG, or by the patient if they 
have symptoms such as: pre-syncope, severe breathlessness or leg pain, which prevents 
further exercise. The final fourth phase is a further Rest Phase lasting 3-5mins, with 
monitoring of heart rate and ECG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1=ECG monitor, 2=Gas exchange monitor, 3=saturation probe, 4=face mask. Image from 
Parasuraman et al. Healthcare professional’s guide to cardiopulmonary exercise testing. Br J 
Cardiol 2015(2015;22:156). 161 
 
 
 
 
 
Figure 3.1. A cardiopulmonary exercise test being performed on a static exercise bike (cycle 
ergometer) at the CPEX laboratory at Norfolk and Norwich University Hospital.  
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3.1.3 CPEX variables 
 
VO2 
The data obtained during a CPEX test includes heart rate, respiratory rate, the volume of 
oxygen inhaled per minute (VO2) and the volume of carbon dioxide exhaled per minute 
(VCO2). Arguably, the most informative value is the volume of oxygen inhaled (VO2), which 
is expressed in millilitres per minute (ml/min) and then divided by the patient’s 
bodyweight in kilograms, to give the unit: VO2ml/kg/min. VO2 provides information on the 
oxygen transport system, which involves the heart, lungs and muscle tissues, where O2 is 
transferred from the environment to muscle mitochondria. This volume at maximal 
exercise intensity is called VO2max and is the gold standard measure of a patient’s aerobic 
fitness.160 In reality, most elderly patients are unable to achieve their true VO2max, as they 
may be limited by co-morbidities (such as knee arthritis). Therefore, VO2peak is used 
instead, which refers to the volume of oxygen consumed when the patient exercises to 
their peak, which may not necessarily reflect their potential VO2max. Despite the 
differences between VO2max and VO2peak, both variables are often used interchangeably, 
which may not necessarily be correct.  
 
Anaerobic threshold 
The VO2 at anaerobic threshold (AT) is another important variable. Broadly this represents 
the onset of lactate-related anaerobic metabolism, where the glycolytic pathway 
supplements the oxidative pathway in ATP production. In reality, there is likely to be a 
degree of anaerobic metabolism at all work rates.162 However, AT can be thought of as 
the estimated point at which there is a rapid increase in the concentration of blood 
lactate. This point can be measured non-invasively using VCO2; as an increase in lactate is 
accompanied by an almost equal reduction of bicarbonate concentration, with a resultant 
increase in CO2 output (independent of O2 uptake).162 The VO2 at AT can be estimated 
using the V-slope method, which describes the point at which VCO2 relative to VO2 
increases (in the absence of hyperventilation). 159 This is a distinct point because at 
exercise intensity below AT, both VO2 and VCO2 increase linearly.162 As opposed to VO2, 
which is volitional (an unmotivated patient may not wish to exercise to their peak, a 
patient with knee pain may be prohibited from doing so), AT is not. Therefore, AT may be 
a more reliable measure of aerobic fitness, particularly in patients with co-morbidities.163 
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However, because AT is often estimated using the V-slope method there is an element of 
inter and intra-observer variability in its visual detection. 159 This is not the case for VO2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The arrow indicates the approximate point of anaerobic threshold. Image from Parasuraman, et 
al. Healthcare professional’s guide to cardiopulmonary exercise testing. Br J Cardiol 
2015(2015;22:156).161 
 
Figure 3.3 The CPEX reference values for VO2peak and AT for healthy volunteers according to 
recreational exercise behaviour (active or s edentary) and age group (55-64 and 65-74).  
Adapted from Herdy et al. Reference values for cardiopulmonary exercise testing for sedentary 
and active men and women. Arq Bras Cardiol 2011;96(1):54-9.164 
  Age range: 55-64 years Age range: 65-74 years 
Active men VO2peak  35.3 ± 6.2 ml/kg/min 30.0 ± 6.1 ml/kg/min 
AT 23.3 ± 5.2 ml/kg/min 19.9 ± 4.8 ml/kg/min 
Active women VO2peak 28.6 ± 6.1 ml/kg/min 25.1 ± 4.4 ml/kg/min 
AT 18.9 ± 4.4 ml/kg/min 17.4 ± 3.1 ml/kg/min 
Sedentary men VO2peak 30.0 ± 6.3 ml/kg/min 23.1 ± 6.3 ml/kg/min 
AT 19.1 ± 4.0 ml/kg/min 15.9 ± 6.3 ml/kg/min 
Sedentary women VO2peak 23.9 ± 4.2 ml/kg/min 21.2 ± 3.4 ml/kg/min 
AT 16.1 ± 2.8 ml/kg/min 14.9 ± 2.9 ml/kg/min 
Figure 3.2 A graph demonstrating the V-slope method for detecting anaerobic threshold in CPEX testing.  
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VE/VCO2 
A final important variable is VE/VCO2 at AT. This is a ratio of the volume of air exhaled per 
minute (VE) to VCO2. Patients with lung disease, such as chronic obstructive pulmonary 
disease (COPD) may require a greater volume of ventilation to eliminate CO2. Therefore,  
patients with a high VE/VCO2 at AT have an inefficiency of CO2 excretion, or a ventilatory 
inefficiency.165  
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3.2 The association between preoperative CPEX variables and 
outcome after major cancer resection surgery: a review of the 
literature 
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3.2.1 Abstract 
 
Background: Postoperative complications after major surgery are thought to be 
associated with reduced fitness. Surgical cancer patients are often malnourished, cachexic 
and receive neoadjuvant chemotherapy resulting in low preoperative fitness levels. This 
literature review examined the associations between aerobic fitness, as determined 
objectively by preoperative cardiopulmonary exercise testing (CPEX), and short-term 
morbidity after cancer surgery.  
 
Methods: A literature search was undertaken using PubMed, Medline, Embase, CINAHL 
and the Cochrane Library for studies that examined associations between preoperative 
CPEX variables and postoperative complications following surgery for the ten commonest 
cancers.  
 
Results: A total of 21 observational studies were identif ied with 4 957 patients that 
underwent CPEX testing prior to: lung, colorectal, liver, oesophagogastric, bladder and 
pancreas resections.  The median sample size was 105 patients (range 64 – 1 684). No 
studies were found for breast or brain cancers or lymphomas. In lung cancer patients 
undergoing thoracotomy, a VO2peak ≤15ml/kg/min was associated with an increased risk 
of respiratory complications and death. None of the studies in other cancer types had 
adequate sample sizes to report on mortality. CPEX testing had poor to average 
discriminatory accuracy to predict postoperative morbidity in other cancer resection 
surgeries. Findings across the studies were inconsistent, and detection and selective 
reporting biases were likely to be significant.   
 
Conclusions: The utility of CPEX testing prior to cancer surgery is questionable and 
currently should not be used as a single discriminatory tool, except perhaps in patients 
undergoing lung cancer resection by thoracotomy. Larger studies with more robust 
methodologies are currently required to determine the utility of CPEX. 
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3.2.2 Introduction 
 
The surgical stress response following major surgery results in muscle wasting and 
systemic inflammation, with a large increase in tissue oxygen demand and consumption;  
109 increasing the risk of ischaemic events.105  Furthermore, postoperative bed-rest and 
incisional pain inhibits normal lung mechanics, promoting shallow breathing, atelectasis 
and infective lung consolidation.111 These physiological challenges are in part met by a 
patient’s cardiopulmonary reserves, or their ability to increase cardiac output and 
ventilation to meet increased demand. Such reserves are greater in physiologically ‘fitter’ 
patients. Cancer patients represent a specific population, more likely to have underlying 
malnutrition and cachexia than non-cancer patients, with depleted fitness levels.149 166 
Neoadjuvant chemotherapy has also been shown to independently reduce aerobic 
fitness. 5 By measuring a patient’s preoperative cardiopulmonary reserve, or functional 
capacity, we may hypothetically be able to discriminate patients that may or may not 
tolerate the physiological insult associated with surgery. Therefore, measurement of 
preoperative fitness may serve as a preoperative risk prediction tool for the development 
of complications prior to major cancer resection.  
 
CPEX testing represents the gold standard test of aerobic fitness. VO2peak (the maximal 
oxygen consumed at the peak of exercise) and VO2 at estimated anaerobic threshold (AT), 
(a measure of sustainable aerobic activity) are two CPEX variables which have shown 
promise in observational studies to predict both morbidity and mortality after major 
elective surgery.167 In a seminal study from 1993, of 187 elderly patients undergoing major 
abdominal surgery, a preoperative AT cut-off of 11ml/kg/min had a sensitivity of 91% and 
specificity of 74% for predicting postoperative mortality after major abdominal surgery.131 
Since then, multiple, often small, observational studies have been published in various 
cancer surgery specialities. However, the results from these are inconsistent, possibly 
explained by biases inherent in the methodology such as performance and detection 
biases (due to unblinded clinical teams and outcome assessors, respectively) as  well as 
selective reporting bias, which is likely to be substantial.168 Although 3 reviews of CPEX 
testing and major surgeries have been published,167 169 170 all included non-cancer patients 
and excluded common cancers such as lung and bladder. Furthermore, important sources 
of bias do not appear to have been adequately considered previously.  The aim of this 
review was to assess the association between CPEX testing and short-term postoperative 
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morbidity and mortality after common major cancer resection surgery; with due and full 
consideration of potential biases both in terms of their magnitude and direction. If a 
convincing inverse association exists, it may not only support the preoperative use of CPEX 
to determine operability and postoperative monitoring and management, but also 
identify fitness as a modifiable risk factor for investigation in randomised controlled trials 
of surgical cancer patients.   
 
 
3.2.3 Methods 
 
The preferred reporting items for systematic reviews (PRISMA) guidelines were used to 
standardise the methods of conducting and reporting this review. 171 The ten commonest 
causes of cancer deaths in the UK in 2014 50 were identified (lung, bowel, breast, prostate, 
pancreas, oesophagus, bladder, brain, liver and lymphoma) and a literature search was 
conducted using PubMed, Medline, Embase, CINAHL and the Cochrane library (from 
commencement to 5th July 2017) for studies that examined associations between 
preoperative CPEX and postoperative complications following cancer resection surgery. 
The search terms used were: CPEX, CPET, exercise testing, anaerobic threshold, VCO2, 
ventilatory inefficiency, oxygen consumption, VO2, preoperative exercise, aerobic 
exercise. For each cancer, additional specific search terms were added (appendix  2).  
 
Inclusion/exclusion criteria 
Analytical studies (cohort, case-control, randomised controlled trials) that investigated 
the association between preoperative CPEX variables and short-term (up to 90 days) 
morbidity and mortality were included.  Due to the large number of initial studies 
identified across all surgical specialities, studies were excluded with sample sizes <100 
patients, unless there were <2 studies in that surgical population in which case the total 
sample size needed to be at least 60 patients, which was considered the minimum size to 
determine associations with a moderate event rate.172 In order to select studies which 
examined only cancer populations, studies with a large proportion (≥25%) of non-cancer 
patients were also excluded (unless cancer patients were analysed separately) as were 
investigations that combined multiple surgical patient populations (e.g. colore ctal, 
urological and upper gastrointestinal cancer patients), unless these groups were sub-
analysed. 
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3.2.4 Results  
 
A total of 21 hospital-based cohort studies (12 prospective, 9 retrospective) were included 
in this review consisting of 4 957 patients that underwent CPEX testing prior to: lung, 138 
139 173-176 colorectal, 177-179  liver, 180-182 oesophagogastric, 134-136 bladder 183-185 and pancreas 
resections 186-188  (figure 3.4). No studies were found in breast, brain or lymphoma cancers. 
No randomised controlled trials of any cancer site were identified. Data was extracted 
from each study (including study design, sample size, outcome measurement and effect 
sizes) and tabulated (table 3.1).  
 
 
 
 
 
 
 
Figure 3.4 PRISMA diagram  
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Lung cancer 
Four hundred and three studies were identified, with 63 potentially relevant papers by 
title. A review of these abstracts identified 23 potentially relevant papers. Six studies 138 139 
173-176 met the inclusion criteria and were included in this review. All were observational 
cohort studies (2 prospective, 4 retrospective), with a total of 2 814 patients from 
hospitals within Europe and the USA. The largest study was a retrospective analysis of  1 
684 patients who had lung cancer surgery identified from the European Society of 
Thoracic Surgeons (ESTS) database, 139 which is voluntarily contributed to by clinicians 
from 235 sites across Europe. The authors reported no association between VO2peak and 
all cause morbidity (for either video assisted thoracoscopic surgery (VATS) or thoracotomy 
resections), but a significant association with mortality in patients undergoing 
thoracotomy resection with a VOpeak <15ml/kg/min (X2 test, p=0.008). Whilst this study 
had several strengths including, a large sample size and use of propensity matching to 
reduce selection bias, it had significant limitations, which were acknowledged by the 
authors. The largest of these was the potential for measurement error for complications 
through the use of a voluntary multi-institutional database, where the accuracy of the 
data entry has not been validated.139 Inaccurate recording of outcome would lead to an 
attenuation of any associations between CPEX variables and outcome.  
 
The second largest study was a multi-centre (9 centres) prospective observational 
investigation of 346 patients from the USA who underwent thoracotomy and lung cancer 
resection surgery.138 In contrast to the results of the previous study, the authors reported 
that VO2peak was significantly lower in the group with complications (15.2ml/kg/min) 
compared to those without (16.7ml/kg/min) although the mean difference was small:  -
1.47ml/kg/min (95% CI 0.55-2.4), p=0.002. The authors also undertook a further sub-
analysis in patients with the outcomes of respiratory failure (n=33) and death (n=15). Both 
events were associated with a lower mean VO2peak (14.7ml/kg/min), p=0.041 compared 
to those without complications (mean difference 2ml/kg/min), although the small 
number of events is noted. Whilst the large sample size, prospective design and multi-
centre participation increases power, reduces bias and enables generalisability, 
respectively, there were limitations. A pre-defined criteria for what constituted each 
complication was not established, nor were the postoperative outcomes measured in a 
blinded fashion, both of which could contribute to detection bias resulting in spurious 
over-estimation of the associations found. Furthermore, the authors defined 
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postoperative morbidity as a composite outcome, which included complications lacking a 
clear plausible mechanistic relationship with aerobic fitness; such as red blood cell 
transfusions (n=38). Such an event is more likely to be associated with intra-operative 
blood loss (perhaps due to longer operating times in patients with underly ing lung 
disease), suggesting that residual confounding may explain some of the associations 
found.  
 
The other 4 studies in lung cancer patients were all hospital -based cohort studies, which 
reported inconsistent findings.173-176 Two of the investigations were conducted by the 
same research group,174 176 which reported an inverse association between VO2peak and 
respiratory complications (p=0.015) in one of their studies, 174 but were unable to 
subsequently replicate this finding (p=0.50) in the other176  - despite similar 
methodologies and patient populations. Detection bias due to non-blinded assessment of 
outcomes may have contributed to the variability in the findings. The two other studies 
reported an inverse association between higher VO2peak and cardiopulmonary 
complications, OR 0.05 (95% CI 0.01-0.58), p=0.02175 and OR 0.79, 95% CI 0.71-0.88, 
p=<0.0001.173 However, the large variation in the effect size estimates and wide 
confidence intervals reflects the imprecision of their findings. Again, outcome assessment 
was not blinded, which may have spuriously inflated the reported effect sizes if the CPEX 
scores were known to the assessor.  
 
Summary of findings: Observational studies have reported that VO2peak is associated with 
complications after lung cancer resection surgery. More specifically, the two largest 
studies reported that a VO2peak <15ml/kg/min was associated with an increased risk of 
respiratory failure 13 and death following lung cancer resection by thoracotomy.138 139 This 
association is plausible given the nature of the surgery. However, only one study in lung 
cancer surgery examined outcomes after VATS and found no association between VO2peak 
and morbidity or mortality.139 As VATS is increasingly becoming used for lung cancer 
resection, the utility of CPEX testing needs to be updated to determine if it is of value in 
less invasive surgeries for lung cancer resection.  
 
Colorectal cancer 
The literature search identified 431 studies, of which 30 were considered relevant based 
on their title. These were reduced to 13 after reading the abstracts, of which 3 met the 
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inclusion and exclusion criteria and were included in this review.177-179 The main reason 
for excluding other investigations was their inclusion of >25% of non-cancer patients. All 
3 were observational studies from the same UK group. The largest was a retrospective 
multi-centre (6 sites) UK investigation179 of 703 patients, most of which had malignant 
disease (87%). In contrast to the studies in lung cancer surgery, all cause morbidity was 
measured using a validated PostOperative Morbidity Survey (POMS) 189 at postoperative 
day 5.158 The severity of complications were graded using the system devised by Clavien 
and Dindo.158 This grading system is based upon the level of intervention required to treat 
a complication; from normal postoperative adjuncts such as supplementary oxygen, 
analgesia and anti-emetics (grade 1), to additional medicines above usual standard care, 
including antibiotics (grade 2). Grade 3 is a complication requiring operative intervention 
and grade 4 complications require organ support in critical care. The authors reported a 
significant difference in both median VO2peak and AT in patients with and without all cause 
morbidity of any Clavien-Dindo grade (p=0.031 and p=0.002, respectively). Receiver 
Operator Characteristic (ROC) Curve analyses were also undertaken to show how 
sensitivity and specificity varied with changing thresholds, which was expressed as an area 
under the ROC curve (AUC). The AUC takes into consideration the accuracy of a diagnostic 
test (in terms of sensitivity and specificity) across a range of threshold values. 190 In the 
context of CPEX testing, where the association may be inverse, the AUC is equal to the 
probability that if a pair of patients (one with a complication and one without) are selected 
at random, the patient with a complication will have a lower CPEX value than the 
complication-free patient.190 An AUC of 1.0 indicates a perfect test, and 0.5 a completely 
uninformative one, i.e., a result occurring by chance. An AUC of <0.7 would be indicative 
of a  poor predictive test, 0.7-0.8 average accuracy and >0.8 good accuracy as a diagnostic 
test across a range of thresholds.190 In this study, AT had average discrimination (i.e. 0.70-
0.80) with an AUC of 0.79, 95% CI 0.76-0.83 with an optimal cut-point at 11.1ml/kg/min 
(78% sensitivity and 71% specificity). The AUC for VO2peak was 0.77, 95% CI 0.71-0.82 with 
an optimal cut-point of 18.2ml/kg/min (70% sensitivity and 72% specificity).  However, 
similar to the previous studies in lung cancer, the outcome assessors were not blinded to 
CPEX data, so detection bias could explain the associations found. Indeed, there were 
significant variations (p=<0.001) in AUC values across recruited hospital sites 
(supplementary material), where the largest recruiting centre (239 patients) had more 
modest values for VO2peak (AUC 0.73) and AT (AUC 0.68) compared to the above pooled 
values.  Complications without a clear plausible biological relationship with aerobic fitness 
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were associated with CPEX values including; postoperative pain and gastrointestinal 
symptoms (such as ileus). Therefore, residual confounding may explain some inverse 
associations found. The same group previously published a prospective blinded 
observational study in 136 patients undergoing colonic surgery, most of whom (89%) had 
malignant disease.178 With detection bias removed, the predictive performance of CPEX 
for day 5 morbidity was poor (AUC <70). For AT the AUC was 0.63, 95% CI 0.54-0.73, with 
a lower optimal cut-point at 10.1ml/kg/min (68% sensitivity and 58% specificity). The AUC 
for VO2peak was 0.63, 95% CI 0.53-0.73 with an optimal cut-point of 16.7ml/kg/min (55% 
sensitivity and 69% specificity).  Furthermore, 14% of their sample who underwent CPEX 
testing and surgery were excluded as they “lacked complete data”. It is unclear whether 
these data were missing at random, and may therefore represent a source of selection 
bias.  
 
The final study by the same group investigated 95 rectal cancer patients undergoing 
resection surgery, 68 of whom received neoadjuvant treatment. 177 Morbidity and 
mortality were measured blinded, using the same methods reported in their other 
work.178 179 Both VO2peak and AT were associated with total morbidity at day postoperative 
day 5. For AT, the AUC showed good accuracy at 0.87 (95% CI 0.79-0.95) with an optimal 
cut-point of 10.6ml/kg/min (84% sensitivity and 92% specificity). VO2peak had an AUC of 
0.85 (95% CI 0.77-0.93) and cut-point of 18.6ml/kg/min (82% sensitivity and 80% 
specificity). However, the small sample size increased the risk of a chance finding.  
 
Summary of findings: Overall the association between preoperative CPEX and 
postoperative outcome following colorectal cancer surgery is derived from observational 
studies from the same research group. There were inverse associations between VO2peak 
and AT and all cause morbidity at day 5 post surgery. However, detection bias and residual 
confounding could not be excluded. Furthermore, 5 day POMS morbidity measured 
complications of a low severity (Clavien-Dindo ≤2) in the majority of patients, which 
makes the clinical usefulness of these findings questionable. POMS has also not been 
validated as an index of overall morbidity.189 The decision of whether or not to undergo 
surgery is unlikely to be meaningfully informed by this work. Larger multicentre studies 
are required to address whether improved fitness prior to colorectal surgery reduces the 
risk of major postoperative outcomes including death for which there are plausible 
biological mechanisms, with morbidity measured by assesors blinded to CPEX data.   
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Liver Cancer 
One hundred and eight studies were identified using the search terms, of which 7 were 
considered relevant based on their title. These were reduced to 4 after reading the 
abstracts and 3 met the inclusion criteria and were included in this review. 180-182 All 3 
were UK hospital-based cohort investigations (2 prospective and 1 retrospective) of 
patients that underwent both major and minor hepatectomies.180-182 The largest, a 
retrospective study of 197 patients, found no associations between in-hospital morbidity 
and VO2peak or AT.181 The study did not measure complications using a validated outcome 
measure or blind its assessors to CPEX values. However, the result of such bias may inflate, 
rather than reduce, the effect size reported. The second largest study, a UK prospective 
cohort of 104 patients, did report an association between both VO 2peak, AT and 
complications.182 This used a validated outcome measure (POMS) with assessors blinded 
to the CPEX scores. However, the authors chose to report complications at postoperative 
day 3, which is not a conventional time at which to report outcomes. This timeframe was 
not defended in the study, and in the absence of a pre -defined protocol, selective 
reporting bias cannot be ruled out, which may have produced a false positive result. 
Furthermore, the high complication rate (70%) likely reflects routine, less severe, 
postoperative interventions (analgesia, urinary catheter, oxygen supplementation), which 
are likely to be clinically insignificant and rare beyond day 3.189 When the authors graded 
the severity of complications according to Clavien-Dindo they found no associations 
between CPEX variables and complications of grade 3 (needing surgical intervention) or 
above. The final study was a UK prospective cohort investigation of 92 patients, which 
reported no associations between VO2peak or AT and 30 day morbidity (as measured by 
POMS).180 The authors did document that VE/VCO2 (a CPEX measure of ventilatory 
efficiency) was associated with complications, but its predictive value was poor; where a 
value of 34.5 provided a sensitivity of only 47% for complications.  
 
Summary of findings: Currently, there is insufficient data demonstrating an association 
between CPEX and outcome following hepatic resection. A large well designed 
multicentre study, with 30-day complication data measured blinded to CPEX data, is 
needed to assess CPEX in liver surgeries.  
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Oesophageal Cancer 
Four hundred and seventy eight studies were identified of which 11 were considered 
relevant based on their title, and reduced to 5 after reading the abstracts. Of these, 3 met 
the inclusion criteria and were included in this review.134-136 All 3 were retrospective 
hospital-based cohort studies with small sample sizes from single institutions. The largest 
was a Japanese analysis of 91 patients who underwent McKeown oesophagectomy for 
squamous cell carcinoma.134  Only cardiopulmonary complications were measured and 
occurred in 19% of patients. The mean VO2peak was lower in patients with, vs. those 
without cardiopulmonary complications (789ml/min/m2 vs. 966ml/min/m2, t-test 
p=<0.001). These values approximate to 20.9ml/kg/min vs. 25.6ml/kg/min [conversion 
using the average height and weight of a Japanese male].191 No association was found 
between AT and complications (t-test, p=0.12). The second largest study was a UK 
investigation of 78 patients, predominantly with adenocarcinoma (74%), undergoing 
oesophagectomy (64% receiving neoadjuvant chemotherapy).136 Cardiopulmonary 
outcomes occurred in 42% of patients (n=33) and non-cardiopulmonary in 24% (n=19). 
Similar to the Japanese study, a low mean VO2peak was associated with cardiopulmonary 
complications although the mean difference was small (19.2ml/kg/min in those with 
complications vs. 21.4ml/kg/min in those without, t-test p=0.04). AT was also not 
associated with complications (13.2ml/kg/min in those with complications vs. 
14.4ml/kg/min in those without, t-test p=0.07). ROC curve analysis estimated the 
predictive value of both VO2peak and AT to be poor (i.e., <70), AUC 0.63 (95% CI 0.50-0.76, 
p=0.02) and 0.62 (95% CI 0.49-0.75, p=0.03), respectively. The same group subsequently 
published a further study of 103 patients with both oesophageal and gastric cancers that 
underwent CPEX testing prior to oesophagectomy (62%) and gastrectomy.135  The findings 
were the reverse of their previous work, in that, this time; a lower AT was associated with 
cardiopulmonary complications (9.9ml/kg/min in those with complications vs. 
11.2ml/kg/min in those without, p=0.05), while VO2peak was not (16.6ml/kg/min in those 
with complications vs. 14.6ml/kg/min in those without, p=0.07). ROC analysis again 
reported both AT and VO2peak to be poorly predictive of complications (AUC 0.62 (95% CI 
0.50-0.74, p=0.06) and 0.60 (95% CI 0.48-0.72, p=0.08, respectively). The most significant 
limitation of all three studies, apart from their small sample sizes and single institution 
design was the potential for detection bias for complications due to unblinded outcome 
assessments, particularly for complications which can be subjectively diagnosed (e.g. 
pneumonia). This bias could lead to an over-estimate of the association between CPEX 
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variables and outcomes. Such methodological error may explain why the same group 
were unable to replicate their previous findings.135 136 
 
Summary of findings: Associations between CPEX variables and outcome after 
oesophagectomy are from small retrospective observational studies that did not use a 
validated measure of postoperative outcomes, or capture complications with blinding to 
CPEX values. The absence of blinding could result in an inflation of the association 
between CPEX values and postoperative outcomes.  Further large studies where 
complications are strictly defined and measured by assessors blinded to CPEX values are 
needed.  
 
Bladder Cancer 
Thirty five studies were identified, with 9 potentially relevant papers identified by their 
title. A review of these 9 abstracts identified 5 potentially relevant papers, but only 3 met 
the inclusion criteria.  All were prospective hospital -based cohort studies, with a total of 
256 patients from hospitals in the UK.183-185 The largest was of 105 patients who 
underwent preoperative CPEX testing prior to either robot assisted (n=38) or open (n=67) 
cystectomy.184 Complications were measured at day 90 by blinded assessors and were 
associated with a significantly lower median AT (10.6 vs 11.8, U-test p=0.007) and VO2peak 
(14.3 vs 15.4, U-test p=0.02) compared to patients without complications. Additionally 
VE/VECO2 was higher in the complication group than in those without (33.3 vs 30.3, U-
test p=0.007). Whilst these findings are convincing in that there is consistency of 
associations across 3 CPEX values, the small study sample from a single institution 
presents a significant limitation to a more generalised interpretation of the ir results.  The 
second largest study was of 82 patients who underwent CPEX prior to intracorporal 
robotic assisted radical cystectomy.185 There were no associations between any CPEX 
variables and outcome. However, both the small sample size and low number of 
complications (n=14) results in a lack of statistical power to detect clinically meaningful 
associations with CPEX. The smallest prospective cohort study was of 69 patients who 
underwent radical cystectomy. Again, no CPEX values were predictive of complications 
when the patients were divided into two groups, composed of those with and without a 
complication. However, sub-analysis according to the presence of a Clavien-Dindo grade 
≥3 complication (n=13 vs n=56) found an inverse association between AT and major 
complication risk, OR 0.74 (95% CI 0.57-0.97). Again, the results of this single institution 
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study with a small sample size are difficult to interpret, particularly when no post-hoc 
analyses according to different complication severities were undertaken, which increases 
the risk of a chance finding in a small sub-group.  
 
Summary of findings: The evidence of an association between CPEX and post-cystectomy 
outcomes is from small single institution studies, which reported conflicting findings. 
Therefore, larger studies which limit sources of bias are required to clarify whether an 
association exists. 
 
Pancreatic Cancer 
Thirty one studies were identified, with 8 potentially relevant papers by title. A review of 
these 8 abstracts identified 3 potentially relevant papers and all 3 met the inclusion 
criteria.186-188 These were UK hospital based-cohort studies (2 retrospective, 1 
prospective) with a total of 288 patients. None of the studies used blinded outcome 
assessments. The largest was a retrospective study of 124 patients who had CPEX testing 
prior to pancreaticoduodenectomy.186 Complications occurred in 44% of patients and 
were defined using POMS189 and the International Study Group definition of Pancreatic 
Fistula (ISGPF).192 There was no association between VO2peak and complications, including 
pancreatic leak. AT was dichotomised using a cut-point of 10.1ml/kg/min (a value derived 
from their previous work),193  and included in a multivariable logistic regression model, 
which estimated that AT <10.1ml/kg/min greatly increased the odds of a pancreatic leak, 
OR=5.79 (95% CI 1.62-20.63). The imprecision of this estimate likely reflects both the 
dichotomisation of a continuous variable and the small pancreatic leak events in the total 
sample (n=29). The second largest study was a retrospective analyses of 100 patients that 
underwent preoperative CPEX and major pancreatic surgery (98% 
pancreaticoduodenectomy).187 Again, AT was dichotomised, rather than treated as a 
continuous variable. The chosen point of dichotomisation (10ml/kg/min) was not justified 
in the report and it was unclear if chosen a priori. The results showed a greater frequency 
of pancreatic leak (occurring in 25 patients), when AT was <10ml/kg/min (35.4% vs. 16%, 
p=0.028). However, statistical significance was lost when leaks were graded according to 
the ISGPS classification (p=0.091). Selective reporting bias cannot be excluded, 
particularly when a seemingly arbitrary threshold was used to dichotomise a continuous 
variable. Furthermore, dichotomisation during analysis, results in a loss of  statistical 
power and increases the risk of a false positive result.194 The final investigation was a 
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prospective cohort study of 64 patients who underwent pancreaticoduodenectomy, 
which included a per-protocol statistical analysis.188  The authors reported no associations 
between AT or VO2peak and all complications, OR 1.07 (95% CI 0.83-1.39) and OR 1.00 (95% 
CI 0.86-1.18), respectively.  
 
Summary of findings: The studies in pancreatic cancer surgery have small patient 
numbers and potential sources of detection and selective reporting biases which makes 
interpretation of their findings difficult. Similar to other cancer resection surgeries, large 
well-designed studies are needed to clarify whether there is an association between 
fitness, as determined by CPEX testing, and outcome.  
 
3.2.5 Discussion  
 
Overall, the evidence for associations between preoperative CPEX values and 
postoperative outcome after cancer resection surgeries is mostly derived from small 
observational studies.  Many were underpowered to report on the risk of mortality, which 
was usually a secondary outcome measure. However, in the largest study of its kind, a low 
VO2peak was associated with increased mortality after lung cancer resection by 
thoracotomy.139 However, minimal access lung cancer surgery (VATS) is now becoming 
increasingly common, with 40% of all lobectomies for lung cancer in 2016 performed via 
this approach (vs. 30% in 2014).195 Therefore, the evidence base for CPEX needs to be 
updated to reflect changes in operative practice. For morbidity, preoperative CPEX testing 
has at best, poor135 136 178 to average179 discriminatory accuracy to predict postoperative 
outcomes after cancer resection surgery, so has limited utility as an isolated preoperative 
screening tool. Furthermore, investigations often used composite outcomes and included 
low Clavien-Dindo graded complications,178 179 182 which reduces the clinical 
meaningfulness of associations found.196 Much research in CPEX testing has been a 
continuation of the seminal work of Older et al, in a paper published in 1993; reporting 
that AT may predict postoperative cardiac related death after major surgery.131 However, 
subsequently there seems to have been incorrect interpretations of this original plausible 
hypothesis. Cardiac related death has a relationship with aerobic fitness; mortality events 
are a reflection of how patients respond once complications have occurred. 163  Patients 
that die as a result of such complications are likely to lack the necessary cardiopulmonary 
and musculoskeletal reserves, which are required when there are ongoing physiological 
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stresses and prolonged ITU bed-rest.163 These outcomes are very different to those 
measured in some of the CPEX studies in this review, which include surgical wound 
infection on postoperative day 3 182 or increased analgesia need due to postoperative pain 
179 (as measured by POMS 189). Ideally, observational studies investigating cardiac death 
are now required, but pragmatically may be difficult due to the small number of such 
events. However, to justify preoperative use of CPEX in cancer surgery, it should be shown 
that CPEX can accurately identify patients at risk of significant postoperative 
complications which have a substantial impact on clinical care. 
 
Early evidence from randomised controlled trials (RCTs) suggests that cardiopulmonary 
fitness may not be an interventional target to reduce complications after surgery. A 
double-blinded RCT sought to improve cardiac output in unfit patients using 
intraoperative stroke volume optimisation with intravenous fluids in 220 patients having 
either rectal resections (n=208) or cystectomy (n=12).197 However, the authors reported 
no significant difference between the intervention and standard care groups in 
postoperative complication rates (p=0.72), or length of stay (p=0.091). Complication 
rates, including major events such as anastomotic leak and re-operation, were no more 
frequent in patients with an AT <11ml/kg/min than those above this threshold. The first 
RCT of a preoperative exercise intervention in lung cancer patients was recently 
published. This Swiss trial of 151 lung cancer patients, compared a high intensity exercise 
programme with standard care and found that whilst VO2peak was significantly increased 
in the intervention group, this did not translate into a significant reduction in 
postoperative complications (X2 p=0.08).148 Although the authors noted that a larger 
sample size may have detected a smaller effect size. To date, there are no published 
exercise intervention RCTs in oesophageal surgery.  
 
In conclusion, it is plausible that physiological changes in the cardiopulmonary and 
skeletal muscle systems through exercise training could reduce some postoperative 
complications and deaths following major cancer resection surgery. However, the 
evidence from observational studies suggests that the effect size, if present at all, is likely 
to be small. This unintuitive finding may be explained by the size of the physiological insult 
associated with major cancer resection surgery. Taking oesophagectomy as an example; 
resection and reconstruction of the upper gastrointestinal tract results in a complication 
profile reflective of the operative field rather than fitness, where the cardiopulmonary 
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system is directly affected. However, cardiorespiratory and musculoskeletal reserves may 
be critical in the ability of a patient to respond once a complication has occurred. 163 To 
assess the relationship between CPEX variables and mortality requires a large multi-centre 
observational study to acquire an adequate sample size. Until this evidence is available, 
CPEX testing in isolation is unlikely to meaningfully inform cancer surgery practice, and 
RCTs of fitness interventions to improve short term outcomes after cancer surgery are not 
currently justified.  
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Author, year Study design Sample 
size 
(n=) 
Postoperative 
complications 
measured (rate of 
occurrence) 
Diagnostic 
criteria for 
complications? 
Complication 
severity 
classified? 
Blinded 
complication 
assessment? 
Association 
between VO2peak 
and measured 
complications 
(effect size) 
Association between AT 
and measured 
complications (effect 
size) 
Lung cancer        
Begum, 
201512 
Retrospective 
case-matched 
multi-centre 
cohort s tudy 
1 684 In-hospital 
cardiopulmonary 
compl ications (30%) 
 
 
   No association Not measured 
Brunelli, 
201217 
Retrospective 
hospital-based 
cohort s tudy 
225 30-day cardiopulmonary 
compl ications (23%) 
 
✔   No association Not measured 
Licker, 201114 Retrospective 
hospital-based 
cohort s tudy 
210 In-hospital 
cardiopulmonary 
compl ications (22%) 
✔   OR = 0.79, 95% CI 
0.71-0.88, 
p=<0.0001 
Not measured 
Torchio, 
201016 
Retrospective 
hospital-based 
cohort s tudy 
145 30-day cardiopulmonary 
compl ications (15%) 
✔   OR 0.05, 95% CI 
0.01-0.58, p=0.017 
Not measured 
Brunelli, 
200915 
Prospective 
hospital-based 
cohort s tudy 
204 In-hospital 
cardiopulmonary 
compl ications (23%) 
✔   No association No association 
Loewen, 
200713 
Prospective 
hospital-based 
multi-centre 
cohort s tudy 
346 30-day cardiopulmonary 
compl ications (40%) 
   Yes , but no 
RR/OR/HR reported 
Not measured 
Table 3.1 Characteristics of studies investigating the association between preoperative CPEX and postoperative complications following major cancer resection surgery 
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Table 3.1 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author, year Study design Sample 
size (n=) 
Postoperative 
complications 
measured (rate of 
occurrence) 
Diagnostic 
criteria for 
complications 
stated? 
Complication 
severity 
classified? 
Blinded 
complication 
assessment? 
Association 
between VO2peak 
and measured 
complications 
(effect size) 
Association between AT 
and measured 
complications (effect 
size) 
Colorectal  cancer        
West, 201620 Retrospective 
multi-centre 
cohort s tudy 
703 Al l  cause morbidity at 
postoperative day 5 
(36.7%) 
POMS Clavien-
Dindo 
 ≤18.2ml/kg/min, OR 
2.15, 95% CI 1.01-
4.59, p=0.05 
≤11.1ml/kg/min, OR 
7.56, 95% CI 4.44-12.86, 
p=<0.001) 
West, 201418 Retrospective 
hospital-based 
cohort s tudy 
95 Al l  cause morbidity at 
postoperative day 5 
(48%) 
POMS Clavien-
Dindo 
✔ ≥18.8ml/kg/min, OR 
0.07, 95% CI 0.03-
0.19, p=<0.001 
≥11.2ml/kg/min,  OR 
0.07, 95% CI 0.03-0.19, 
p=<0.001) 
West, 201419 Prospective 
hospital-based 
cohort s tudy 
136 Al l  cause morbidity at 
postoperative day 5 
(48%) 
POMS Clavien-
Dindo 
✔ No RR/OR/HR 
reported) 
OR 0.77, 95% CI 0.66-
0.89, p=0.0005) 
Liver cancer        
Kas ivisvanathan, 
201523 
Prospective  
hospital-based 
cohort s tudy 
108 3-day a ll cause 
morbidity (70%) 
POMS  Clavien-
Dindo 
✔ Uninterpretable 
from data provided 
Uninterpretable from 
data  provided 
Dunne, 201422 Retrospective 
hospital-based 
cohort s tudy 
197 Al l  cause in-hospital 
morbidity (44%) 
 Clavien-
Dindo 
 No association No association 
Junejo, 201221 Prospective  
hospital-based 
cohort s tudy 
92 Al l  cause in-hospital 
morbidity (51%) 
POMS None  No association No association 
         
POMS=Postoperative Morbidity Survey (a validated measure of postoperative complication outcomes). Clavien-Dindo is a standardised therapy orientated grading system for the severity of 
postoperative compilations in surgical practice.  
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Author, year Study design Sample 
size (n=) 
Postoperative 
complications 
measured (rate of 
occurrence) 
Diagnostic 
criteria for 
complications 
stated? 
Complication 
severity 
classified? 
Blinded 
complication 
assessment? 
Association 
between VO2peak 
and measured 
complications 
(effect size) 
Association between AT 
and measured 
complications (effect 
size) 
Oesophageal  cancer  
      
Moyes , 201325 Retrospective 
hospital-based 
cohort s tudy 
103 Al l  cause in-hospital 
morbidity (55%) 
CTCAE   No association Yes , but no RR/OR/HR 
reported 
Forshaw, 200824 Retrospective 
hospital-based 
cohort s tudy 
78 Al l  cause in-hospital 
morbidity (not stated) 
CTCAE   Yes , but no 
RR/OR/HR reported 
No association 
Nagamatsu, 
200126 
Retrospective 
hospital-based 
cohort s tudy 
91 In-hospital 
cardiopulmonary 
compl ications (19%) 
   Yes , but no 
RR/OR/HR reported 
No association 
Bladder cancer        
Lamb, 201629 Prospective  
hospital-based 
cohort s tudy 
82 30-day Clavien-Dindo 
grade ≥3 a ll cause 
morbidity (12.6%) 
 
 Clavien-
Dindo 
(grade≥3 
only) 
 No association No association 
Tolchard, 201428 Prospective  
hospital-based 
cohort s tudy 
105 90-day a ll cause 
morbidity (31%) 
 Clavien-
Dindo 
✔ Yes , but no 
RR/OR/HR reported 
AT ≥11.0ml/kg/min, OR 
0.72, 95% CI 0.58-0.91) 
Prentis, 201327 Prospective  
hospital-based 
cohort s tudy 
69 In-hospital all cause 
morbidity (56%) 
 Clavien-Dindo ✔ 
No association No association 
         
CTCAE=Common Terminology for Adverse Events (a descriptive terminology used in Adverse Event (AE) reporting, usually in clini cal drug trials) 
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Table 3.1 (continued) 
 
 
 
 
 
 
 
Author, year Study design Sample 
size (n=) 
Postoperative 
complications 
measured (rate of 
occurrence) 
Diagnostic 
criteria for 
complications 
stated? 
Complication 
severity 
classified? 
Blinded 
complication 
assessment? 
Association 
between VO2peak 
and measured 
complications 
(effect size) 
Association between AT 
and measured 
complications (effect 
size) 
Pancreatic cancer  
      
Chandrabalan, 
201331 
Retrospective 
hospital-based 
cohort s tudy 
100 Not s tated ISGPF Clavien-
Dindo  
Not s tated No association 
Junejo, 201332 Prospective 
hospital-based 
cohort s tudy 
64 In-hospital all cause 
morbidity (64%) 
ISGPF Fis tula by 
ISGPF  
 No association No association 
Ausania, 201230 Retrospective 
hospital-based 
cohort s tudy 
124 In-hospital all cause 
morbidity (44%) 
ISGPF & POMS Fis tula by 
ISGPF  
 No association AT ≤10.1ml/kg/min, OR 
5.79, 95% CI 1.62-20.63) 
         
ISGPF=International study group on Pancreatic Fistula (a definition derived by an international panel of pancreatic surgeons) 
131 
 
 
 
 
 
 
 
 
 
 
3.3 The association between preoperative cardiopulmonary exercise 
test variables and short-term morbidity following oesophagectomy: 
a hospital-based cohort study. 
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3.3.1 Abstract 
 
Background: Postoperative complications after oesophagectomy are thought to be 
associated with reduced fitness. This observational study explored the associations 
between aerobic fitness, as determined objectively by preoperative cardiopulmonary 
exercise testing (CPEX), and 30-day morbidity after oesophagectomy.  
 
Methods: Two hundred and fifty four consecutive patients that underwent 
oesophagectomy at a single academic teaching hospital between September 2011 and 
March 2017 were retrospectively identified. Postoperative complication data were 
measured using the Esophageal Complications Consensus Group definitions and graded 
using the Clavien-Dindo classification system of severity (blinded to CPEX values). 
Associations between preoperative CPEX variables and postoperative outcomes were 
estimated using logistic regression.  
 
Results: Two hundred and six patients (77% male) were included in the analyses, with a 
mean age of 67 years (SD 9). The mean values for VO2peak and AT were 21.1ml/kg/min (SD 
4.5) and 12.4ml/kg/min (SD 2.8), respectively. The vast majority of patients (98.5%) had 
malignant disease; predominantly adenocarcinoma (84.5%), for which most received 
neoadjuvant chemotherapy (79%) and underwent minimally invasive Ivor Lewis 
oesophagectomy (53%). Complications at postoperative day 30 occurred in 111 patients 
(54%), the majority of which were cardiopulmonary (72%). No associations were found 
between preoperative CPEX variables and morbidity for either VO2peak (OR 1.00, 95% CI 
0.94-1.07) or AT (OR 0.98, 95% CI 0.89-1.09).  
 
Conclusions: Preoperative CPEX variables were not associated with 30-day complications 
following oesophagectomy. This suggests that the effect of aerobic fitness on 
postoperative outcome, is at best likely to be small. The findings do not support the use 
of CPEX as an isolated preoperative screening tool to predict short-term morbidity after 
oesophagectomy. However, replication of these findings in other representative 
populations is now required before definitive conclusions can be drawn.  
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3.3.2 Background 
 
Oesophageal resection and reconstruction (oesophagectomy) is the only consistent 
treatment modality that offers a potential cure for oesophageal cancer,198 but carries a 
high risk of postoperative complications. UK national audit figures report that 33% of 
patients suffer a complication after oesophagectomy, most of which (74%) affect the 
cardiopulmonary system (52% respiratory and 22% cardiac).125 Increased preoperative 
physical fitness may reduce the number of postoperative complications. Exercise results 
in a greater cardiac output, improved respiratory muscle strength and skeletal muscle 
adaptations (improved transport and metabolism of oxygen to produce adenosine 
triphosphate (ATP)).98  These adaptations may attenuate the physiological insults of 
oesophagectomy which include; disruption of normal lung mechanics through incisional 
pain and diaphragmatic dysfunction;111 blood loss and sympathetic activation, resulting in 
splanchnic vasoconstriction - which jeopardises any newly formed gastroesophageal 
anastomosis; and a surgical stress response, resulting in catabolism of skeletal muscle 
protein 106 and increased oxygen demand and consumption.109 Accurate measurement of 
preoperative cardiopulmonary fitness may identify patients at higher risk of complications 
due to low cardiopulmonary reserves. This could allow better perioperative management 
to improve outcomes, including modification of fitness with an exercise programme.   
 
CPEX is an objective, quantitative and composite measure of a person’s overall aerobic 
fitness. There have only been 3 relatively small observational studies of CPEX testing prior 
to oesophagectomy (n=78,136 n=91,134 n=103 135) and its association with complications. 
Whilst two of these studies reported an inverse association between VO2peak and 
cardiopulmonary complications 134 136, one did not.135  Similar conflicting findings were 
found for AT, with only one study reporting a significant association. 135  Differences in the 
measurement of outcomes by non-blinded assessors is likely to have introduced 
significant methodological error, which may explain the variation in findings. As such, the 
utility of CPEX prior to oesophagectomy has not been determined. This study aimed to 
clarify the associations between CPEX variables, specifically VO2peak and AT, and 30-day 
morbidity after oesophagectomy through the use of a larger sample size and 
measurement of outcomes using a standardised assessment tool, blinded to CPEX data. 
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3.3.3 Methods 
 
Study setting and patient population 
This hospital-based cohort study was conducted in the Department of Upper 
Gastrointestinal (UGI) Surgery at the Norfolk and Norwich University Hospitals (NNUH) 
Foundation Trust, Norwich, United Kingdom. The NNUH is a 1,000 bed teaching hospital, 
which provides care to a population of approximately 825,000 residents in Norfolk and 
adjacent counties. Approximately 45 oesophagectomies are performed at this unit each 
year. I retrospectively identified all patients that underwent an oesophagectomy at the 
NNUH between 1st September 2011 (the date of the first CPEX test prior to 
oesophagectomy) and 9th March 2017 (the latest date that would allow 30-day outcome 
assessment). Data was pseudo-anonymised and entered onto a database using Microsoft 
Access (2013). Patients were excluded if they had emergency or palliative surgery, a 
pharyngolaryngo-oesophagectomy, oesophagectomy and gastrectomy or did not 
undergo CPEX testing. The study protocol (appendix 5) was registered on 
ClinicalTrials.Gov (NCT03216694) and formal ethical approval was granted by the North 
West - Liverpool Central Research Ethics Committee after proportionate review 
(17/NW/0435, IRAS Project ID: 222793). 
 
Cardiopulmonary exercise testing 
CPEX testing was undertaken as per the protocol in section 2.4.3. The median time 
between CPEX testing and surgery was 11 days (interquartile range (IQR) = 7-19 days). At 
surgery, patients underwent either: McKeown, partially laparoscopic assisted (hybrid), or 
fully laparoscopic (minimally invasive) Ivor Lewis oesophagectomy. All patients were 
admitted to a high dependency unit (HDU) for the first night following surgery. Step down 
to ward care was decided by the HDU consultant.  
 
Measurement of variables 
The following patient data were obtained by review of medical notes: age, gender, 
smoking status (never, former, current), body mass index (BMI), comorbidities (classified 
according to the Charlson comorbidity index), TNM staging, chemotherapy regimen, type 
of surgery received and histology. To reduce the risk of selective reporting bias, CPEX 
variables of interest (VO2peak and AT) were decided a priori under a registered protocol.  
CPEX data was obtained by an investigator who was not involved in the collection of 
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outcome data.  Similarly, the outcome assessor was blinded to preoperative CPEX values 
and not involved in the collection of CPEX data. In order to reduce complication 
measurement error, short-term morbidity was measured by review of the medical notes, 
in strict accordance with Esophageal Complications Consensus Group (ECCG) 
definitions.157 Each complication was then graded in accordance with the Clavien-Dindo 
classification.158 The primary aim was to establish the association between the 
preoperative CPEX variables VO2peak and AT and 30-day morbidity (all cause, 
cardiopulmonary and non-cardiopulmonary) as defined by ECCG of Clavien-Dindo grade 
2 or above (complications of significant clinical importance). Secondary aims were to 
measure associations between CPEX variables and specific common complications and 30 
and 90 day mortality. 
 
Statistical methods 
Continuous variables were reported as the mean and standard deviation or the median 
and IQR depending on their distributions. Categorical variables were presented as 
frequency (%) to assess differences between groups. P-values were obtained using 
Student-t tests, X2 or Fisher’s exact tests. For the comparative analyses in table 2, 
statistical significance was taken at p=0.0008 after Bonferroni correction for multiple 
statistical testing. A multivariable logistic regression model was constructed based on 
variables with both a plausible and univariable association with outcome , with CPEX 
values treated as a continuous variable. All statistical analyses were done using Stata 
(version 12.1). 
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3.3.4 Results 
 
Between 1st September 2011 and 9th March 2017 (5 ½ years) 254 patients underwent an 
oesophagectomy at the NNUH. Of these patients, 48 (18.9%) were excluded: 40 did not 
undergo CPEX testing, 4 had emergency surgery and 4 had extended and palliative 
oesophagectomies.  Therefore, 206 patients (77% male) were included in the analyses, 
with a mean age of 67 years (SD 9) at the time of surgery (table 3.2). In the whole cohort, 
the mean values for VO2peak and AT were 21.1ml/kg/min (SD 4.5) and 12.4 ml/kg/min (SD 
2.8), respectively. The vast majority of patients (98.5%) had malignant disease; 
predominantly adenocarcinoma (84.5%), for which most received neoadjuvant 
chemotherapy (79%) and underwent minimally invasive Ivor Lewis oesophagectomy 
(53%). Thirty day complications occurred in 111 patients (54%), the majority of which 
were cardiopulmonary (72%).  The 40 patients that underwent oesophagectomy without 
preoperative CPEX were similar in their demographics and outcomes compared to those 
with CPEX data (supplementary table 3.1). The reasons for absence of CPEX testing was 
not documented in the notes, and were most were likely due to logistical issues associated 
with arranging these tests. The assumption was that these data were missing completely 
at random (MCAR). There was no documented evidence that any of these patients were 
selected not to undergo CPEX testing. The median length of hospital stay was 9 days (IQR 
7-14 days). No deaths occurred at postoperative day 30, but 7 patients died at day 90 
(3.4%); 2 due to malignant progression, 2 due to cardiopulmonary complications (VO2peak 
16.2 and 21.1ml/kg/min and AT 10.1 and 9.5ml/kg/min), and 3 due to non-
cardiopulmonary complications (VO2peak 14.5, 15.6 and 20.8ml/kg/min and AT 8.7, 8.8 and 
10.6ml/kg/min).  
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Table 3.2 Patient characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Study cohort (n=206) 
Number and percentage 
(unless otherwise stated) 
Gender (male) 
 
158 (76.7) 
Age at operation in years (mean + SD) 
 
66.9 (9.2) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
 
128 (62.1) 
48 (23.3) 
19 (9.2) 
11 (5.4) 
WHO BMI category (kg/m2) 
Underweight (<18.5) 
Normal weight (18.5-24.9) 
Overweight (25-29.9) 
Class I  obesity (30-34.9) 
Class I I obesity (35-39.9) 
Class I II obesity (≥40) 
 
5 (2.4) 
56 (27.2) 
89 (43.2) 
42 (20.4) 
10 (4.9) 
4 (1.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
 
65 (31.6) 
120 (58.3) 
12 (5.8) 
9 (4.4) 
T staging (TNM) 
T1 
T2 
T3 
T4 
Unable to be staged  
 
14 (6.8) 
25 (12.1) 
156 (75.7) 
6 (2.9) 
5 (2.4) 
N staging (TNM) 
N0 
N1 
N2 
Unable to be staged  
 
93 (45.1) 
66 (32.1) 
45 (21.8) 
2 (1.0) 
 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, high-grade dysplasia) 
 
 
174 (84.5) 
29 (14.1) 
3 (1.5) 
 
Received neoadjuvant chemotherapy 
 
162 (78.6) 
 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic assisted Ivor Lewis 
Ful ly laparoscopic (minimally invasive) Ivor Lewis 
 
 
14 (6.8) 
83 (40.3) 
109 (52.9) 
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Table 3.3 shows patients grouped by whether or not they suffered; any complication; a 
cardiopulmonary; or a non-cardiopulmonary complication. These groups differed in ASA 
grade I, type of operation, duration of surgery and length of stay. However, only length of 
stay met statistical significance after adjustment for multiple statistical testing (Bonferroni 
correction, p=0.0008). Neither VO2peak or AT were associated with complications of any 
type or severity (table 3.4). Patients were further grouped by whether or not they suffered 
one of the commonest complications, namely pneumonia, atrial fibrillation or 
anastomotic leak (supplementary table 3.2). Length of hospital stay in patients that 
suffered an anastomotic leak was significantly increased compared to those without this 
event (8 vs. 22 days, p=<0.00001), but no other variables were significantly different 
between groups after correction for multiple testing.   
 
Finally, univariable logistic regression analyses were undertaken using variables with a 
plausible association with outcome (age, gender, Charlson comorbidity index, smoking 
status, BMI, and type of operation) and estimated ORs, in turn, for; any complication; 
cardiopulmonary; and non-cardiopulmonary complications. Only age and operation type 
showed associations (<p=0.10) and were included in a multivariable regression model as 
shown in table 3.5 (values are from the model excluding CPEX variables). The CPEX 
variables VO2peak and AT were then added individually (due to collinearity) to the model 
to derive their ORs. No associations were found between preoperative CPEX variables and 
morbidity for either VO2peak (OR 1.00, 95% CI 0.94-1.07) or AT (OR 0.98, 95% CI 0.89-1.09)  
and any type of complication. Similar null associations were found for cardiopulmonary 
and non-cardiopulmonary complications.  
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Table 3.3 Comparisons between variables of interest according to postoperative complications after 
oesophagectomy  
Variable Any complication Cardiopulmonary complication Non-cardiopulmonary 
complication 
 Yes (n=111) No (n=95) Yes (n=80) No (n=126) Yes (n=59) No (n=147) 
Gender (male) 82 (74%) 76 (80%) 62 (78%) 96 (76%) 42 (71%) 116 (79%) 
Mean age at operation (years 
+ SD) 
 
66.0 (9.4) 
 
67.9 (9.0) 
 
66.2 (10.0) 
 
67.3 (8.7) 
 
65.0 (8.5) 
 
67.6 (9.4) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
73 (65.8) 
22 (19.8) 
10 (9.0) 
6 (5.4) 
 
55 (57.9) 
26 (27.4) 
9 (9.5) 
5 (5.3) 
 
48 (60.0) 
17 (21.3) 
10 (12.5) 
5 (6.3) 
 
80 (63.5) 
31 (24.6) 
9 (7.1) 
6 (4.8) 
 
37 (62.7) 
12 (20.3) 
6 (10.2) 
4 (6.8) 
 
91 (61.9) 
36 (24.5) 
13 (8.8) 
7 (4.8) 
BMI  (mean in kg/m2  + SD) 27.5 (5.7) 27.0 (4.7) 27.5 (5.2) 27.1 (5.3) 27.3 (6.0) 27.3 (4.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
35 (31.5) 
65 (58.6) 
7 (6.3) 
4 (3.6) 
 
30 (31.6) 
55 (57.9) 
5 (5.3) 
5 (5.3) 
 
25 (31.3) 
45 (56.3) 
7 (8.8) 
3 (3.8) 
 
40 (31.7) 
75 (59.5) 
5 (4.0) 
6 (4.8) 
 
17 (28.8) 
36 (61.0) 
5 (8.5) 
1 (1.7) 
 
48 (32.7) 
84 (57.1) 
7 (4.8) 
8 (5.4) 
T staging 
T1 
T2 
T3 
T4 
Unable to be staged  
 
9 (8.1) 
15 (13.5) 
80 (72.1) 
4 (3.6) 
3 (2.7) 
 
5 (5.3) 
10 (10.5) 
76 (80.0) 
2 (2.1) 
2 (2.1) 
 
7 (8.8) 
14 (17.5) 
52 (65.0) 
4 (5.0) 
3 (3.8) 
 
7 (5.6) 
11 (8.7) 
104 (82.5) 
2 (1.6) 
2 (1.6) 
 
6 (10.2) 
7 (11.9) 
43 (72.9) 
1 (1.7) 
2 (3.4) 
 
8 (5.4) 
18 (12.2) 
113 (76.9) 
5 (3.4) 
3 (2.0) 
N staging 
N0 
N1 
N2 
Unable to be staged  
 
53 (47.7) 
35 (31.5) 
22 (19.8) 
1 (0.9) 
 
40 (42.1) 
31 (32.6) 
23 (24.2) 
1 (1.1) 
 
40 (50) 
23 (28.8) 
16 (20.0) 
1 (1.3) 
 
53 (42.1) 
43 (34.1) 
29 (23.0) 
1 (0.8) 
 
31(52.5) 
18 (30.5) 
10 (16.9) 
0 
 
62 (42.2) 
48 (32.7) 
35 (23.8) 
2 (1.4) 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, HGD) 
 
91 (82.0) 
18 (16.2) 
2 (1.8) 
 
83 (87.4) 
11 (11.6) 
1 (1.1) 
 
64 (80.0) 
14 (17.5) 
2 (2.5) 
 
110 (87.3) 
15 (11.9) 
1 (0.8) 
 
51 (86.4) 
8 (13.6) 
0  
 
123 (83.7) 
21 (14.3) 
3 (2.0) 
Received neoadjuvant 
chemotherapy 
 
85 (76.6) 
 
77 (81.1) 
 
59 (73.8) 
 
103 (81.7) 
 
46 (78.0) 
 
116 (78.9) 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic 
assisted Ivor Lewis 
Fully laparoscopic (minimally 
invasive) Ivor Lewis 
 
10 (9.0) 
 
48 (43.2) 
 
53 (47.7) 
 
4 (4.2) 
 
35 (36.8) 
 
56 (58.9) 
 
5 (6.3) 
 
32 (40.0) 
 
43 (53.8) 
 
9 (7.1) 
 
51 (40.5) 
 
66 (52.4) 
 
8 (13.6) 
 
32 (54.2) 
 
19 (32.2) 
 
6 (4.1)d 
 
51 (34.7)c 
 
90 (61.2)b 
Duration of surgery in mins 
(median, 25th- 75th percentile) 
 
464 (365-542) 
 
455 (381-525) 
 
478 (391-556) 
 
443 (369-519)f 
 
424 (334-509) 
 
465 (385-541)e 
Length of stay in days  
(median, 25th-75th percentile) 
 
12 (8 – 20) 
 
7 (6-9)a 
 
11.5 (8-18.5) 
 
8 (6-11)a 
 
17 (12-29) 
 
8 (7-10)a 
 
Data shown are the number of patients and percentage unless otherwise stated.  For categorical variable, X2 tests were used, but only when 
total cell counts were >50, otherwise Fisher’s exact tests were applied. For continuous variables with a normal distribution, Students-t tests 
were used, where distribution was non-normal, Mann-Whitney U tests were used. All percentages represent the proportion of patients with or 
without a complications (yes/no). P-values reaching conventional statistical significance (p=0.05) are shown in superscript. Bonferroni adjusted 
significance is p=0.0008, in which case the superscript is shown in bold. aP=<0.00001, bP=0.001, cP=0.01, dP=0.02, eP=0.04, fP=0.05. 
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Table 3.4 Comparisons between mean cardiopulmonary exercise testing variables according to 
postoperative complication outcomes. 
CPEX variable Type of complication P-value 
 Any complication (n=111) No complication (n=95)  
VO2peak (ml/kg/min) 21.3 (4.7) 20.9 (4.2) 0.54 
AT (ml/kg/min) 12.4 (2.9) 12.4 (2.8) 0.95 
 Any complication of C-D grade 3 (n=39) No complication (n=95)  
VO2peak (ml/kg/min) 20.4 (4.4) 20.9 (4.2) 0.52 
AT (ml/kg/min) 12.2 (3.1) 12.4 (2.8) 0.73 
 Any complication of C-D grade 4 (n=16) No complication (n=95)  
VO2peak (ml/kg/min) 21.0 (3.3) 20.9 (4.2) 0.94 
AT (ml/kg/min) 13.0 (3.1) 12.4 (2.8) 0.42 
 Cardiopulmonary complication (n=80) No cardiopulmonary complication (n=126)  
VO2peak (ml/kg/min) 21.7 (5.0) 20.8 (4.1) 0.14 
AT (ml/kg/min) 12.5 (2.9) 12.3 (2.8) 0.59 
 Non-cardiopulmonary complication (n=59) No non-cardiopulmonary complication (n=143)  
VO2peak (ml/kg/min) 20.8 (4.1) 21.2 (4.6) 0.56 
AT (ml/kg/min) 12.4 (2.9) 12.3 (2.8) 0.91 
Data shown are the means and standard deviations. C-D= Clavien-Dindo severity classification (grade 3 = 
surgical, endoscopic or radiological intervention required and grade 4 = l ife-threatening complication 
requiring intensive care unit management). All  P-values obtained using Student-t tests.  
 
 
 
 
Table 3.5. Multivariable logistic regression modelling of the association between CPEX variables and 
postoperative complications after oesophagectomy. 
CPEX variable Any complication 
Odds ratio , 95% CI and P-value 
Cardiopulmonary complication 
Odds ratio , 95% CI and P-value 
Non-cardiopulmonary complication 
Odds ratio , 95% CI and P-value 
 
VO2peak (ml/kg/min) 
 
 
1.00 (0.94-1.07), p=0.862 
 
 
1.04 (0.98-1.12), p=0.204 
 
0.98 (0.88-1.03), p=0.191 
 
AT (ml/kg/min) 0.98 (0.89-1.09), p=0.769 1.02 (0.92-1.13), p=0.675 0.98 (0.88-1.11), p=0.792 
Adjustments are for age and type of operation by category (minimally invasive, open or hybrid Ivor Lewis, 
McKeown oesophagectomy).  
 
 
141 
 
3.3.5 Discussion 
This study investigated the association between preoperative CPEX values and 30-day 
morbidity in 206 patients undergoing oesophagectomy. No associations were found 
between preoperative cardiopulmonary fitness, as measured by CPEX testing and short-
term postoperative morbidity.  This finding is surprising in that it contradicts a seemingly 
intuitive inverse association. CPEX testing is a measure of how efficiently patients are able 
to deliver oxygen from the environment to cellular mitochondria and we would therefore 
expect patients with large volumes of VO2peak to have a lower risk of complications in the 
early postoperative period, when the demand for oxygen is increased up to 1.5 times the 
normal resting state.109 However, oesophagectomy is a complex operation which delivers 
a large physiological insult, with complications related to the operative field (anastomotic 
leak, pneumonia and atrial fibrillation). Therefore, the effect of improved aerobic fitness, 
if present, is likely to have a small effect on complications directly related to the surgery. 
However, cardiorespiratory and musculoskeletal reserves may be critical in the ability of 
a patient to respond once a complication has occurred.163 This study was unable to analyse 
this association as mortality was a rare event (n=7).  
 
Three similar, but smaller, studies on CPEX prior to oesophagectomy  have been published 
to date 134-136 and are described in detail in section 3.2.4 of this thesis.   Whilst all 3 studies 
reported inverse associations between complications and either VO2peak134 136 or AT135 
there were potential sources of bias.  The most significant in all three studies, apart from 
their small sample sizes and single institution design, was the potential for detection bias 
due to unblinded outcome assessment, particularly for complications which can be 
subjectively diagnosed. This would lead to an inflation of the association between CPEX 
variables and outcomes.  
 
The strengths of this present study included the use of a defined diagnostic criteria for 
complications, which would reduce measurement error of outcomes. Outcome 
assessment was also blinded, which would limit detection bias.  Furthermore, this work is 
the largest study of its kind, with a sufficiently high event rate to detect associations. A 
post-hoc power calculation estimated that this sample size (n=206) could identify a mean 
difference in VO2peak, (between groups with and without a complication of any cause) of 
1.75ml/kg/min and 1.1ml/kg/min for AT, with 80% power and alpha level at 0.05. This 
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suggests that this study had adequate power to detect a small difference in CPEX variables 
between groups if it were indeed present. 
However, there are limitations associated with the study methodology. As with all 
observational work, residual confounding cannot be excluded. However, as the aim was 
to determine associations between fitness and complications it is difficult to understand 
how confounding could operate. CPEX data were also missing in 16% of the patient 
population who otherwise met the inclusion criteria. However, data was likely to be 
missing completely at random (MCAR) and this group was comparable to the included 
group in demography and outcome (supplementary table 1), which reduced the risk of 
selection bias. Finally, this study sample represents a select population of patients whom 
were deemed fit for both neoadjuvant chemotherapy and major surgery. However, this 
selected population had a large range of CPEX values (figure 3.4). I am therefore satisfied 
that patients with ‘low’ scores were included in the analyses, with 35% of patients (n=72) 
having an AT of ≤11ml/kg/min. Finally, as death was a rare event, I was unable to examine 
the associations between fitness and mortality.  
 
Figure 3.5 Dot plots showing the distribution of VO2peak (A) and AT (B) for patients with and without any 
complications  
 
   A              B 
n=206, 0=absence of a complication, 1=presence of a complication. For VO2peak the median value 
for the whole cohort was 20.8ml/kg/min (range 11.6 to 34.9). For AT the median value for the 
whole cohort was 12.1ml/kg/min (range 7.1 to 22.8)  
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3.3.6 Conclusions 
CPEX testing provides an objective measure of fitness in patient’s undergoing 
oesophagectomy. However, this work has shown, that in this specific population, aerobic 
fitness was not associated with 30-day morbidity. I postulated that aerobic fitness was 
likely to have an effect on complication rates, as there are plausible biological mechanisms 
to support this hypothesis. However, any effect size, if present, in the context of the 
magnitude of an oesophagectomy, is likely to be small (explaining why it could not be 
measured in the present modestly sized study). The findings from this study, as well as 
from previous observational work, challenges the utility of CPEX testing as a preoperative 
screening tool prior to oesophagectomy, which is poorly discriminatory at best. 135 136 But 
also, and perhaps more importantly, the results question whether fitness modification is 
a worthwhile target in interventional studies as such a small effect size would require a 
large population of patients to demonstrate any benefit. However, these findings are 
derived from retrospective observational work and further investigations, ideally blinded 
prospective cohort studies, are required to clarify the relationship between preoperative 
cardiopulmonary fitness and postoperative outcome. Such work would justify whether 
RCTs should be instigated in the future. 
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Supplementary table 3.1 Comparison of cohorts with and without CPEX data by complications (The 
association between preoperative cardiopulmonary exercise test variables and short-term morbidity 
following oesophagectomy: a hospital -based cohort study). 
Variable Any complication of included cohort 
(n=206) 
Any complication of excluded cohort 
(n=40) 
 Yes  (n=111) No (n=95) Yes  (n=19) No (n=21) 
Gender (male) 82 (74) 76 (80) 13 (68.4) 17 (81.0) 
Mean age at operation 
(years + SD) 
 
66.0 (9.4) 
 
67.9 (9.0) 
 
66.7 (9.8) 
 
63.8 (9.1) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
73 (65.8) 
22 (19.8) 
10 (9.0) 
6 (5.4) 
 
55 (57.9) 
26 (27.4) 
9 (9.5) 
5 (5.3) 
 
15 (78.9) 
4 (21.1) 
0 
0 
 
16 (76.2) 
4 (19.0) 
1 (4.8) 
0 
Smoking status 
Never 
Former 
Current 
Missing 
 
35 (31.5) 
65 (58.6) 
7 (6.3) 
4 (3.6) 
 
30 (31.6) 
55 (57.9) 
5 (5.3) 
5 (5.3) 
 
4 (21.1) 
10 (52.6) 
4 (21.1) 
1 (5.3) 
 
9 (42.9) 
11 (52.4) 
0 
1 (4.8) 
T staging 
T1 
T2 
T3 
T4 
Unable to be staged  
 
9 (8.1) 
15 (13.5) 
80 (72.1) 
4 (3.6) 
3 (2.7) 
 
5 (5.3) 
10 (10.5) 
76 (80.0) 
2 (2.1) 
2 (2.1) 
 
3 (15.8) 
3 (15.8) 
13 (68.4) 
0 
0 
 
2 (9.5) 
3 (14.3) 
16 (76.2) 
0 
0 
N staging 
N0 
N1 
N2 
Unable to be staged  
 
53 (47.7) 
35 (31.5) 
22 (19.8) 
1 (0.9) 
 
40 (42.1) 
31 (32.6) 
23 (24.2) 
1 (1.1) 
 
8 (42.1) 
5 (26.3 
5 (26.3) 
1 (5.3) 
 
13 (61.9) 
6 (28.6) 
2 (9.5) 
0 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, HGD) 
 
91 (82.0) 
18 (16.2) 
2 (1.8) 
 
83 (87.4) 
11 (11.6) 
1 (1.1) 
 
14 (73.7) 
5 (26.3) 
0 
 
18 (85.7) 
3 (14.3) 
0 
Received neoadjuvant 
chemotherapy 
 
85 (76.6) 
 
77 (81.1) 
 
15 (78.9) 
 
18 (85.7) 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic 
assisted Ivor Lewis 
Ful ly laparoscopic (minimally 
invasive) Ivor Lewis 
 
10 (9.0) 
 
48 (43.2) 
 
53 (47.7) 
 
4 (4.2) 
 
35 (36.8) 
 
56 (58.9) 
 
3 (15.8) 
 
8 (42.1) 
 
8 (42.1) 
 
1 (4.8) 
 
12 (57.1) 
 
8 (38.1) 
Length of stay in days  
(median, 25th-75th percentile) 
 
12 (8 – 20) 
 
7 (6-9)  
 
11 (10-22) 
 
7 (6-7) 
Duration of surgery in mins 
(median, 25th- 75th percentile) 
 
464 (365-542) 
 
455 (381-525) 
 
421 (337-519) 
 
416 (345-480) 
Data shown are the number of patients and percentage unless otherwise stated.  
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Supplementary table 3.2 Comparisons between variables of interest according to common postoperative 
complications (The association between preoperative cardiopulmonary exercise test variables and short-term 
morbidity following oesophagectomy: a hospital -based cohort study). 
Data shown are the number of patients and percentage unless otherwise stated. For categorical variable, X2 tests were used, but only when 
total cell counts were >50, otherwise Fisher’s exact tests were applied. For continuous variables with a normal distribution, Students-t tests 
were used, where distribution was non-normal, Mann-Whitney U tests were used. All percentages represent the proportion of patients with 
or without a complications (yes/no). P-values reaching conventional statistical significance (p=<0.05) are shown in superscript. Bonferroni 
adjusted significance is p=0.0008, in which case the superscript is shown in bold. aP=<0.00001, bP=0.0008, cP=0.007, dP=0.01, eP=0.02, fP=0.04. 
 
 
 
 
 
 
 
Variable Pneumonia 
 
Atrial fibrillation Anastomotic leak 
 Yes (n=42) No (n=164) Yes (n=36) No (n=170) Yes (n=39) No (n=167) 
Gender (male) 35 (83.3) 123 (75.0) 26 (72.2) 132 (77.6) 31 (79.5) 127 (76.0) 
Mean age at operation 
(years + SD) 
68.1 (9.1) 66.6 (9.3) 68.3 (8.9) 66.6 (9.3) 64.1 (8.5) 67.5 (9.3)f 
COPD diagnosis 8 (19.0) 18 (11.0) 9 (25.0) d 17 (10.0)  8 (20.5) 18 (10.8) 
Previous MI 6 (14.3) 12 (7.3) 3 (8.3) 15 (8.8) 5 (12.8) 13 (7.8) 
BMI  
(mean in kg/m2  + SD) 
27.7 (5.2) 27.2 (5.2) 27.6 (5.2) 27.2 (5.3) 28.0 (6.6) 27.1 (4.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
14 (33.3) 
23 (54.8) 
3 (7.1) 
2 (4.8) 
 
51 (31.1) 
97 (59.1) 
9 (5.5) 
7 (4.3) 
 
11 (30.6) 
24 (66.7) 
1 (2.8) 
0 
 
54 (31.8) 
96 (56.5) 
11 (6.5) 
9 (5.3) 
 
9 (23.1) 
24 (61.5) 
4 (10.3) 
2 (5.1) 
 
56 (33.5) 
96 (57.5) 
8 (4.8) 
7 (4.2) 
Had neoadjuvant 
chemotherapy 
 
27 (64.3) 
 
135 (82.3) d 
 
29 (80.6) 
 
133 (78.2) 
 
32 (82.1) 
 
130 (77.8) 
Type of oesophagectomy  
Open McKeown 
Open or partially 
laparoscopic assisted Ivor 
Lewis 
Fully laparoscopic (minimally 
invasive) Ivor Lewis 
 
2 (4.8) 
 
 
19 (45.2) 
 
21 (50) 
 
12 (7.3) 
 
 
64 (39.0) 
 
88 (53.7) 
 
2 (5.6) 
 
 
11 (30.6) 
 
23 (63.9) 
 
12 (7.1) 
 
 
72 (42.4) 
 
86 (50.6) 
 
6 (15.4) 
 
 
20 (51.3) 
 
13 (33.3) 
 
8 (4.8)e 
 
 
63 (37.7) 
 
96 (57.5)c 
Duration of surgery (mins) 475 (344-545) 455 (370-526) 489 (427-556) 451 (365-526) f 406 (334-490) 462 (381-536) f 
Length of stay in days  
(median, 25th to 75th 
percentile) 
 
 
10 (8-15) 
 
 
8.5 (7-13) 
 
 
13 (8-19.5) 
 
 
8 (7-12) b 
 
 
22 (15-35) 
 
 
8 (7-10) a 
CPEX (mean + SD) 
VO2peak (ml/kg/min) 
AT (ml/kg/min) 
 
20.8 (5.0) 
12.0 (2.6) 
 
21.2 (4.3) 
12.5 (2.9) 
 
21.2 (5.2) 
12.5 (3.2) 
 
21.1 (4.3) 
12.3 (2.8) 
 
20.7 (3.7) 
12.7 (2.9) 
 
21.2 (4.6) 
12.3 (2.8) 
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Chapter Four: A summary of the thesis findings 
 
 
1) Occupational activity may influence the development of Barrett’s oesophagus and 
oesophageal adenocarcinoma 
New evidence from this thesis suggests that occupational activity may be associated with 
the development of Barrett’s oesophagus in a U-shaped manner, where moderate levels 
of activity in standing occupations may be protective over sedentary jobs, but heavy 
manual occupations may be hazardous. Further epidemiological work to investigate 
whether these associations exists for oesophageal adenocarcinoma is worth pursuing in 
order to determine if physical activity should be added to the aetiological model of this 
increasingly common cancer.  
 
2) Prehabilitation prior to oesophagectomy is possible 
I have shown for the first time ‘proof of concept’ for a randomised controlled trial of 
prehabilitation prior to oesophagectomy. Elderly patients were willing and able to engage 
in aerobic and muscle strengthening exercises during and after neoadjuvant 
chemotherapy. Such exercise in this patient population was also safe and adhered to. 
Further feasibility work is required to determine if prehabilitation can produce statistically 
significant improvements in fitness. This would then inform a full RCT to determine 
whether improvement in fitness results in reduced complications after oesophagectomy. 
However, further observational work is firstly required to determine whe ther increased 
fitness is indeed inversely associated with post-oesophagectomy outcome to justify 
prehabilitation interventions.  
 
2) The effect of preoperative aerobic fitness on post-oesophagectomy outcome needs 
to be clarified. 
This thesis includes the largest observational study to examine the associations between 
preoperative fitness, as determined objectively by CPEX testing, and postoperative 
complications after oesophagectomy. The findings contradict the seemingly intuitive 
positive association between fitness and improved clinical outcomes. This observational 
work highlights the need for a further large cohort study examining the associations 
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between preoperative CPEX and outcomes after oesophagectomy to look for consistency 
in my findings. Future research worth pursuing is a national multi-centre retrospective 
observational study examining whether there is an association between preoperative 
CPEX variables and mortality after oesophagectomy. If an inverse association does exist, 
then future prehabilitation interventional studies may be justified, which the trial work in 
this thesis demonstrates are possible. However, if it is indeed shown that there is no 
association, this would challenge a long-standing presumption that poor aerobic fitness is 
associated with a high risk of post-operative complications. Such a finding would be 
equally valuable in that it could justify curative surgery for oesophageal cancer patients 
who would previously have been deemed too ‘unfit’.  
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Appendix 1. Physical activity questionnaire (The association between physical activity 
and the risk of symptomatic Barrett’s oesophagus – a UK prospective cohort study) 
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Appendix 2. Search strategy (The association between preoperative CPEX variables and 
outcome after major cancer resection surgery: a review of the literature) 
Search terms for cardiopulmonary exercise testing: 
“cardiopulmonary exercise”, “CPEX”, “CPET”, “exercise testing”, “anaerobic threshold”, “VCO 2”, 
“ventilatory inefficiency”, “oxygen consumption”, “VO2”, “preoperative exercise”, “aerobic 
exercise”.  
 
Search terms for outcomes: 
“morbidity”, “mortality”, “outcome”, “complication". 
 
Additional search terms for lung cancer: 
 “lung cancer surgery”, “lung resection”, “lobectomy”, “pneumonectomy” 
 
Additional search terms for colorectal cancer: 
“colorectal”, “colon”, “colectomy”, “rectal”, “rectum”, surgery”, “resection” 
 
Additional search terms for colorectal cancer: 
“hepatic”, “hepatectomy”, “liver surgery” 
 
Additional search terms for oesophageal cancer: 
“oesophagectomy”, “oesophagogastrectomy” 
 
Additional search terms for bladder cancer: 
“bladder cancer”, “cystectomy” 
 
Additional search terms for pancreatic cancer: 
“pancreatic surgery”, “pancreatic resection”, “pancreaticoduodenectomy” 
 
An example for the whole search string for colorectal cancer: 
"(((cardiopulmonary exercise).ti,ab OR (cpex).ti,ab OR (cpet).ti,ab OR (exercise testing).ti,ab OR 
(anerobic threshold).ti,ab OR (VCO2).ti,ab OR (ventilatory inefficiency).ti,ab OR (oxygen 
consumption).ti,ab OR (VO2).ti,ab OR (preoperative exercise).ti,ab OR (aerobic exercise).ti,ab) 
AND (((colorectal).ti,ab OR (colon).ti,ab OR (colectomy).ti,ab OR (rectal).ti,ab OR (rectum).ti,ab) 
AND ((surgery).ti,ab OR (resection).ti,ab))) AND ((complications).ti,ab OR (outcome).ti,ab OR 
(morbidity).ti,ab OR (mortality).ti,ab)" 
 
ti=title, ab=abstract 
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Appendix 3. Study protocol for (Prehabilitation to improve physical fitness and reduce 
postoperative cardiopulmonary complications after oesophagectomy in patients with 
oesophageal adenocarcinoma – a feasibility randomised controlled trial. The ExPO Trial 
(Exercise Prior to Oesophagectomy) 
 
 
 
Protocol: Version 1.0, dated 24th May 2016 
The ExPO trial (Exercise Prior to Oesophagectomy). 
Prehabilitation to reduce cardiopulmonary complications 
after oesophagectomy in patients with oesophageal 
adenocarcinoma – a feasibility randomised controlled trial.  
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163 
 
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich,  
NR4 7UY. 
Email: stephen.lam@nnuh.nhs.uk 
 
Principal Investigators: Mr Edward Cheong, 
Consultant Oesophagogastric and Laparoscopic Surgeon 
and Upper Gastrointestinal Cancer Lead for Norfolk and 
Norwich University Hospital, 
Department of Upper Gastrointestinal Surgery, 
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich,  
NR4 7UY. 
Email: edward.cheong@nnuh.nhs.uk 
 
Mr Filip Van Tornout, 
Consultant Cardiothoracic Surgeon, 
Department of Thoracic Surgery,  
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, Norwich,  
NR4 7UY. 
Email: filip.vantornout@nnuh.nhs.uk           
 
Research and Clinical Team: Dr Allan Clark, 
Senior Lecturer in Medical Statistics, 
Norwich Medical School,  
University of East Anglia,  
Norwich, 
NR4 7TJ.                                                                                                                                             
Email: allan.clark@uea.ac.uk 
 
 Andreia Soares, 
Research Associate in Psychology, 
Centre for 20th Century Interdisciplinary Studies 
(CEIS20), 
University of Coimbra, 
Rua Filipe Simões nº 33, 
3000-186 Coimbra, 
Portugal. 
Email: andreiamsoares2@gmail.com 
  
Mr Bhaskar Kumar, 
Consultant Upper Gastrointestinal Surgeon, 
Department of Upper Gastrointestinal Surgery, 
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich,  
NR4 7UY. 
Email: bhaskar.kumar@nnuh.nhs.uk 
164 
 
Mr Michael Lewis, 
Consultant Upper Gastrointestinal Surgeon, 
Department of Upper Gastrointestinal Surgery, 
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich,  
NR4 7UY. 
Email: michael.lewis@nnuh.nhs.uk 
 
Mr Hugh Warren, 
Consultant Upper Gastrointestinal Surgeon,  
The Queen Elizabeth Hospital King’s Lynn NHS 
Foundation Trust,  
Gayton Road,  
King’s Lynn,  
PE30 4ET. 
email: hugh.warren@qehkl.nhs.uk 
 
Mr James Hernon, 
Consultant Colorectal Surgeon, 
 Department of General Surgery,  
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich,  
NR4 7UY. 
    Email: james.hernon@nnuh.nhs.uk 
 
Mr Pedro Serralheiro, 
Clinical Fellow in Upper Gastrointestinal Surgery, 
Department of Upper Gastrointestinal Surgery,  
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, Norwich,  
NR4 7UY. 
Email: pedro.serralheiro@nnuh.nhs.uk 
 
Dr Tom Roques, 
Consultant Oncologist, 
 Department of Oncology,  
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, 
Norwich, 
NR4 7UY. 
    Email: tom.roques@nnuh.nhs.uk 
 
 
 
 
 
 
 
 
165 
 
Dr Kamal Al-Naimi, 
Consultant of Anaesthesia, 
Department of Anaesthetics, 
Norfolk and Norwich University Hospitals NHS 
Foundation Trust 
Norwich,  
NR4 7UY. 
Email: kamal.alnaimi@nnuh.nhs.uk 
     
Dr Leo Alexandre, 
 NIHR Doctoral Research Fellow, 
Norwich Medical School,  
University of East Anglia,  
Norwich,  
NR4 7TJ. 
Email: leo.alexandre@uea.ac.uk               
 
Sarah Walkeden, 
Clinical Lead Physiotherapist  
Oncology, Haematology and Palliative Care 
 Department of Physiotherapy, 
              Norfolk and Norwich University Hospitals NHS 
Foundation Trust 
Norwich,  
NR4 7UY, 
Email: sarah.walkeden@nnuh.nhs.uk 
 
Jane Dixon, 
Upper Gastrointestinal Clinical Specialist Nurse, 
 Department of Upper Gastrointestinal Surgery, 
              Norfolk and Norwich University Hospitals NHS 
Foundation Trust 
Norwich,  
NR4 7UY. 
Email: jane.dixon2@nnuh.nhs.uk 
 
Sponsor Representative: Yvonne Kirkam, 
University of East Anglia Research and Enterprise 
Services,  
    West Office, 
    Norwich Research Park, 
    Norwich, 
    NR4 7TJ. 
    Email: y.kirkham@uea.ac.uk 
 
                                                
 
 
 
 
166 
 
Host NHS representative: Michael Sheridan, Research Study Facilitator, Research 
and Development Office,  
Norfolk and Norwich University Hospitals NHS 
Foundation Trust, Colney Lane,  
Norwich,  
NR4 7UY. 
 Email: michael.sheridan@nnuh.nhs.uk 
 
Funding Charitable funds from Oesophageal Patients’ Association 
and the Norfolk and Norwich University Hospital Medical 
Gastroenterology Research Fund. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
167 
 
ExPO TRIAL SUMMARY 
Trial Title A pre-operative personalised exercise programme (my-PEP) to improve fitness and reduce post-operative 
cardiopulmonary complications after oesophagectomy in patients with oesophageal adenocarcinoma –a 
feasibility randomised controlled trial.  
 Short title The ExPO Tria l  (Exercise Prior to Oesophagectomy). 
Trial Design Single centre, para l lel  group, s ingle bl inded, randomised control led tria l .  
Study Setting Norfolk and Norwich Univers i ty Hospita ls  NHS Foundation Trust.  
Trial Participants Adults with oesophageal adenocarcinoma due to undergo neoadjuvant chemotherapy and subsequent 
oesophagectomy. 
Planned Sample Size 32 participants  (16 per arm). 
Intervention arm A pre-operative personalised exercise programme (my-PEP) consisting of: 1) advice to promote exercise, 
us ing behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a  home exercise 
programme (HEP) - which is also current standard care, 4) a  4 week hospital-supervised aerobic and muscle 
s trengthening programme (Hos -PEP) .  
 
Control arm Standard care home exercise programme (HEP) of written advice to attempt ≥150 mins of moderate or ≥75 
mins  of vigorous  aerobic exercise per week (identica l  to the HEP in the intervention arm). 
Treatment duration Approximately 16 weeks  pre -oesophagectomy. 
Follow up duration 90 days  post-oesophagectomy for cardiopulmonary compl ications . 
Planned Trial Period 24 months . 
Feasibility Objectives Feasibility Outcome Measures 
To measure: eligibility, recruitment and retention of 
participants  in my-PEP. 
The el igibility, recrui tment and retention proportions of patients in my-PEP 
(patients with oesophageal adenocarcinoma referred for oesophagectomy). 
To document and address reasons for non-
participation in the ExPO tria l . 
The number of patients that decline to participate in the trial and assessment of 
their reasons  for non-participation. 
To compare the demographics and cl inical 
characteristics of participants and non-participants 
to assess  genera l i sabi l i ty of the results . 
Comparison of the demographic and clinical information of those that do and 
do not participate in the tria l . 
To measure baseline physical activity levels in the 
whole group.  
The level of physical activity prior to participation in the trial measured by the 
International  Phys ica l  Acti vi ty Questionnaire (IPAQ). 
To assess facilitators and barriers to engaging with 
my-PEP. 
The factors which promote or inhibit engagement with my-PEP, measured using 
the Determinants  of Phys ica l  Activi ty Questionnaire (DPAQ).  
To assess  adherence with my-PEP. The number of my-PEP exercise sessions (at home and in hospital) engaged in.  
To assess  the safety of my-PEP.  The number of adverse events related to my-PEP compared to standard care 
(HEP) as  defined by CTCAE.  
To assess i f my-PEP results in a  greater 
improvement in VO2max than the physical activity of 
s tandard care (HEP). 
The di fference in change of mean VO2max as  measured by CPEX between the 
intervention and control  arm.  
To assess i f my-PEP results in a  greater 
improvement in Pi-max than the physical activity of 
s tandard care (HEP). 
The di fference in change of mean Pi-max (as measured by an inspiratory mouth 
pressure test) between the intervention and control  arm. 
To give an estimate of the mean difference and SD 
in the number of post-operative cardiopulmonary 
compl ications (CPCs) per patient between arms. 
The mean number of CPCs  per patient in both arms, determined by review of 
the medical notes (when discharged from hospita l  and at days  30 and 90).  
To estimate the mean difference and SD per patient 
in the number of post-operative non-
cardiopulmonary complications, length of hospital 
s tay (LOS) and morta l i ty between arms. 
The mean number of a ll non-cardiopulmonary complications per patient, LOS 
and mortality in each group determined by review of the medical notes (when 
discharged from hospita l  and at days  30 and 90 after surgery).  
To compare qual i ty of l i fe (QOL) between arms. The di fference in change in QOL between the two arms measured by EORTC 
QLQ-C30 and QLQ-OGC25 questionnaires . 
To assess  overa l l  experience with my-PEP. Expectations, evaluation, and satisfaction with my-PEP recorded via qualitative 
interview. 
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Background 
In the western world, the incidence of oesophageal adenocarcinoma (OAC) has increased 
by at least 6-fold in the last 30 years.1 Surgery is the only consistent treatment modality 
that offers a  potential cure.2 However, oesophageal cancer resection and reconstruction 
(oesophagectomy) carries a high risk of serious post-operative complications. Recent UK 
national audit figures reported 33% of patients suffered a complication after 
oesophagectomy, most of which (74%) were cardiopulmonary (22% cardiac and 52% 
respiratory).3 Interventions to reduce the high rate of CPCs are required.  
In the first few days after major surgery, the patient enters a catabolic phase, with 
increased oxygen consumption and breakdown of skeletal muscle reserves for energy.4 
Lack of mobility and post-surgical pain inhibits normal respiratory function.5  Aerobic 
exercise and inspiratory muscle training improves heart and lung function, while 
resistance training of all major muscle groups builds muscle bulk. Therefore, pre -operative 
exercise, or prehabilitation, may increase such reserves, allowing patients to better 
withstand a surgical insult. Observational data reports that enhanced physical fitness prior 
to oesophagectomy is associated with fewer post-operative complications.6-12 A UK study 
of 78 consecutive oesophagectomy patients reported a significantly lower pre -operative 
VO2max for patients with CPCs compared to those without (mean difference of 
2.3ml/kg/min (p=0.04) between groups).11 A systematic review of 4 randomised trials and 
6 observational studies, totalling 524 patients, reported that exercise training prior to: 
cardiac, lung and colorectal surgery was effective in improving physical fitness and was 
safe, feasible and well tolerated, but did not report postoperative complication 
outcomes.13 There is evidence from systematic reviews that a 2-4 week programme of 
pre-operative endurance inspiratory muscle training is safe and effective at reducing 
pulmonary complications after major cardiac14 15 and non-oesophageal abdominal 
surgery.15  
To the best of our knowledge, no trial has investigated a multimodal exercise intervention 
in patients undergoing oesophagectomy combining both aerobic exercise, resistance 
training and inspiratory muscle training. However, before a full RCT is started to assess 
such an exercise intervention, important feasibility criteria need to be fulfilled to both 
justify and inform its conduct. These are demonstrating that a short period of exercise 
prior to oesophagectomy is safe and that sufficient participants are suitable, can be 
recruited and retained, with evidence that a pre-operative personalised exercise 
programme (my-PEP) is superior to standard care in improving physiological measures of 
physical fitness. The feasibility trial would also give an imprecise estimate of the mean 
number of complications and SD of adverse events in each arm of the trial and allow 
calculation of the sample size of a subsequent definitive trial. If a future RCT could 
demonstrate benefits to patients this would support the use of my-PEP prior to 
oesophagectomy as standard care across the NHS to reduce the current high number of 
post-operative CPCs and improve patient outcomes and quality of life. 
 
Methods/Design 
Trial design summary 
The ExPO trial is a single centre, single-blinded, parallel group feasibility RCT in patients 
with OAC to justify and inform a future full RCT investigating a personal ised exercise 
programme (my-PEP) vs standard care (written advice to exercise at home), prior to 
oesophagectomy, to reduce the incidence of 30-day and 90-day post-operative CPCs. 
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Participants referred for neoadjuvant chemotherapy and scheduled for oesophagectomy 
will be randomised to receive either a multimodal exercise intervention ( my-PEP) or 
standard care advice. Both cardiopulmonary fitness and respiratory muscle strength will 
be assessed in both arms of the trial before and after the intervention, using CPEX and 
maximal inspiratory mouth pressure, respectively. After completion of the intervention 
participants undergo oesophagectomy and are followed up until 90 days after surgery to 
record post-operative cardiopulmonary complications. Participants must give their 
written informed consent to participate in the trial. The protocol has been approved by 
the East Midlands Leicester South Research Ethics Committee (ref: 16/EM/0317) and the 
Health Research Authority, UK (IRAS ID: 206608).  
Trial setting 
This single centre clinical trial will be conducted in the Norfolk and Norwich University 
Hospitals’ (NNUH) Oesophagogastric Cancer Centre. The NNUH takes referrals from its 
neighbouring hospitals, namely the James Paget University Hospital (JPUH) and Queen 
Elizabeth Hospital (QEH). Approximately 80 oesophagogastric cancer resections are 
performed at the centre each year.   
Trial Population                  
Patients with OAC who are scheduled for neoadjuvant chemotherapy and subsequent 
oesophagectomy. 
Inclusion Criteria 
 
i. Male and female 
ii. Aged 18 years or above 
iii. Histological evidence of OAC 
iv. Capable of giving informed consent and complying with trial procedures.  
 
Exclusion Criteria 
 
i. Patients with oesophageal squamous cell carcinoma. 
ii. Patients with concomitant illness or disability that makes them unsuitable for an 
exercise programme, as assessed by a clinician (e.g. severe musculoskeletal or 
neurological disease, unstable angina, severe aortic stenosis, uncontrolled 
dysrhythmias and uncompensated heart failure). 
iii. WHO performance status 3 (capable of only limited self-care, confined to a bed 
or chair more that 50% of waking hours) or greater. 
iv. Grade 5 on MRC dyspnoea scale (too breathless to leave the house, or breathless 
when undressing). 
 
Recruitment 
 
Participants will be identified at the NNUH Oesophagogastric cancer specialist MDT 
(SMDT). Recruitment will take place over 11 months (September 2016 –August 2017). 
Patients attending post-SMDT surgical clinics are provided with an information sheet by 
their surgeon. Those that express a wish to participate will be contacted by the trial team 
to arrange a research meeting at which time written informed consent will be obtained 
to participant in the trial.  
 
 
170 
 
Randomisation 
 
Using a CPEX VO2max of 15ml/kg/min, participants will be stratified into ‘high’ and ‘low’ 
score groups. Stratification will help to equally distribute those with a ‘low’ level of fitness 
between trial arms, reducing the risk of selection bias, which can occur with relatively 
small numbers of patients.  The 32 participants will be randomised into suitable blocks, 
using random block sizes generated by computerised randomisation 
(www.randomzation.com) by the trial statistician. Allocations will be placed in opaque 
envelops by a secretary independent of the trial. The patient pathway following 
randomisation consists of 3 months of NAC followed 5-6 weeks of recovery before 
oesophagectomy. 
 
The Intervention arm  
my-PEP consists of 4 main components.  
1) Inspiratory muscle training/IMT (during and after chemotherapy) 
IMT using should be done for a total of 20 mins every day at home during and after NAC 
(a period of approximately 4 months). The IMT programme is as per Hulzebos, et al16 and 
is detailed below: 
 Maximal inspiratory pressure (P i-max)   will be measured at baseline. 
 Participants will be given an inspiratory threshold-loading device and shown how 
to use it. 
 Participants start breathing exercise with resistance set on the device equal to 
30% of Pi-max and instructed to perform IMT for 20 mins 7 days a week.  
 The resistance of the inspiratory threshold-loading device is increased 
incrementally, based on the rate of perceived exertion scored on the New 
Category (0-10) Borg RPE Scale, where 0 is “nothing at all” and 10 is “very, very 
strong”.17 If the rate of perceived exertion is less than 5, with 5 being “strong”, 
the resistance of the inspiratory threshold trainer is increased incrementally by 
5%. 
 Participants are instructed to record daily IMT exercises in a diary.  
 
2) Home exercise programme (HEP) (during and after chemotherapy)  
The home aerobic exercise, which is the same as in the standard care arm, is based upon 
UK Department of Health (DH) 18 and American College of Sports Medicine (ACSM) 
guidelines 19, summarised below: 
 Patients will be asked to engage in cardiorespiratory exercise training for ≥30 
min/day (in continuous bouts of at least 10mins) on ≥ 5 days/week to achieve a 
total of ≥150 min/week of moderate intensity exercise (perceived exertion should 
be to 12-13 on the 6-20 Borg Scale, or “somewhat hard”.  
 Alternatively, patients may engage in cardiorespiratory exercise training ≥20 
min/day on ≥ 3 days/week to achieve a total of ≥75min/week of vigorous intensity 
exercise (perceived exertion should be to 14-17 on the 6-20 Borg Scale, 
“somewhat hard” to “hard”).  
 Additionally, a combination of moderate and vigorous intensity exercise may be 
engaged in to achieve approximately the same energy expenditure (≥500-1000 
MET/min/week) as a moderate or vigorous regime. 
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 Patients in the my-PEP am are instructed to record the amount and intensity of 
daily exercise, complaints, and any adverse events in a diary. 
3) Hospital personalised exercise programme (Hos-PEP)    
There are approximately 6 weeks between completion of NAC and oesophagectomy to 
allow patients to recover prior to surgery. Around 1 week after NAC has finished, the 
participant will be invited to attend a 4-week out-patient Hos-PEP. This hospital 
supervised exercise component of my-PEP is based upon UK DH and ACSM guidelines. The 
muscle strengthening regime is as per Barakat, et al.20 Participants will be invited to attend 
8 supervised out-patient hospital exercise sessions over 4 weeks (2 sessions per week), 
with each lasting approximately 60-90 minutes. The timing of the hospital exercise 
programme is to allow participation in exercise in the routine time between the 
completion of chemotherapy and surgery (currently a minimum of 5-6 weeks). During this 
time participants will aslo be encouraged to continue their home exercise sessions. The 
Hos-PEP has aerobic and a muscle strengthening components as detailed below:  
Aerobic component of Hos-PEP      
The participant will be invited to begin each session with 5 mins of warm up by cycling on 
a static exercise bike to their perceived exercise intensity of ‘light’ on the Borg scale (score 
9-11). After the warm up and remaining on the bike, the participant will be invited to 
engage in aerobic interval training aiming to achieve up to 30 mins of moderate intensity 
(Borg scale rate of perceived exertion (RPE) of 12-13) aerobic exercise. The pedal 
resistance of the static bike will be adjusted to achieve this.  
At subsequent Hos-PEP sessions, participants who feel they may progress above the 
moderate level, and have demonstrated that this may be possible from previous sessions, 
will be encouraged to do so. Progression will be by increasing intensity whilst decreasing 
the duration and rest period. 
Muscle strengthening component of Hos-PEP    
Before or after the aerobic component (based upon participant preference), the 
participant will be invited to attempt the following sets of muscle strengthening exercises:  
 Heel-raises for 2 minutes (rise up and down to ‘tip toes’ in a standing position). 
 Knee extensions against resistance for 2 minutes (extend the knee with attached 
ankle weights in a seated position; each leg exercised separately).  
 Dumbbells’ biceps curls for 2 minutes (flex both arms while holding dumbbells in 
a standing position). 
 Step-up lunges for 2 minutes (step up and down from an exercise step). 
 Knee bends against resistance for 2 minutes (flex the knee with attached ankle 
weights in a standing position; each leg exercised separately).  
 
4) Behavioural Change Techniques (BCTs) 
An important component of my-PEP is identifying participant’s exercise-related needs and 
the use of tailored strategies to promote adherence. Behavioural change techniques 
(BCTs) will be employed to improve participant adherence to my-PEP.21 The use of BCTs 
will be individualised to each participant. To identify participants’ actual and perceived 
barriers to exercise a specific validated and reliable questionnaire, the Determinants of 
Physical Activity Questionnaire (DPAQ), will be used.22 All patients randomised to the my-
PEP arm will be offered a one-to-one discussion with the trial team to discuss the results 
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and implications of their DPAQ results and, based on these, the trial team can deliver the 
required tailored BCTs.  For example, if the participant scores low in the domain 
“knowledge” then information about the recommended levels of physical activity could 
be provided. 
Standard Care  
 
Participants randomly allocated to standard care will be given written advice on a home 
exercise programme. This explains the level of physical activity recommended by the UK 
DH18 and the ACSM19, namely to engage in ≥150 mins of moderate or ≥75 mins of vigorous 
aerobic exercise each week. Aerobic exercise may be in any form that the participant 
chooses including: on a bicycle, a static exercise bike, walking, power-walking, jogging or 
swimming.  
 
Questionnaires 
1) The International Physical Activity Questionnaire (IPAQ) (all participants)    
At the initial research visit, all participants will be asked to complete the IPAQ, which 
consists of 4 questions. Each is related to physical activity performed in the last 7 days. 
Exercise levels will then be compared before and after the my-PEP intervention or 
standard care. 
2)  Quality of life (all participants) 
All participants will be asked to complete both the quality of life (QOL) questionnaires 
EORTC QLQ-C30 and disease specific Oesophago-Gastric QLQ-OGC25 at the beginning and 
end of the trial to assess the impact of both my-PEP and standard care (HEP) on QOL.  
3) The Determinants of Physical Activity Questionnaire (DPAQ)           
Only participants in the my-PEP arm will be invited to complete the Determinants of 
Physical Activity Questionnaire (DPAQ). This contains 34 questions relating to 11 domains 
(adapted from a theoretical domains framework (TDF)) including participants’ knowledge 
about exercise, social influences, levels of motivation and emotional responses to physical 
activity. These theoretically underpinned measures of determinants of physical activity 
will provide information about factors that may represent personal barriers or facilitators 
to participating in an exercise programme. These can then be addressed or encouraged 
both before and during Hos-PEP by applying pre-selected BCTs. 
 
Feasibility objectives and outcome measures 
The purpose of the ExPO trial is to provide the following feasibility information to both 
justify and inform a future RCT: 
 To justify: 
i. To measure the: eligibility, recruitment and retention rates of patients to my-PEP 
who have OAC and are referred for NAC and oesophagectomy. 
 
ii. To assess the generalisability of trial participants, compared to patients that 
decline to participate in terms of demographics and clinical characteristics.  
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iii. To measure the level of baseline exercise prior to participation determined by the 
International Physical Activity Questionnaire/IPAQ. 
 
iv. To measure QOL reported in both arms using the European Organisation for 
Research and Treatment (EORTC) quality of life questionnaire, EORTC QLQ-C30 
and disease specific Oesophago-Gastric QLQ-OGC25 module to determine the 
effect of the intervention on QOL.  
 
v. To measure the adherence to my-PEP. 
 
vi. To define the safety profile of my-PEP.  
 
vii. To investigate if my-PEP provides a greater increase in VO2max and Pi-max than 
standard care (HEP).  
 
To inform: 
 
i. To record reasons for non-participation, which may be addressed in a future trial. 
 
ii. To assess participants’ facilitators and barriers to engaging with my-PEP. 
 
iii. To record the mean number + SD of 30 and 90 day post-operative 
cardiopulmonary complications per patient, defined according to the 
‘Complications Basic Platform’ of the Esophagectomy Complications Consensus 
Group/ECCG9. The severity of complications will be graded according to the 
Clavien-Dindo Classification. With the number of participants in the trial (n=32), 
we will be able to provide an estimate of the difference in the mean number of 
complications per patient to allow calculation of the sample size required for a 
future trial, where the number of CPCs would be the primary outcome measure.  
 
iv. To record the number of 30 and 90 day post-operative non-cardiopulmonary 
complications per patient (defined according to the ECCG), the length of in-
hospital stay following oesophagectomy, and the number of 30-day and 90-day 
post-operative deaths. 
 
v. To assess the overall participant experience (expectations, evaluation, 
satisfaction and suggestions) with my-PEP (recorded in a qualitative interview).  
 
Complication data          
Following surgery, participants will be followed up for CPCs. Post-operative complication 
data will be assessed by consultant clinicians who are blinded to the intervention and have 
no role in any other part of the trial or in the patient’s routine clinical care.  The 30-day 
and 90-day CPCs will be defined according to the ‘Complications Basic Platform’ defined 
by the Eosophagectomy Complications Consensus Group (ECCG).23 The severity of the 
complication will be classified according to the Clavien-Dindo grading system from 1 to 5. 
For the purpose of this trial, only grade 2 complications and above will be included in the 
analysis. The 30-day and 90-day non-CPCs will also be defined according to the 
‘Complications Basic Platform’ agreed by the ECCG and graded as per Clavien-Dindo. 
Length of stay and mortality data will also be collected. 
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Statistical analysis        
The baseline participant demographic and clinical characteristics and trial outcomes for 
participants in each of the 2 arms (my-PEP and HEP) of the trial will be reported. For 
categorical variables, the numbers and percentages will be presented and for continuous 
variables the means (and standard deviations) or medians (and interquartile ranges) 
depending on their distributions. Differences between the groups will be compared using 
the most appropriate statistical test. 
Sample Size calculation 
As this is a feasibility trial, a formal sample size calculation is not required to determine 
the statistical significance of the effect size of the intervention on the number of CPCs. 
However, this trial is powered to detect a statistically significant change in VO2max of 
3.6ml/kg/min between the two groups after the intervention. The sample size calculation 
was based on data from previous observational studies24 25 and a randomised controlled 
trial26 investigating pre-operative exercise therapy of similar durations to that in our 
proposed trial. These studies suggest that an in-hospital exercise regime may increase 
baseline VO2max by 2.6ml/kg/min. This was calculated from two observational studies, 
where VO2max was increased by 2.8 and 2.4ml/kg/min after 4-6 week out-patient exercise 
programmes.24 25 To estimate the effect size in the baseline standard care arm we used 
information from a randomised controlled trial of 35 subjects, demonstrating that 
standard advice to exercise at home may cause a worsening of VO2max of at least -
1ml/kg/min.26 Therefore, assuming a mean difference of VO2max of 3.6ml/kg/min and a 
standard deviation of 3.0,24-26 then using a two sample t-test the trial would require 11 
individuals per group for the trial to have 80% power at the 5% level of significance to 
detect a statistically significant difference in VO2max between treatment arms. Accounting 
for a participant drop-out rate of 27%,25 26 at least 30 subjects would be need to be 
recruited to achieve 11 individuals per group for a per-protocol analysis.  Based on the 
above information we aim to recruit 32 patients in total. 
Discussion/Conclusion  
The ExPO feasibility trial aims to determine whether a multimodal exercise intervention 
(my-PEP) is justified, feasible and superior to standard care in improving physiological 
fitness prior to oesophagectomy. If my-PEP is suitable for this patient population, as well 
as safe, with good participant adherence, and also improves physical fitness, this will 
inform and justify a future large definitive RCT to determine whether the multi -modal 
exercise package can decrease the frequency of post-oesophagectomy CPCs. If so, this 
would lead to an established peri-operative exercise programme prior to esophageal 
resection surgery to improve patient outcomes in patients with this aggressive cancer.  
Abbreviations: ACSM: American College of Sports Medicine, AT: Anaerobic Threshold 
(CPEX Parameter), BCT: Behavioural Change Techniques, CPC: Cardiopulmonary 
Complication, CPEX: Cardiopulmonary Exercise Test, DPAQ: Determinates of Physical 
Activity Questionnaire, ECCG: Eosophagectomy Complications Consensus Group, ExPO: 
Exercise Prior to Oesophagectomy, HEP: Home Exercise Programme, Hos-PEP: Hospital 
Personalised Exercise Programme, IMT: Inspiratory Muscle Training 
IPAQ: International Physical Activity Questionnaire, LOS: Length of Stay 
MDT: Multi-disciplinary Team, MET: Metabolic Equivalent for Task, MRC: Medical 
Research Council, my-PEP: My-Personalised Exercise Programme, NAC: Neoadjuvant 
Chemotherapy, NNUH: Norfolk and Norwich University Hospital, Non-CPC: Non-
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Cardiopulmonary Complication, OAC: Oesophageal Adenocarcinoma, PA: Physical 
Activity, Pi-max: Maximal inspiratory Pressure, QEH: Queen Elizabeth Hospital, QLQ: 
Quality of Life Questionnaire, QOL: Quality of Life, RCT: Randomised Controlled Trial, REC: 
Research Ethics Committee, RPE: Rating of Perceived Exertion, SMDP: Specialist Multi-
disciplinary Team, TDF: Theoretical Domains Framework, VO2: Volume of Oxygen Used 
(CPEX Parameter), VO2max: Maximum Volume of Oxygen Used (CPEX Parameter) 
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East Midlands Leicester South Research Ethics Committee (ref: 16/EM/0317) and the 
Health Research Authority, UK (IRAS ID: 206608).  
Consent for publication: Not applicable as all individual identifiable data will be removed. 
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datasets were generated or analysed during the time of submission. When data are 
generated it will be available on reasonable request to the author.  
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Trial Flow Diagram 
 
1 PURPOSE 
The purpose of the EXPO Safety Management Plan (SMP) is to describe the safety 
measures and management procedures for the feasibility trial. This includes the definition 
of the roles and responsibilities for relevant parties for managing Serious Adverse Events 
(SAEs) and the compilation of safety reports. This document also describes procedures for 
handling data relating to pregnancies in trial participants, although this is highly unlikely 
in this patient group. The SMP will be reviewed and approved by the Trial Management 
Group (TMG) and sponsor.  
2 ExPO SAFETY MEASURES 
2.1 Possible Expected Adverse Events with Exercise  
Based on results from previous trials, significant adverse events related to exercise in 
ExPO are expected to be rare. Those that do occur are likely to be both transient and mild. 
Adverse events due to exercise in the post-operative period (at least one week after the 
last exercise session) are particularly unlikely. A systematic review of 4 randomised trials 
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and 6 observational studies totalling 524 patients awaiting: cardiac, lung and colorectal 
surgery reported exercise therapy, similar to the duration and intensity in this trial, to be 
safe with only 2 mild exercise-related adverse events (transient hypotension) reported 
across all studies. 
Adverse events may include: 
i. exacerbation of an existing medical condition (e.g. coronary artery disease).  
ii. delayed onset muscle soreness (DOMS) 
iii. soft tissue strains/sprains 
iv. nausea and light-headedness 
v. transient hypotension 
 
Procedures to help participants avoid these symptoms are: 
 Participants are asked prior to stating exercise if they feel well enough to 
participate 
 Participants will be advised to wear loose clothing and well -fitting sports shoes. 
 All exercise equipment will be tailored to the participant including an 
appropriately adjusted cycle seat height, and appropriate weights sizes.  
 A warm up period precedes the exercise programme to prevent soft tissue 
sprains/strains and DOMS. 
 A cool down period is incorporated into the exercise programme to prevent soft 
tissue sprains/strains and DOMS. 
 Muscle stretches after the exercise programme as a warm down to prevent soft 
tissue sprains/strains and DOMS. 
 Regular rest periods throughout the exercise programme have been incorporated 
to prevent: nausea, light-headiness, soft tissue sprains/strains and DOMS. 
 Hydration fluids (water and isotonic drinks) will be available throughout the 
exercise programme to prevent dehydration resulting in nausea, light-
headedness and hypotension. 
 Participants may cease exercising at any time of their choice. 
2.2   Additional Safety Measures 
The my-PEP (personalised exercise programme) of the ExPO trial has been designed in 
accordance with UK Department of Health guidelines which recommends that all adults, 
including those older than 65 years, should aim to complete ≥150 minutes of moderate 
physical activity (e.g. brisk walking), or ≥75 mins of vigorous activity, (e.g. running) each 
week, or a combination of both. Nonetheless, adverse events due to exercise are possible. 
Therefore, the following measures are included to ensure safety in the ExPO trial.  
 Recruiting patients referred for major surgery, who will have been deemed 
medically fit for an operation by consultant clinicians.  
 Initial participant health screening assessment (to ensure there are no co-existing 
diseases which may be exacerbated by exercise) will be obtained prior to exercise. 
This includes review of the medical notes and direct interview of the participant. 
 Baseline cardiopulmonary exercise testing (CPEX), which is also a diagnostic tool 
to identify any cardiopulmonary deficiency which may be exacerbated by 
exercise. This measure will be taken into account when personalising each 
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participants exercise plan. Any CPEX values of concern will be discussed with the 
clinical team. 
 Exercise is tailored to each participant’s perceived exertion level, which is 
frequently re-assessed so that they may rest or stop exercise if they feel they are 
over-exerting themselves.  
 Oral consent to commence exercise will be obtained from the participant prior to 
each exercise session to ensure ongoing approval  for continuation in the 
programme. The trial team will also re-enforce that the participant may stop 
exercising at any time during the exercise session should they wish.  
 A short medical history will be re-taken at each exercise visit, to ensure the 
patient is suitable for exercise. 
 A medically qualified doctor, nurse or physiotherapist will be present during all 
Hos-PEP sessions trained in life support with resuscitation equipment available.  
 The participants will undergo baseline observations of heart rate  (HR), blood 
pressure (BP), respiratory rate (RR), temperature and oxygen saturation 
monitoring before the start of the exercise session and HR and saturation during 
exercise to ensure that they are within acceptable limits. Exercise will be stopped 
should any of the observations cause concern to the health professional 
supervising the programme.  
 The participants are informed that they may cease any or all components of 
exercise at any stage at their choice without prejudicing their future care.  
3 DEFINITIONS 
The following definitions have been adapted from Directive 2001/20/EC, ICH E2A ‘Clinical 
Safety Data Management: Definitions and Standards for Expedited Reporting’, ICH GCP E6 
and ‘CT-3’ (v 2011/C 172/01), to have standard definitions that are relevant to all studies 
(CTIMP and non-CTIMP).  
3.1 Adverse Event (AE) 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical research 
participant who has been administered any research procedure, which does not 
necessarily have a causal relationship with the treatment or procedure. An AE can be any 
unfavourable and unintended sign (including an abnormal laboratory finding), symptom 
or disease temporally associated with taking part in research procedures, whether or not 
related to a research procedure.  
3.2 Adverse Reaction (AR) 
An AR is any untoward and unintended response to a research procedure (in this trial – 
exercise) at least possibly causally related to that procedure. A causal relationship 
between a research procedure and an AE is at least possibly related, i.e. a relationship 
cannot be definitively ruled out. 
3.3 Causality definitions 
A causality assessment between the event and the research procedure will take into 
account the following factors: 
 The existence of a temporal relationship between the event and procedure. 
 The established risks of the research intervention as outlined in the protocol.  
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 Factors which, according to medical assessment, are responsible for the event 
other than the trial intervention, such as prescription of concomitant medication, 
natural history of oesophageal adenocarcinoma, study procedures, etc.  
 
Causality 
assessment 
Description Event type 
None There is no evidence of any causal relationship. Unrelated AE 
Unlikely There is little evidence to suggest that there is 
a causal relationship (e.g. the event did not 
occur within a reasonable time after 
administration of the trial procedure). There is 
another reasonable explanation for the event 
(e.g. the participant’s clinical condition). 
Unrelated AE 
Possible There is some evidence to suggest a causal 
relationship (e.g. because the event occurs 
within a reasonable time after administration 
of the trial procedure and/or it follows a 
clinically reasonable response on withdrawal). 
However, the influence of other factors may 
have contributed to the event (e.g. the 
participant’s clinical condition). 
AR 
Probable  There is evidence to suggest a causal 
relationship and the influence of other factors 
is unlikely. 
AR 
Definite  There is clear evidence to suggest a causal 
relationship and other possible contributing 
factors can be ruled out. Re-challenge 
information, where applicable, demonstrates 
reappearance of similar reactions.  
AR 
3.4 Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) 
For the purposes of the EXPO trial, SAEs and SARs include the following: 
I. results in death  
II. results in hospitalisation or prolonged hospital admission 
III. is life threatening (‘life threatening’ refers to an event in which the patient is at 
risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe).  
IV. results in persistent or significant disability or incapacity 
V. a congenital anomaly or birth defect or spontaneous abortion  
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VI. one that is otherwise medically significant (e.g. important medical events that 
may not be immediately life-threatening or result in death or hospitalisation, but 
may jeopardise the patient or may require intervention to prevent one of the 
other outcomes listed above). 
All SAEs should be reported to the sponsor within 24 hours of the CI becoming aware 
(during working hours) of the event. SAEs which do not require reporting include 
admissions or death secondary to known complications of adjuvant chemotherapy (e.g. 
neutropenic sepsis, symptomatic anaemia, venous thromboembolism, cardiotoxicity and 
diarrhoea) or due to index cancer (e.g. dysphagia or gastro-intestinal bleeding due to local 
tumour recurrence, ascites, metastatic disease, deep vein thrombosis or pulmonary 
embolism) or surgery (pneumonia, empyema, acute respiratory distress syndrome, 
pulmonary embolism, pleural effusion, surgical conduit dysfunction, anastomotic leak, 
wound infection, wound dehiscence, oesophageal stricture or pain over the surgical scar). 
This is not an exhaustive list, there may be other unlisted AEs related to the cancer or its 
treatment as judges by clinicians. These will be recorded in both the CRF and clinical notes. 
All SAEs that develop between randomisation to 90 days following surgery will be 
recorded. 
3.5 Suspected Unexpected Serious Adverse Reaction (SUSAR) 
A SUSAR is a SAR, the nature or severity of which is inconsistent with the known expected 
events associated with the intervention. The event is categorised as having either: none, 
unlikely, possible, probable or definite relationship to a trial intervention and is 
unexpected for that trial. The expectedness of an event is assessed by CI or their delegate. 
4 Additional AE guidance 
AEs will be reviewed during the trial and recorded in the medical notes, CRF, and if classed 
as serious on the SAE form and SAE database.  
 
An adverse event is one occurring after randomisation and would include, but is not 
limited to: 
 A change, excluding minor fluctuations, in the nature, severity, frequency, or 
duration of a pre-existing condition.  
 Any unfavourable and unintended sign, symptom, or disease temporally associated 
with engagement with the research procedures. 
 Injury or accidents: if a medical condition is known to have caused the injury or 
accident, the medical condition and the accident should be reported as two separate 
medical events (e.g. for a fall secondary to dizziness, both “dizziness” and “fall” 
should be recorded separately). 
 Any deterioration in measurements of a laboratory value or other clinical test (e.g. 
electrocardiogram (ECG) or X-ray that is associated with least one of the following: 
 Is associated with clinical signs or symptoms judged by the investigator to 
have a significant clinical impact. 
 Requires intervention or any other therapeutic intervention. 
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 Results in discontinuation of exercise or withdrawal of the participant from 
the trial.   
 Requires additional diagnostic evaluation. 
An adverse event does not include:   
 Elective medical or surgical procedures (e.g. surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an adverse event. Planned 
surgical measures permitted by the clinical study protocol and the condition(s) 
leading to these measures are not adverse events, if the condition was known prior 
to signing consent for study participation. In the latter case, the condition should be 
reported as part of the participant’s medical history.  
 Pre-existing diseases or conditions present or detected after randomisation that do 
not worsen. 
 Situations where an untoward medical event has not occurred (e.g. hospitalization 
for elective surgery, social and/or convenience admissions).  
4.1 Notable events 
Notable events are significant events that are identified by the: CI, TT or investigators 
based on knowledge of the characteristics of the intervention.  
5 RESPONSIBILITY FOR SAFETY OF PARTICIPANTS 
5.1 Trial Team (TT) 
The TT is responsible for processing all SAEs and pregnancy reports in line with this 
Working Practice Document. The TT ensures that all safety data is dealt with appropriately 
and that the responsibilities of the Sponsor as set out and applicable regulations are 
adhered to. The CI in collaboration with the TT and TMG, will ensure appropriate safety 
recording and reporting procedures and subsequently during the trial where necessary. 
They will check that all trial documentation has the appropriate safety reporting 
information and guidance i.e. protocols, case report forms (CRFs) which record AEs and 
trial specific Working Practices, including the SAE reporting form. CRFs will be reviewed 
by the CI or delegate, which may identify trends in AEs. All SAEs will be reviewed by the 
CI or delegate, which are documented in the CRF and TMF. 
5.2 Trial Management Group (TMG) 
The CI takes ultimate responsibility for all safety aspects of the trial. Other members of 
the Trial Team (TT) will be delegated responsibility for the processing of recording and 
reporting (where appropriate) SAEs and AEs. These include Research Ethics Committee 
(REC) reports, Safety Committee (SC) and Trial Steering Committee (TSC) updates. The CI 
in collaboration with the TT and TMG will review procedures in order to support 
standardisation and consistency in SAE reporting and will ensure that safety is monitored 
according to Quality Control (QC) processes described in the trial specific QMMP. 
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5.3 Safety Committee (SC) & Trial Steering Committee (TSC) 
The SC safeguards the interests of trial participants. The committee consists of two 
independent members who have experience with patients undergoing neoadjuvant 
chemotherapy and oesophagectomy. Every six months (or more frequently if required) 
they review all AEs, and comment on whether these are events are either: of no concern, 
possible concern or cause for concern. Based on the emerging safety data, they judge 
whether the trial should either continue or be suspended (temporarily or permanently). 
The SC report their findings to the TSC, CI, sponsor and TT. The TSC consists of 
independent members and includes clinicians in the relevant specialties, lay members and 
a representative of the sponsor and site R&D department. The TSC, which meets every 6 
months safeguards the interests of trial participants and monitors the main safety 
measures, overall trial conduct and progress. The EXPO SC and TSC charters document the 
responsibilities and membership of these two committees. Both have open sessions with 
members of the TMG and closed sessions. 
6 PROCEDURES FOR SAFETY RECORDING AND REPORTING 
As per the approved study protocol, AEs will be recorded, and if required reported, from 
randomisation (start of trial procedures) until 90 days after surgery. AEs are recorded in 
the clinical notes, CRF and for SAEs an SAE reporting form, ‘Report or Serious Adverse 
Event (SAE)’ (see appendix 1). The information on adverse events are: description, 
severity, causality, seriousness and category. 
6.1 SAE Reporting and clinical review 
As soon as possible, and within 24 hours following notification of an SAE (during working 
hours), the CI or delegate is required to: 
a) Complete the ‘Report or Serious Adverse Event (SAE)’ form as provided in the TMF 
and in doing so provide sufficient information on: how the event met the regulatory 
definition of an SAE and details of the event. 
b) Sign and send the SAE form to the sponsor by fax or email.  
The CI is required to send the SAE form even if the information is incomplete or it is 
obvious that more data will be needed for a complete assessment. 
As this is a randomised trial, the evaluation of causality must be performed assuming that 
the patient is in the intervention arm. Expectedness is assessed against the expected 
adverse events for exercise as listed in the protocol. An event may be cons idered 
unexpected if the severity or duration of the event is not consistent with that documented 
in the protocol. The CI or delegate is required to send any applicable supporting 
documents in a timely fashion to the sponsor to ensure accurate follow-up in each case. 
The supporting documents may include, but are not limited to:  
a) Copies of concomitant medication/medical history,  
b) Admission/discharge summary,  
c) Clinical laboratory reports,  
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d) Death certificates.   
Such documents will be anonymised by the CI or delegate in terms of patient information 
and will be coded with the SAE number, initials, and date of birth, gender and site.  
Documents can be scanned and sent electronically.  
If a member of the TT has a question regarding safety reporting they should contact the 
EXPO Trial Team co-ordinator by telephone (0757 830 1811) or by e-mail 
(expo@nnuh.nhs.uk), or the CI by telephone 01603 593611, email (a.hart@uea.ac.uk), or 
fax 01603 593752. For SAEs, the patient must be followed up until clinical recovery is 
complete and laboratory results have normalised, or clinical agreement is reached to close 
the event.  
6.2 Immediate clinical review 
SUSARs will require immediate clinical review by the CI or suitable delegate. If an 
investigator reports a SUSAR and the CI or delegate is unavailable to perform the 
immediate review within the required timeline for reporting, the TT should request senior 
support from a member of the TMG and report the SUSAR to the Research Ethics 
Committee (REC), R+D departments and sponsor. The trial specific clinical review should 
take place as soon as possible and any necessary follow-up submitted. 
6.3 Follow-up of SAEs 
The CI or delegate is responsible for ensuring all reportable SAEs are followed until 
resolution. SAEs will be considered medically closed when the SAE has resolved or 
stabilised, all fields on the SAE report are appropriately completed, and relevant 
anonymised supporting documentation (hospital discharge summary, death certificate, 
autopsy report, etc) are obtained. Where the CI or delegate is certain there will be no 
more information available on an SAE, the sponsor should be informed and the event 
closed on the SAE log, following CI/TMG approval. If the CI and/or TMG agree to close an 
unresolved SAE, the reasons should be clearly documented on the log and in the minutes 
of the meeting where the event was discussed.   
6.4 Causality assessment 
The causality assessment should be initially performed by the CI or the ir clinical delegate. 
If there is no delegated clinician available to sign the form, the event should be reported 
and signed by another member of the site TT, but procedures must be in place for review 
by a delegated clinician as soon as possible.  The clinician’s assessment, and any follow-
up information, should be faxed or e-mailed to CI (fax number: 01603 593752, email: 
a.hart@uea.ac.uk). There should be documented evidence that the event has been 
assessed by a medical doctor with a counter signature of the SAE form. The assessment 
at the time cannot be subsequently overruled by the CI. In the case of disagreement 
between the person reporting the incident and CI, both opinions will be provided in 
reports to the REC. Documentation of relevant discussions should be made and filed. If a 
difference in opinion on causality results in the need for an expedited report (i.e. the event 
is deemed a SUSAR by one of the clinical reviewers), the clinical reviewer’s comments 
should be included on the cover sheet and it should be sent to all parties who need to 
receive the SUSAR report. The timelines for expedited reporting begin from the date the 
clinical reviewer identified the event as a SUSAR. The TT or delegate should ensure that 
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only medically qualified staff are de legated for causality assessment on the trial’s 
delegation of responsibilities log. 
6.5 Expectedness 
The events against which expectedness is judged is stated in the EXPO protocol (see 
section 7.7). The CI must confirm the expectedness as part of the SAE processing 
procedure trial. Appropriate documentation of discussions and decisions should be made 
and filed. Where decisions are made that result in modifications on the SAE form, these 
should be initialled and dated. Where agreement is reached that a SSAR should be 
reclassified as a SUSAR, the event should be reported to the appropriate REC within the 
expedited timelines. The timelines for expedited reporting begin from the date the event 
is first classified as a SUSAR. 
6.6 SAE report sign off 
The TT will record the SAE form has been reviewed by the CI or his delegate. 
6.7 Safety data entry 
Data from paper SAE reports will be entered (including severity, causality and type) on the 
e-CRF database and also in the trial specific SAE log and stored in the TMF. 
6.8 Reporting of SUSARS to the REC within 15 days 
The CI has responsibility for the reporting of SUSARs to the REC within 15 days of 
becoming aware of the event using the ‘Report of Serious Adverse Event (SAE)’ form for 
non-CTIMPs as published on the HRA website (appendix 1).  The intervention allocation 
will be unblinded and if allocation reveals active intervention the SUSAR will be reported. 
The same form will also be used for reporting to the sponsor, TSC and SC.  
Documentation of submission/ receipt of SUSAR submissions should be filed in the TMF. 
6.9 Other expedited reporting 
Any finding considered significant and reportable by the SC or TSC should also be 
evaluated for reporting to appropriate REC and sponsor. 
6.10 Follow-up SUSAR reports 
If additional information is received after the initial SUSAR report has been submitted, a 
follow-up SUSAR report must be submitted to all those in receipt of the initial report.  
6.11 Unblinding of intervention for SUSAR reporting 
Local clinicians may make a request for unblinding to the CI of member of the TT. During 
working hours all requests for unblinding should be discussed with the CI or their 
delegate. Unblinding, including out of hours can be performed by the trial co-ordinator, 
who is unblinded and has access to the allocation data. Alternatively, in the event an SAE 
reported to CI is subsequently determined to be a SUSAR and where unblinding has not 
already been performed, the CI can perform unblinding. In the event of a SUSAR the CI 
must ensure that all exercise activities have stopped. Wherever possible, members of the 
TT (including the CI) and clinical team will be kept blinded to the status of the participant. 
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All SUSARs will be unblinded before expedited reporting. Participants carry an ExPO trial 
card, which gives the phone number that clinicians may contact the CI or TT on.  
6.18 Internal safety reporting and review 
6.18.1 Trial Team and Trial Management Group reporting and review 
SAEs, SSARs and SUSARs arising will be reviewed and documented at the TMG, SC and TSC 
meetings.  The TT and TMG will monitor safety data for any events considered to be 
caused by trial related procedures. In the event that any trial procedures appear to be 
resulting in adverse events, the CI/TMG must be contacted immediately for their opinion 
on whether it is necessary to implement any urgent safety measures and whether the 
conduct of the trial should be reviewed. 
The TT & TMG will monitor safety data for an increase in the incidence or severity of AEs 
with direct consideration of the frequency of AEs considered rare or very rare. Should this 
be detected, a report compiled by the TMG and CI detailing the findings must be 
submitted to the REC and sponsor. The CI and TMG must agree the content of the report 
before submission. 
6.18.2 SC reporting and review 
The SC meetings will be held every 6 months during the trial, but more frequently if 
required.  Their purpose and the reporting procedures are described in the EXPO safety 
committee charter. The SC report is submitted to the TSC & TMG. 
6.18.3 Coding of events 
Events that are reported in a trial will be recorded in the eCRF which will automatically 
assign an AE number. 
6.18.4 Other considerations 
The Quality Management and Monitoring Plan (QMMP) documents that safety is 
monitored through TT real time review of data.  A monitoring report is also produced and 
reviewed every 3 months. This information is: completion of all inclusion & exclusion 
criteria, respiratory laboratory results as entered in the eCRF, exercise progression and 
review of submitted SAE forms. All AE data is reviewed by the CI with safety reports 
compiled and presented to the SC and TSC every 6 months.  On-site monitoring will not 
be routinely performed, however, if there are concerns regarding safety this can be 
instituted.  
6.19 Pregnancies 
Oesophageal adenocarcinoma is uncommon in women of child-bearing age. In the 
extremely unlikely event of a participant becoming pregnant during the trial this will be 
recorded and reported to the sponsor within 24 hours. The participant will be eligible to 
continue in the trial should they so wish, but she will be monitored more closely. 
Pregnancy occurring in a clinical study is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be recorded 
as an AE or SAE and will be followed as such. A spontaneous abortion is always considered 
to be an SAE.  
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If the outcome of the pregnancy involves any of the following, an SAE report should be 
submitted and causality and expectedness assessed as for other SAEs: 
 
 Congenital anomaly(ies) or birth defect in the fetus/neonate 
 Fetal death or spontaneous abortion 
 Any SAE occurring in the neonate. 
 
6.20 Urgent safety measures 
At any time throughout the duration of the trial, it may be decided by the CI/TMG/TT/SC 
or TSC to apply appropriate urgent safety measures in order to protect trial participants 
against any immediate hazard to their health and safety.  
 
6.21 Serious Breaches 
A serious breach is defined as a breach of the conditions and principles of good clinical 
practice, or the trial protocol, that is likely to affect to a significant degree the safety or 
physical or mental integrity of the trial participants, or the scientifi c value of the trial.  
6.22 NHS incident reporting systems 
Regardless of sponsorship, adverse events affecting NHS trust patients must also be 
reported to the Trust’s clinical risk systems.  The CI will take responsibility for this.  
6.23 Out of hours cover  
Patients will be provided with the PIL and a trial card which contain the contact details for 
members of the TT. Participants may alternatively ring the hospital switchboards and ask 
to speak to a member of the ExPO trial team. The TT has the contact number of the  CI or 
his delegate. Participants are also informed of other sources of medical information 
including their general practitioner, specialist and the accident and emergency 
department.    
6.24 References and sources of information 
WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human 
Subjects, available from: http://www.wma.net/en/30publications/10policies/b3/, 
accessed 17th August 2016.  
 
Safety Report Form (Non‐CTIMPs), available from: 
www.hra.nhs.uk/documents/2015/02/safety-report-form-non-ctimp.docx, accessed 
17th August 2016.  
Safety and Progress Reports Table (non-CTIMPs) for UK health departments’ RES version 
2.1 05.06.2015, available from: http://www.hra.nhs.uk/documents/2015/06/safety-
progress-reports-procedural-table-non-ctimps.pdf, accessed 17th August 2016.  
Standard Operating Procedures (SOPs) for Research Ethics Committees Version 6.1, 
available from: http://www.hra.nhs.uk/resources/research-legislation-and-
governance/standard-operating-procedures/#sthash.KNjc7JfA.dpuf, accessed on 17th 
August 2016. 
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Study Summary 
 
Study Title The association between pre-operative cardiopulmonary exercise test 
variables and short-term post-operative morbidity following 
oesophagectomy. A hospital-based cohort study. 
 Short title CPEX prior to oesophagectomy to predict complications 
Trial Design Single centre, retrospective cohort study 
Study Setting Norfolk and Norwich University Hospitals NHS Foundation Trust (NNUH). 
Study 
Participants 
All patients who underwent both oesophagectomy and pre-operative 
CPEX testing between the dates September 2011 to February 2017 at 
the NNUH. 
Planned 
Sample Size 
254 
Aims Primary Outcome Measures 
To determine if the pre-operative CPEX 
testing variables (VO2peak and AT) can 
predict the risk of early post-operative 
complications following oesophagectomy. 
30 day complications as defined by ECCG 
and graded as per Clavien-Dindo.  
 Secondary Outcome Measures 
To determine if the pre-operative CPEX 
testing variables (VO2peak and AT) can 
predict the risk of early post-operative 
mortality following oesophagectomy. 
Post-operative mortality rates at 30 and 
90 days. 
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Background Rationale 
In the western world, the incidence of oesophageal adenocarcinoma (OAC) has increased 
by at least 6-fold in the last 30 years1 with surgery as the only consistent treatment 
modality that offers a potential cure.2 However, oesophageal cancer resection and 
reconstruction (oesophagectomy) carries a high risk of post-operative complications. 
Recent UK national audit figures reported that 33% of patients suffered a complication 
after oesophagectomy, most of which (74%) were cardiopulmonary (52% respiratory and 
22% cardiac).3 An accurate and objective clinical risk tool to predict patients at higher risk 
of CPCs post-oesophagectomy could allow better perioperative management to improve 
outcomes.   
The surgical stress response in the early post-operative period results in metabolic 
catabolism, with a large increase in oxygen consumption.4  Early post-operative bed-rest 
and incisional pain inhibits normal respiratory function, promoting shallow breathing, 
atelectasis and infective consolidation.5 These physiological challenges are in part met by 
a patients’ cardiopulmonary reserves, or their ability to increase  cardiac output and 
ventilation to meet increased demand. Such reserves are likely to be greater in 
physiologically ‘fitter’ patients. By measuring a patient’s cardiopulmonary reserve, or 
functional capacity, we may theoretically be able to discriminate those that may or may 
not best tolerate the physiological insult associated with oesophagectomy.  
CPEX is a fitness ‘stress test’, whereby a patient exercises, usually on a static bicycle, in 
laboratory conditions, allowing an objective, qualitative and composite measure of their 
overall physiological fitness. Pedal resistance or workload is systematically increased until 
the patient can no longer continue, ideally, due to exhaustion. Two important CPEX 
variables are captured by analysis of gas exchange at the mouth, VO2max (the maximal 
oxygen consumed at the peak of exercise) and VO2 at estimated anaerobic threshold (AT). 
Both parameters have shown great promise in observational studies to predict both 
morbidity and mortality.6-12 In a study of 187 elderly patients undergoing major abdominal 
surgery, a pre-operative AT cut-off of 11ml/kg/min had a sensitivity of 91% and specificity 
of 74% for predicting mortality.6 In a muti-centre study of 346 patients undergoing 
thoracotomy a VO2max cut-off of 16ml/kg/min predicted patients more likely to suffer a 
complication (p=0.0001).13 Unfortunately, no such threshold values have been reported 
specifically for oesophagectomy surgery. To the best of our knowledge, there have been 
3 relatively small observational studies, which although reported inverse associations 
between VO2max, AT and CPCs, were unable to estimate clinically useful cut-off values to 
predict morbidity or mortality.9-11 Differences in both the definition of outcome variables 
and patient populations makes pooling of the data from these individual studies 
problematic due to such inconsistencies. This is reflected in the statistical heterogeneity 
of any such attempted meta-analysis as in figure 1 below (chi-squared test, p=0.02, I2 = 
76%). 
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Figure 1.0. Forest plot comparing the mean VO2max of patients with and without 
cardiopulmonary complications.  
 
 
The aim of this study is to examine the correlations between pre-operative CPEX variables 
and post-operative complications in a sample large enough to allow (should significant 
associations exist) calculation of a threshold value. Such a cut-off value may have 
important clinical application in risk stratification of patients prior to oesophagectomy to 
inform perioperative care.  
Study Design 
A single centre, retrospective cohort study.  
Study Setting 
This study will be conducted in the Department of Upper Gastrointestinal (UGI) Surgery 
at the Norfolk and Norwich University Hospitals (NNUH) Foundation Trust. The NNUH is a 
1,000 bed teaching hospital, which provides care to a population of approximately 
825,000 residents in Norfolk and the adjacent counties. Approximately 45 
oesophagectomies are performed in this unit each year. 
Eligibility Criteria 
Inclusion criteria 
v. Male and female 
vi. Underwent an oesophagectomy 
vii. Completed a pre-operative CPEX test 
 
Exclusion Criteria 
v. Patients that were unable to complete a full CPEX test 
 
Patient Identification 
This study will identify patients using the Operating Room Scheduling Office System 
(ORSOS) database at the NNUH. ORSOS is a surgical scheduling system, which allows 
contemporaneous data capture before, during and after an operation. ORSOS can be used 
to generate a list of all oesophagectomies undertaken at the NNUH over a defined time 
period, namely 1st September 2011 to present. The start date is when CPEX testing was 
introduced prior to oesophagectomy at the NNUH.  ORSOS data includes patient details 
(name, hospital number, date of birth, sex) as well as an aesthetic data (ASA, type of 
anesthesia) and details of the surgery (the operating surgeon and assistants, duration of 
procedure, number of procedures).  This study will also obtain data from 1) CPEX 
laboratory software for each patient that underwent a CPEX at the NNUH and 2) co-
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morbidity and post-operative complication data, obtained by a hand review of the 
hospital notes (blinded to CPEX data). 
Outcome Measures 
30-day complications                                  
Post-operative complications (CPCs) will be defined, according to the ‘Complications Basic 
Platform’ defined by the Eosophagectomy Complications Consensus Group (ECCG). 14 The 
ECCG is comprised of 21 oesophageal surgeons working in high patient volume units from 
14 countries, supported by all the major thoracic and UGI societies, who agreed on a 
standardised list for reporting oesophagectomy complications to improve the 
generalisability of outcome reporting in clinical studies.The potential post-
oesophagectomy CPCs are listed below: 
Pulmonary  
 Pneumonia (Definition: American Thoracic Society and Infectious Diseases Society 
of America)15 16 
 Pleural effusion requiring additional drainage procedure  
 Pneumothorax requiring treatment  
 Atelectasis mucous plugging requiring bronchoscopy  
 Respiratory failure requiring reintubation  
 Acute respiratory distress syndrome (Berlin Definition) 17 
 Acute aspiration  
 Tracheobronchial injury  
 Chest tube maintenance for air leak for >10 days postoperatively  
 
Cardiac  
 Cardiac arrest requiring CPR  
 Myocardial infarction (Definition: World Health Organization) 18 
 Dysrhythmia (atrial) requiring treatment  
 Dysrhythmia (ventricular) requiring treatment  
 Congestive heart failure requiring treatment 
 Pericarditis requiring treatment 
 
Gastrointestinal  
 Esophagoenteric leak from anastomosis, staple line, or localized conduit necrosis.  
 Conduit necrosis/failure 
 Ileus defined as small bowel dysfunction preventing or delaying enteral feeding  
 Small bowel obstruction  
 Feeding J-tube complication  
 Pyloromyotomy/pyloroplasty complication  
 Clostridium difficile Infection  
 Gastrointestinal bleeding requiring intervention or transfusion  
 Delayed conduit emptying requiring intervention or delaying discharge or 
requiring maintenance of NG drainage >7 d postoperatively  
 Pancreatitis  
 Liver dysfunction  
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Urological 
 Acute renal insufficiency (defined as doubling of baseline creatinine)  
 Acute renal failure requiring dialysis  
 Urinary tract infection  
 Urinary retention requiring reinsertion of urinary catheter, delaying discharge, or 
discharge with urinary catheter  
 
Thromboembolic  
 Deep venous thrombosis  
 Pulmonary embolus  
 Stroke (CVA)  
 Peripheral thrombophlebitis  
 Neurologic/psychiatric  
 Recurrent nerve injury.  
 Other neurologic injury  
 Acute delirium (Definition: Diagnostic and Statistical Manual of Mental Disorders, 
5th ed) 19 
 Delirium tremens  
 
Infection  
 Wound infection requiring opening wound or antibiotics  
 Central IV line infection requiring removal or antibiotics  
 Intrathoracic/intra-abdominal abscess  
 Generalized sepsis (Definition: CDC) 20 
 Other infections requiring antibiotics  
 
Wound/diaphragm  
 Thoracic wound dehiscence  
 Acute abdominal wall dehiscence/hernia  
 Acute diaphragmatic hernia  
 
Other  
 Chyle leak.  
 Reoperation for reasons other than bleeding, anastomotic leak, or conduit 
necrosis  
 Multiple organ dysfunction syndrome (Definition: American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference Committee)21 
 
The severity of the complication will be classified according to the Clavien-Dindo grading 
system from 1 to 5 (table 1). For the purpose of this study only grade 2 complications and 
above will be recorded and included in the analysis. CPCs will be analysed as the number 
of participants with a complication. The most serious event will be counted as a 
complication in each case. 
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Mortality               
Death from any cause within 30 and 90 days of surgery.  
Length of Stay                   
Number of days in hospital after the date of surgery, with the day of surgery counted as 
day zero. 
Table 1. Clavien-Dindo Classification of Surgical Complications 
 
 
 
DATA ANALYSIS 
          
The following variables will be captured for each patient.  
 Age (continuous variable) 
 Gender (binary variable) 
 BMI (continuous variable) 
 ASA grade (categorical variable as per the grading system) 
 Smoking status (categorical variable: never, former, current) 
 Co-morbidities (categorical variable according to the Charleston comorbidity 
weighted index) 
 TNM (categorical variable as per the classification system) 
 Histology (categorical variable) 
 Surgical approach (categorical variable as per the operation, e.g. 3 stage 
McKeown, 2 stage Ivor Lewis, Minimally invasive 2 stage Ivor Lewis.  
 Duration of surgery (continuous variable) 
 Use of neoadjuvant chemotherapy (binary variable)  
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 VO2max (continuous variable) 
 AT (continuous variable) 
 Post-operative complications (binary variable) 
 Length of stay (continuous variable) 
 Post-operative mortality (binary variable) 
 
Data analysis may require categorisation of a continuous variable to provide clinically 
useful thresholds.   
Patients with and without surgical complications will be grouped. For categorical 
variables, the numbers and percentages will be presented and for continuous variables 
the means (and standard deviation) or medians (and interquartile range) depending on 
their distributions. Differences between the groups will be compared using the most 
appropriate statistical test. Categorical data will be compared using chi -squared tests. 
Continuous data will be compared using the students’t-test and the Mann-Whitney U test 
will be used as appropriate. In the main analysis postoperative complications will be 
treated as a binary variable, logistical regression models will estimate associations 
between both VO2max and AT and CPCs and non-CPCs within each Clavien-Dindo category, 
with confidence intervals and p values of significance at p=<0.05. Length of hospital stay 
will be treated as a continuous variable and correlation coefficients will be calculated for 
association with CPEX variables.  
 
Derivation and Validation 
Depending on the strength of the associations the dataset may be divided into two parts 
to construct a derivation cohort, which will consist of the first 2/3 of consecutive patients 
(based on date); and a validation cohort, which will consist of the later 1/3 of consecutive 
patients. Discrimination performance of VO2max, VO2max percentage predicted and AT may 
then be assessed using the area under the receiver operating curve (AUC) or C-index. A C-
index below 0.70 would indicate poor discrimination, 0.70 to 0.80 average discrimination 
and values above 0.80 good discrimination. The Hosmer-Lemeshow goodness-of-fit-
model will be used to test calibration, or the degree of agreement between the observed 
and expected values with a p value <0.05 indicating lack of fit.  
The Number of Participants 
The study will include 254 patients, a sample which is inclusive of all oesophagectomies 
undertaken at the NNUH where pre-operative CPEX testing was used.  
DATA MANAGEMENT 
Data Recording and Record Keeping 
A study Microsoft Access database will be designed for the purpose of this study. This 
database will be password protected and stored on a computer drive which is access 
restricted and stored on an NHS computer, which is itself password protected. Pseudo-
anonymised data will be transferred to this database and each patient will be assigned a 
study number.  
 
ETHICAL AND REGULATORY CONSIDERATIONS 
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Declaration of Helsinki 
The Investigator will ensure that this trial is conducted in accordance with the principles 
of the Declaration of Helsinki (seventh revision October 2013).  
Regulations 
The investigators will ensure that this study is conducted in full conformity with GCP 
guidelines, the Sponsor’s SOPs, and other regulatory requirements.  
Approvals 
The protocol will be submitted to an appropriate Research Ethics Committee (REC), and 
relevant R&D department for written approval. The investigators will submit and, where 
necessary, obtain approval from the above parties for all substantial amendments to the 
original approved documents. 
Reporting 
The investigators shall submit on request a report to the REC, host organisation and 
Sponsor.   
Participant Confidentiality 
The study staff will ensure that the participants’ anonymity is maintained.  The 
participants will be identified only by a study number on an electronic database.  The 
study will comply with the Data Protection Act, which requires data to be anonymised as 
soon as it is practical to do so.  
Conflict of interest                         
The investigators declare no conflict of interest  
FINANCE AND INSURANCE 
Funding 
Partial funding for the study is from charitable funds (Oesophageal Cancer Research 
Fund, NNUH and a Norfolk and Norwich University Hospital Medical Gastroenterology 
Research Fund. 
Insurance 
NHS bodies are legally liable for the negligent acts and omissions of their employees.  
PUBLICATION POLICY 
The results of the study will be reported at relevant conferences and published in peer-
reviewed medical journals. Acknowledgement will be given to all participants. Ownership 
of the data arising from the study resides with the study team. 
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